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Pandemic preparedness is weakened by uncertainty about the relative importance of 
influenza transmission modes, particularly airborne droplet nuclei (aerosols). A 
human-challenge transmission trial in a controlled environment was conducted to 
address this uncertainty. Healthy, seronegative volunteer ‘Donors’ (N=52) were 
randomly selected for intranasal challenge with influenza A/Wisconsin/67/2005 
(H3N2) and exposed to seronegative ‘Recipients’ randomized to intervention (N=40) 
or control (N=35) groups. Intervention recipients wore face shields and hand sanitized 
frequently to limit large droplet and contact transmission. A transmitted infection, 
confirmed by serology in a control recipient, yielded a 1.3% SAR overall. This was 
significantly less than the expected 16% SAR (p <0.001) based on a proof-of-concept 
study that used half as many Donors and exposure days. The main difference between 
these studies was mechanical building ventilation in the follow-on study, suggesting a 
  
possible role for aerosols. The extent to which Donor viral shedding was similar to 
that of mild, natural infections and may be useful for studying transmission was 
investigated. The only available aerosol shedding comparison data comes from a 
population of adults with influenza A H3 infection enrolled on the basis of febrile 
illness plus cough or sore throat, or positive Quidel QuickVue rapid test (N=83). 
Systematic differences in case selection compared with Donors yielded more severe 
cases and introduced bias. To account for differences in illness severity, propensity 
score matching, stratification, and inverse weighting ultimately demonstrated that the 
experimental and naturally infected groups were too different to compare without 
bias. While acknowledging the uncertainty in the generalizability of the current 
challenge model, observed aerosol shedding and CO2 were used in the rebreathed-air 
version of the Wells-Riley equation to compute average quantum generation rates 
(95% CI) 0.029 (0.027, 0.03) and 0.11 (0.088, 0.12) per hour for infected Donors and 
fine aerosol shedding Donors, respectively. Donors shed 1.4E+5 (1.0E+5, 1.8E+5)  
airborne viral RNA copies per quantum (ID63). This dissertation provides evidence 
for airborne transmission, presents a methodology for estimating an airborne dose, 
and suggests a role for building ventilation in reducing risk and the need for future 
observational studies to evaluate transmission modes in non-experimental settings 
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RESEARCH AIMS AND INTRODUCTION 
 
Specific Research Aims 
 
Seasonal and pandemic influenza remain global threats. Seasonal flu kills up to 
650,000 people each year and pandemics have the potential to cause millions of 
deaths and disrupt societies. Despite this being the 100th year anniversary of the 1918-
19 global influenza pandemic with a death toll estimated over 50 million, present day 
non-pharmaceutical prevention strategies as well as vaccines remain inadequate. It is 
widely appreciated that the quest for improved non-pharmaceutical controls and 
vaccines is dependent upon knowledge of influenza virus transmission via direct 
contact, large droplet spray, and fine-particle aerosol inhalation. However, the 
infection risk posed by each mode is not well known. Influenza intervention trials 
showed that use of hand hygiene and surgical masks to reduce contact and large 
droplet exposure resulted in only mild risk reduction among susceptible household 
contacts of influenza cases, and may have facilitated more airborne transmission 
(Cowling et al., 2013a). Human challenge studies have shown that infection initiated 
through aerosols, compared with nasal instillation (Alford et al., 1966; Henle et al., 
1946), required a lower dose and resulted in more severe disease. Inhalation of 
bioaerosols is likely important for other acute, viral, respiratory infections and was 





models for a deadly SARS-coronavirus outbreak (Yu et al., 2004). The capacity to 
directly measure the extent and intensity of transmission risk posed by bioaerosols 
represents a major uncertainty for which research is urgently needed. Failure to 
quantify the contribution of exhaled bioaerosols impedes the implementation of 
effective control measures and facilitates population vulnerability during seasonal 
epidemics and pandemics. 
 
The long-term goal is to achieve valid estimates of airborne transmission risk for 
respiratory viruses to support optimization of prevention strategies. We build upon 
the quantum theory of airborne infection (Wells, 1955) by quantifying influenza in 
exhaled breath aerosols, and by describing an approach to directly measure airborne 
risk from confirmed transmission events. The central hypothesis is that risk of 
influenza A virus transmission by the airborne mode can be estimated from a human 
challenge transmission trial as a function of exposure to contaminated exhaled breath 
indoors. This research supports the theoretical underpinnings for innovative 
epidemiologic research that moves the field closer to reliably measuring and 
predicting airborne risk, which informs disease control efforts. This research takes 
advantage of data collected from the CDC-funded human influenza challenge 
transmission trial (Evaluating Modes of Influenza Transmission, ClinicalTrials.gov 
number NCT01710111) that tested the effect of transmission mode using face shields 
and hand hygiene randomized exposure groups in a controlled environment. Specific 






1. The fraction of secondary cases attributable to airborne transmission will be greater 
than those attributable to contact and large droplet spray. 
2. The shedding strength of natural, community-acquired influenza cases are well 
approximated by artificial infection initiated by nasal instillation of virus. 
3. The infectious quantum generation rate for influenza is estimated as a function of the 
quantity of infectious aerosols exhaled by infectious cases, and the rate of airborne 
virus removal mainly driven by ventilation, given the susceptible immune status of 
the trial volunteers.  
 
These hypotheses focus on achieving knowledge to support the scientific 
underpinnings of new frameworks to drive investigation of influenza transmission 
risk assessment. Findings lead support future epidemiologic study designs under 
which longitudinal surveillance of contact networks can revolutionize understanding 
of airborne infection transmission by pinpointing transmission routes and refining 
estimates of infection risk by airborne and other modes in indoor spaces. Results from 
this and future work provide key information for guiding the strategic use of 
prevention methods to protect against seasonal epidemics and pandemics, especially 
in shared air spaces and among immunologically vulnerable communities.  
 
Disease burden and public health significance 
 
The Forum of International Respiratory Societies emphasizes that acute respiratory 





million deaths annually. CDC reports that influenza resulted in 9-36 million illnesses 
and up to 56,000 deaths each year since 2010 in the US, with annual estimated direct 
and indirect costs of $87 billion (Molinari et al., 2007). Respiratory infections cost 
over $15 billion annually in the UK (Burki, 2017). Globally, seasonal influenza kills 
up to 675,000 people each year and influenza pandemics have the potential to cause 
millions of deaths and severe societal disruption. The health and economic burdens 
are amplified in developing nations with less access to health services (Fischer et al., 
2014). Trends in spillover of pathogenic avian influenza to humans, and an 
increasingly interconnected world create an urgent case for improved prevention 
methods.  
 
Prevention of these substantial population health threats cannot rely solely on 
vaccines, which are often poorly matched to rapidly evolving strains. During 
pandemics, lag time in the production and dissemination of vaccines leads to 
widespread vulnerability and underscores the need for interventions based on viral 
exposure reduction to interrupt transmission. It is widely appreciated that the quest 
for improved non-pharmaceutical prevention methods (e.g., reducing exposures 
through building ventilation or social distancing), and vaccines is dependent on 
understanding transmission risk via contact, large droplet spray, and fine-particle 
aerosol respiration (i.e., airborne) (Erbelding et al., 2018). Although the risk 
contribution by each of these modes is not well characterized, there is strong evidence 
supporting the critical role of airborne transmission, and it is well-recognized that 





compared to infections initiated by contact or large droplet spray (Alford et al., 1966; 
Henle et al., 1946).  
 
CDC recommends protective behaviors such as washing hands, covering coughs, and 
donning masks to reduce contact and droplet exposure, but does not provide specific 
guidance to mitigate fine-particle aerosols that are capable of penetrating and 
circumventing surgical masks. Intervention trials showed that use of hand hygiene 
and surgical masks to hinder contact and droplet exposure resulted in only mild risk 
reduction among susceptible household contacts of nearly 800 influenza cases, and 
may have promoted a greater proportion of airborne transmission (Cowling et al., 
2013a). Furthermore, those most likely to be exposed to airborne influenza, due to use 
of hand hygiene plus surgical mask, tended to present with more severe symptoms 
characterized by fever and cough. Despite some delays in intervention initiation and 
imperfect adherence, such trial conditions reflect realistic population usage, while 
randomization and robust sensitivity analyses support internal validity to the extent 
possible. Thus, the state of the science urgently demands investigation to quantify 
airborne transmission risk. In the absence of accurate risk estimation, the strategic 
design and implementation of control programs remains elusive. 
 
Prevailing uncertainty about intervention effectiveness permits seasonal epidemics 
and pandemic vulnerability. A clear, dose-response relationship between dormitory 
rebreathed air fraction and likelihood of retrospective, self-reported ARI was 





airborne infection risk model suggested that increased clean air supply can effectively 
control population spread for ARIs including influenza, but may not have much effect 
on highly contagious infections like measles (Rudnick and Milton, 2003a). However 
this study used estimated values of influenza contagiousness based on an airplane 
outbreak (Moser et al., 1979a), where there was uncertainty about outdoor air 
exchange and all secondary influenza cases were assumed to be connected to the 
index.  
 
While modulating airflow and ventilation can influence airborne contamination 
quantities and human exposure, unequivocal evidence from benchtop exposure 
chambers demonstrates the inactivation of aerosolized influenza (McDevitt et al., 
2012) and TB (Riley and Nardell, 1989) under exposure to UV-C light, representing 
another promising strategy for airborne transmission control. But whereas current 
control techniques are unlikely to be strategically deployed, improved 
characterization of risk by transmission mode enable the most effective use of already 
existing control strategies. In the absence of accurate risk estimation, the strategic 
design and implementation of control programs remains elusive. Likewise, the 
motivation to invest by public health officials and community members dwindles. 
Elucidating airborne transmission risk is the next step toward optimizing the control 







Premise for human-transmission trial 
 
A meeting of globally recognized influenza transmission experts was convened by 
CDC in 2010 to address knowledge gaps about the relative importance of influenza 
transmission modes that are reflected in uncertainty about hospital care and general 
population prevention guidelines (Snider et al., 2010). The meeting discussed 
possible animal and human transmission experiments and explored the possibilities of 
conducting epidemiological studies with engineering and/or personal protective 
interventions. Although there was great enthusiasm for studies of population infection 
surveillance with upper room germicidal irradiation (UVGI) or other airborne control 
interventions, preliminary work in this area was lacking. Ultimately it was determined 
that a human challenge-transmission study with interventions to control for 
transmission mode, and surveillance of aerosol shedding, environmental conditions, 
and comparison of aerosol infectivity of experimental and naturally infected influenza 




An abundance of laboratory evidence substantiates the aerobiologic pathway for 
influenza and other acute respiratory infections (ARIs) and supports new 
epidemiologic studies of transmission. The aerobiologic pathway (Roy and Milton, 
2004), consists of: a) generation of particles containing infectious microbes from the 





persistence in the air before reaching a susceptible host, and c) deposition in at least 
one vulnerable locus in the respiratory tract of the new host.  
 
With respect to infectious particle generation, exhaled breath particles contain 
respiratory fluid lining of the small airways and are generated by small airway closure 
and reopening (Almstrand et al., 2010; Fabian et al., 2008; Johnson and Morawska, 
2009). Our group observed 218 half-hour exhaled breath samples from 142 
symptomatic influenza cases. We detected culturable influenza virus in 39% of fine-
particle aerosols with geometric means of 37 infectious particles by fluorescent focus 
assay and 3.8x104 RNA copies by qRT-PCR (geometric standard deviations 4.4 and 
13, respectively) (Yan et al., 2018). Using a G-II bioaerosol collection device to 
sample natural breathing (including incidental coughs), this research clearly shows 
that influenza cases can generate many virus-laden particles.  
 
Once generated, infectious aerosols maintain infectivity and persist in the air before 
reaching a susceptible host. The airborne movement of infectious particles has been 
implicated in human and animal transmission for influenza and other respiratory 
pathogens. Computational fluid dynamics and multi-zone models simulating a three-
dimensional aerosol plume rising upwards and around an apartment building with a 
SARS-coronavirus index case predicted the location of secondary cases (Yu et al., 
2004). Noti et al., 2012 measured infectious influenza in aerosols that had traveled 
across a room. Upward dispersion of aerosols with slow settling velocity has been 





below exposed animals (Mubareka et al., 2009). Numerous ferret studies report 
similar results. The ability for airborne particles to travel and initiate disease was 
implied by two postal workers who became infected with Anthrax following a known 
release of spores and no other known exposures (Fennelly et al., 2004). Biologically 
active airborne particles carry public health significance given the potential for 
prolonged suspension and scenarios of exposure before removal occurs or through 
recirculated air that has not been filtered or sterilized. Studies of biological decay in 
aerosolized virus maintained in a rotating drum demonstrated infectious potential for 
influenza (Harper, 1961) and coronavirus (Ijaz et al., 1985) after 23 hours and 6 days, 
respectively. Although the exact sizes of the laboratory generated aerosols used were 
not reported, these studies demonstrate prolonged infectiousness in particles <10µm. 
The rate of biological decay as a function of temperature and relative humidity has 
been characterized through laboratory manipulation of viral laden droplets in Yang et 
al., 2012; and through airborne simulations with bacteriophage Phi6, a surrogate for 
influenza and coronaviruses, in Prussin et al., 2018. Reduced decay corresponded 
with lower droplet salt concentrations associated with high and low vapor pressures, 
consistent with epidemiologic observation of peak transmission during the hot and 
rainy season in the tropics, and the cold and dry season in temperate climates. 
However other research using aerosolized virus from human airway epithelial fluid 
suggests that influenza virus remains infectious independent of relative humility 
(Kormuth et al., 2018). This latter work may be more convincing given the use of a 






Inhalation of airborne virus and deposition at a vulnerable locus in the respiratory 
tract can initiate infection. A human challenge study demonstrated an infectious dose 
for inhaled influenza A aerosols as low as 0.6-3 TCID50 (Alford et al., 1966). A study 
of exhaled breath from confirmed influenza cases showed that 99 and 87% of 
particles were less than 5 and 1µm, respectively (Fabian et al., 2008). This shows that 
exhaled breath aerosols are well within the size range to penetrate the lower lung. 
Fine particle aerosols exhaled from naturally infected influenza cases have been 
shown to carry infectious virus (Lindsley et al., 2015, 2010; Milton et al., 2013; Noti 
et al., 2012; Yan et al., 2018).   Given that epidemiologic, laboratory, and challenge 
studies fail to definitively confirm human airborne transmission and produce valid 
risk models, there is an urgent need for methods that maximize external validity to 
community settings and enable confirmation of transmission modes for a range of 
ARIs. Observation of community transmission provides an ideal platform to validate 
risk models that parameterize the aforementioned aerobiologic path – viral aerosol 
generation, persistence, and deposition – leading to valid estimation of infectious 
dose. Observation of exposed, asymptomatic individuals satisfies the concerns of 
Fraser et al., 2004, which identified asymptomatic cases as key to pushing R0 above 
1.  
 
Studies of influenza transmission mode and the anisotropic hypothesis 
 
Hand hygiene and face masks have been assessed for their potential to reduce 





Cluster-randomized trial with hand hygiene and facemask interventions found mild 
reductions in risk among intervention users (effect for hand hygiene and facemask 
groups, separately) that did not reach statistical significance (Aiello et al., 2012). This 
finding was consistent with those from studies performed in Hong Kong and Bangkok 
that showed the effect of hand hygiene plus facemask to be small at best (Cowling et 
al., 2013a, 2009; Simmerman et al., 2011). A similar result was observed for 
crowded, urban households in upper Manhattan after 19 months of follow-up in 509 
households (Larson et al., 2010). However a meta-analysis showed that hand hygiene 
plus facemask interventions were associated with a statistically significant 27% 
reduction in transmission risk, while hand hygiene alone had no significant effect, 
showed a trend toward reducing risk under higher humidity and suggesting a 
predominance of aerosol transmission in temperate climates that is weakened in 
tropical climates (Wong et al., 2014). Given that facemasks have been assessed to 
reduce viral RNA copies contained in coarse aerosols by 25-fold and fine aerosols by 
2.8-fold, if such reductions are associated with reduced transmission risk, then the 
meta-analysis findings make sense (Milton et al., 2013). Several other studies and 
review papers provide make a case for the role of airborne particles in influenza 
transmission (Nikitin et al., 2014; Tellier, 2009; Tellier et al., 2019).  
 
The hypothesis that influenza is anisotropic (Milton, 2012)– that the route of 
transmission influences disease presentation (Tellier et al., 2019) – is supported by 
early studies of human exposure to influenza contained in aerosols and nasal droplets 





in typical, influenza-like disease characterized by fever and cough, compared with 
nasal mucosa exposure representative of contact and droplet routes. Henle et al., 1946 
observed similar findings for those with nasal inoculation. Furthermore, community 
infected cases documented by Knight and colleagues exhibited similar 
symptomatology as Alford’s infected volunteers, suggesting a natural tendency 
toward aerosol transmission. These findings were recently borne out in ferrets where 
aerosol-infected animals not only presented with more severe symptoms but also shed 
more virus than their nasally-inoculated counterparts (Gustin et al., 2011).  
 
Overview of thesis 
 
The human challenge-transmission trial, Evaluating Modes of Influenza Transmission 
(EMIT), used in this research was designed to achieve an expected 40% SAR, 
however achieved an actual SAR of 1.3%. This finding on its own fails to provide 
definitive results regarding transmission modes. Comparison of this result with the 
proof-of-concept study that achieved an SAR of 8.3% under much lower exposure 
and ventilation motivates discussion about the role of ventilation and exposure to 
airborne pathogens (Killingley et al., 2012). The next question is whether the EMIT 
human volunteers experimentally infected by intranasal droplets simulate naturally-
acquired infections to a comparable degree. Fortunately, to address this question 
EMIT funded a study of community influenza cases presenting with influenza-like 
illness. Finally, using the CO2 data from the transmission trial, and knowledge of 





Donors’), we can apply the rebreathed-air equation, a modification of the Wells-Riley 
equation, to estimate an infectious quanta generation rate and RNA copy number per 
infectious quanta (Rudnick and Milton, 2003a). Findings from these analyses 
generate new knowledge about influenza infection, disease, and transmission and 






MINIMAL TRANSMISSION IN AN INFLUENZA A (H3N2) 
HUMAN CHALLENGE-TRANSMISSION MODEL WITH 
EXPOSURE EVENTS IN A CONTROLLED 
ENVIRONMENT 
 
By Jonathan S. Nguyen-Van-Tam, Ben Killingley, Joanne Enstone, Michael Hewitt, 
Jovan Pantelic, Michael Grantham, P. Jacob Bueno de Mesquita, Robert Lambkin-
Williams, Anthony Gilbert, Alexander Mann, John Forni, Catherine J. Noakes, Min 
Z. Levine, LaShondra Berman, Stephen Lindstrom, Simon Cauchemez, Werner 
Bischoff, Raymond Tellier, and Donald K. Milton, for the EMIT Consortium. 





Uncertainty about the relative importance of modes of influenza transmission, 
particularly airborne droplet nuclei (aerosols), fuels controversy concerning 
recommendations for healthcare worker protection during pandemics. In-depth 
review by an expert panel, a proof-of-concept study, and an international workshop 
concluded that human challenge-transmission studies in well-controlled environments 
would be the most promising approach to fill this critical knowledge gap.  
 
Methods 
Healthy, seronegative volunteer ‘Donors’ (N=52) were randomly selected for 
intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2). Seronegative 





were exposed to Donors for four days. IRs wore face shields and hand sanitised 
frequently to limit large droplet and contact transmission. Numbers of Donors and 
days of Recipient exposure were increased compared to proof-of-concept to increase 
secondary attack rate (SAR). Symptoms were monitored and viral shedding in 
nasopharyngeal swabs and exhaled breath viral aerosols were quantified by reverse-
transcriptase PCR (qRT-PCR). Serological specimens were analysed for evidence of 
seroconversion. (ClinicalTrials.gov number NCT01710111). 
 
Findings 
Intranasal inoculation produced an infection rate of 81% (42/52); 60% (25/42) of 
infected Donors had influenza-like illness, 14% (6/42) had fever, and 26% (11/42) 
had mild or no symptoms. Viral aerosol shedding was observed from 26% (11/42) of 
the infected Donors. One transmitted infection was confirmed by serology in a CR, 




The SAR observed was significantly less than 16% (p < 0·001) expected based on the 
proof-of-concept study SAR considering that there were twice as many Donors and 
days of exposure to Recipients. The main difference between these studies was 
mechanical building ventilation in the follow-on study, suggesting a possible role for 
aerosols. The low SAR limits this study’s ability to provide definitive evidence 






Research in context 
 
Evidence before this study 
The evidence base for influenza transmission is derived from studies that have 
assessed: virus deposition and survival in the environment; the epidemiology of 
disease in hospitals, nursing homes and other closed or semi-closed settings, 
pharmaceutical and non-pharmaceutical interventions in the setting of natural, and 
experimental infection, animal models, and mathematical models of transmission. 
These approaches have so far failed to produce conclusive answers quantifying the 
relative importance of human-to-human transmission modes. Influenza challenge 
studies in humans have been conducted over several decades to investigate disease 
pathogenesis and the efficacy of antivirals and vaccines. Until recently, experimental 
challenge-transmission studies assessing human-to-human transmission had not been 
performed. In 2009, we demonstrated proof-of-concept that healthy seronegative 
volunteers inoculated intranasally with influenza A/Wisconsin/67/2005 (H3N2) 
would develop symptoms of influenza-like illness (ILI) and, during two days of 
household-like conditions without environmental controls, transmit infection to other 
seronegative volunteers. However, the routes of transmission in the proof-of-concept 
study were not determined and in retrospect, the outcome criteria for secondary 
infection in the proof-of-concept study were judged to be insufficiently rigorous. 
 





To our knowledge, this is the largest human influenza challenge-transmission study 
undertaken to date. The control of indoor air quality during exposure, of exposure 
modes via randomized intervention groups, and the analysis of viral shedding from 
the mucosa and exhaled breath were designed to allow for a comprehensive 
understanding of viral shedding and the potential for transmission by the various 
modes. The low overall secondary attack rate shows that, as currently implemented, 
the challenge-transmission model results in negligible transmission. The significantly 
lower than expected secondary attack rate, based on the results of the prior proof-of-
concept study, was possibly attributable to greater ventilation in the current study, and 
adds to evidence that limiting exposure to infectious droplet-nuclei (aerosols) may 
make an important contribution to controlling influenza transmission.   
 
Implications of all the available evidence 
Understanding the relative importance of influenza modes of transmission informs 
strategic use of preventive measures to reduce influenza risk in high-risk settings such 
as hospitals and is important for pandemic preparedness. Given the increasing 
evidence from epidemiological modelling, exhaled viral aerosol, and aerobiological 
survival studies supporting a role for aerosol transmission and the potential benefit of 
respirators (and other precautions designed to prevent inhalation of aerosols) versus 
surgical masks (mainly effective for reducing exposure to large droplets) to protect 
healthcare workers, more studies are needed to evaluate the extent of risk posed by 
different modes of transmission. Future human challenge-transmission studies should 





However, the low secondary attack rate also suggests that the current challenge-
transmission model may no longer be a more promising approach to resolving 
questions about transmission modes than community-based studies employing 
environmental monitoring and newer, state-of-the-art deep sequencing-based 




Influenza virus is a pathogen of global public health significance, but human-to-
human transmission remains poorly understood. In particular, the relative importance 
of the different modes of transmission (direct and indirect contact, large droplet, and 
aerosols (airborne droplet nuclei)) remains uncertain during symptomatic and 
asymptomatic infection (Brankston et al., 2007; Killingley and Nguyen-Van-Tam, 
2013; Tellier, 2009, 2006). 
 
The evidence base for influenza transmission is derived from studies that have 
assessed: virus deposition and survival in the environment; the epidemiology of 
disease; pharmaceutical and non-pharmaceutical interventions; animal models; and 
mathematical models of transmission. Those approaches have so far failed to produce 
conclusive data quantifying the relative importance of human-human transmission 






Infection control guidance for pandemic and seasonal influenza assumes that most 
transmission occurs during symptomatic infection, predominantly via large droplet 
spread at short range (1-2m).(Brankston et al., 2007)  Thus, social distancing 
measures are often proposed to mitigate the spread and impact of a pandemic; and 
hand washing and respiratory etiquette are promoted as ways to reduce transmission 
of seasonal and pandemic influenza. Evidence to support the possibility of aerosol 
transmission has grown over recent years (Cowling et al., 2013b; Kormuth et al., 
2018; Yan et al., 2018) and leads to controversies about when and if filtering 
facepiece respirators (and other precautions designed to prevent inhalation of 
aerosols) versus surgical masks (mainly capable of reducing large droplets and some 
fine particles) should be used to protect healthcare workers, particularly during a 
severe pandemic (Bischoff et al., 2013; Brankston et al., 2007; Makison Booth et al., 
2013; Milton et al., 2013; Tellier, 2009, 2006). 
 
An expert panel, after in-depth review of the challenges facing community- and 
workplace-based intervention studies and their failure thus far to provide definitive 
evidence regarding the relative contribution of the various modes, concluded that a 
human challenge-transmission study would be a more promising direction for future 
research.(Killingley et al., 2011)  Influenza challenge studies in humans have been 
conducted to investigate disease pathogenesis and the efficacy of antivirals and 
vaccines. Challenge studies assessing human-to-human transmission had not been 
performed (Killingley et al., 2011). In 2009, we demonstrated proof-of-concept that 





A/Wisconsin/67/2005 (A/WI), an H3N2 virus, would develop symptoms of 
influenza-like illness (ILI) and, under two days of household-like conditions without 
environmental controls, transmit infection to other seronegative volunteers. This 
suggested that larger scale human challenge-transmission models might be useful to 
evaluate modes of transmission. A subsequent international workshop discussed these 
findings and the potential that human challenge-transmission studies, with appropriate 
interventions, monitoring of aerosol shedding, and environmental controls, could 
provide definitive results (Snider et al., 2010). Here, we report a large follow-on 
study, including design factors aimed at assessing the importance of aerosol 
transmission in human-to-human transmission of influenza virus. 
 
Materials and Methods 
 
The randomized challenge-transmission trial took place from March to June 2013 in a 
closed quarantine facility, was conducted with written informed consent from healthy 
volunteers in accordance with the principles of the Declaration of Helsinki, in full 
compliance with UK regulatory and ethical (IRB) requirements, and registered with 
ClinicalTrials.gov (number NCT01710111). Volunteers, screened for serologic 
susceptibility, were randomly selected for intranasal challenge with A/WI (Killingley 
et al., 2012) – becoming ‘Donors’ (D). After allowing for a short incubation period, 
Donors were then introduced to other sero-susceptible volunteers – ‘Recipients’ (R) – 
under controlled household-like conditions for four days. Recipients were randomised 





evaluated to interrupt large droplet transmission but to be permissive to aerosols (SI 
Appendix 2.1); in addition, IRs hand sanitised (using alcohol-based Deb® 
InstantFOAM, 72% ethyl alcohol) once every 15 minutes to minimise the possibility 
of contact transmission. IRs were only allowed to touch face via single use wooden 
spatulas. Thus, IRs would be exposed to influenza only via aerosols. CRs did not 
wear face shields or use hand sanitiser and were allowed to touch face freely; 
therefore, CRs would have been exposed via all routes of transmission consistent with 




Influenza A/WI manufactured and processed under current good manufacturing 
practices (cGMP) was obtained from Baxter BioScience, (Vienna, Austria). Stocks of 
this virus preparation have been sequenced and its evolution in the upper respiratory 
track of inoculated volunteers extensively analysed (Sobel Leonard et al., 2016). 
 
Screening 
Volunteers were screened from 3-56 days in advance of the experiment to determine 
humoral immunity to A/WI before undergoing further screening against inclusion and 
exclusion criteria (SI, Appendix 2.2). Volunteers needed to be healthy, between the 
ages of 18 and 45 years, not living with anyone deemed at high risk of influenza 
complications on discharge, and not to have had a seasonal influenza vaccine in the 





quarantine entry for repeat serology, although results were not available until after the 
study. An initial screening haemagglutination inhibition assay (HAI) titre of ≤10 was 
considered evidence of susceptibility to infection.  
 
Power calculation 
We calculated, based on the reported SAR of the proof-of-concept study,(Killingley 
et al., 2012) (SI, Appendix 2.2) that over a range of scenarios the statistical power of 
the whole study would be between 63% and 84%, typically 80% in the most realistic 
scenario, if a sample size of 125 Recipients was achieved (70 IR, 55 CR). To increase 
the SAR from that observed in the proof-of-concept study, we opted to inoculate 4 
(rather than 2) Donors per 5 Recipients and to conduct exposure events on days 1-4 
(rather than 2-3) post inoculation.  
 
Study Design and Conduct 
Pre-exposure 
Screened, eligible, volunteers entered a closed, quarantine unit on Day -2 and were 
randomised to Donor or Recipient (IR and CR) groups; thereafter Donors and 
Recipients were segregated. Donors and Recipients were immediately screened for a 
panel of 7 imported ‘contaminant’ respiratory viruses (influenza A, B; adenovirus; 
respiratory syncytial virus; parainfluenza 1, 2, 3) by a direct fluorescence antibody 
assay (DFA) (LIGHT DIAGNOSTICS™ SimulFluor1 Respiratory Screen, Merck 
Millipore) and any with a positive test were immediately discharged. On day 0 (zero) 





0.5ml per nostril of a suspension containing 5·5 log10TCID50/ml of influenza A/WI 
(Zaas et al., 2013, 2009). 
 
Exposure Events 
The study was conducted in three separate identically-designed quarantine events 
(Q1, Q2, and Q3). From Day 1 to Day 4 of each quarantine event, all volunteers took 
part in an Exposure Event (EE). Individual Donors and Recipients were each 
allocated to a single exposure room per day where they interacted at close distances 
for approximately 15 hours/day, for four consecutive days. In-room staff supervised 
activities such as playing board games, watching films, playing pool and table 
football, whilst ensuring that volunteers mixed freely, and that IR volunteers 
complied with face shield use, hand sanitisation and no-touch-face rules. Donor, IR 
and CR groups were moved into different corners of the rooms for meal breaks, and 
Donor and Recipient groups were housed separately at night, including further 
separation and withdrawal of any Recipients with symptoms to prevent any 
contamination of the results by Recipient-Recipient secondary transmission. Five 
exposure rooms were used ranging from 17-30m2 floor area and 50-87m3 volume. 
Four Donors were non-randomly allocated to each exposure group to ensure even 
distribution of subjects actively shedding virus. This was achieved by assessing 
symptom scores and the results of influenza rapid tests (Quidel Sofia®) performed on 
Days 1 and 2. From Day 2 onwards, Donors remained in their allocated group and 
were not redistributed further. Once assigned to an exposure group, Recipients 





like illness (ILI) and were withdrawn to a separate isolation area. On each day of EE, 
each exposure group rotated to a different exposure room. 
 
Environmental controls 
Each exposure room was assessed pre-quarantine by building and ventilation 
engineers and thereafter modified to achieve a ventilation rate of approximately 
4L/second/person (based on planned occupancy during the study), temperature range 
18-22oC, and relative humidity 45-65%, to produce conditions favourable to influenza 
transmission,(Lowen et al., 2007) balanced against tolerability for occupants, and the 
capability of the building systems to provide a controlled environment comparable 
across all three quarantine studies. During each EE, rooms were monitored at 5-
minute intervals for CO2 concentration (as a proxy for ventilation rate), temperature 




All subjects underwent thrice daily monitoring of respiratory and systemic symptoms; 
each symptom was reported as grade 0 (not present) to 3 (severe). Paired venous 
blood specimens for serology were taken on Day -2 and Day 28. Nasopharyngeal 
swabs (NPS) were taken daily from all subjects. Respiratory specimens were analysed 
by quantitative reverse-transcriptase PCR (qRT-PCR) and serological specimens by 
HAI and microneutralisation (MN) assays. The qRT-PCR and HAI were performed in 





Track Diagnostics qRT-PCR kit) and the U.S. Centers for Disease Control and 
Prevention (CDC), Atlanta; MN assays were performed by CDC as described 
previously.(World Health Organization, 2011) 
 
Exhaled breath sampling 
Donors were assigned to provide exhaled breath samples on two, randomly selected 
days within the exposure event, collected using a Gesundheit-II cone collection 
apparatus allowing for fractionation of particle sizes into ‘fine’ <5μm and ‘coarse’ 
≥5μm aerosol samples (McDevitt et al., 2013; Milton et al., 2013). Each sample 
collection session lasted for 30 minutes. Breath samples were concentrated, extracted, 
stored at -80˚C, and evaluated by qRT-PCR using protocols and materials specified 




After completion of the EE, Donors were discharged on active treatment with 
oseltamivir (75mg b.i.d. 5 days), whereas Recipients were observed for 7 days, then 
discharged with oseltamivir on day 8. All volunteers attended for 28-day (+/-3 days) 







Respiratory symptoms, defined as self-reported grade ≥1 of runny nose, stuffy nose, 
sneeze, sore throat, cough, or shortness of breath ‘lasting ≥24 hours’ (SI, Appendix 
2.2). Fever was defined as temperature >37·9 oC.  
 
Symptomatic was defined as evidence of any respiratory symptom lasting ≥24 hours 
during study days 1-6.  
 
Influenza-like Illness (ILI) was defined as an illness >24 hours duration with: either 
fever and at least one respiratory symptom; or two or more symptoms of grade ≥1, 
one of which must have been respiratory; eligible non-respiratory symptoms were 
headache, muscle/joint ache, and malaise.  
 
Laboratory confirmed infection was defined as: a 4-fold or greater rise in HAI or MN 
titres between Day -2 (baseline) and Day 28; or two or more positive NPS test results 
by qRT-PCR. These differed from the proof-of-concept study, which used 
seroconversion or a single positive nasal wash (SI, Appendix 2.5). 
 
Comparisons were made between groups using Fisher’s exact test for binomial 









Between January and June 2013, 496 seronegative (HAI ≤ 10) volunteers underwent 
study-specific screening and 166 entered the quarantine unit, of whom 127 proved 
suitable for final study entry. Thirty-nine subjects were discharged before inoculation 
or exposure per protocol as described in methods. Three separate quarantine EEs took 
place in March, April, and June 2013 involving Q1: 41 (20 D; 11 CR; 10 IR), Q2: 31 
(12 D; 9 CR; 10 IR) and Q3: 55 (20 D; 15 CR; 20 IR) subjects respectively, with 4 
Donors and 4 to 7 Recipients per exposure group. No serious adverse events were 
recorded in volunteers who commenced the study. Information about volunteer 
baseline characteristics and group randomisation is given in SI Appendices 3 and 4. 
 
Environmental control 
In Q1 relative humidity averaged 40% (Standard Deviation 9%), room temperature 
averaged 20·2 oC (0·4 oC) and CO2 concentration averaged 1430ppm (110ppm). For 
Q2 and Q3, respectively, the corresponding values were 44% (4%), 21·4oC (0·3 oC), 
1810ppm (160ppm), and 57% (4%), 21·4oC (0·3 oC), 1810ppm (160ppm). Outdoor 
CO2 concentration proxies, taken from the average of CO2 measurements during 
2:00am-3:00am were 418, 435, and 422 ppm, for Q1, Q2, and Q3, respectively.  
 
Donor status 
Donor status is summarised by quarantine study in Table 2.1. Over all quarantines 
combined, intranasal inoculation produced an infection rate of 81% (42/52) among 
inoculated volunteers. Of the 42 lab-confirmed infected Donors 25 (60%) had ILI and 






Ten Donors had greater than anticipated immunity on admission, as identified by 
retrospective serology (HAI > 10 or MN ≥ 80). Four of the 10 seroconverted (i.e. had 
a 4-fold rise in HAI or MN titres) between admission to quarantine and follow-up. 
Five of the 10 met laboratory case definition by qRT-PCR including all four who 
seroconverted. The one additional qRT-PCR positive case had positive swabs on 
study days 2 and 3 in Q2.  
 
Virus shedding by donors 
Overall, 36 Donors had NPS that tested positive by PCR for A/WI. Of these 36: 53% 
(n=19) were positive on day 1 post-challenge; 94% (34) on day 2; 97% (35) on day 3; 
86% (31) on day 4; 92% (33) on day 5; and 67% (24) on day 6 (Figure 2.2). 
 
Aerosol shedding was determined for 25 Donors on day 1, 31 on day 2, 30 on day 3, 
and 24 on day 4, and for a total of 36 person-days in Q1, 34 person-days in Q2, and 
40 person-days in Q3. Aerosol shedding from infected Donors, detected in 
Gesundheit-II samples, is summarised in Table 2.2. Six (7%) of the coarse and 14 
(16%) of the fine aerosol samples had detectable viral RNA. We observed aerosol 
shedding from 11 (26%) of the 42 successfully infected Donors. The geometric mean 
(GM) and geometric standard deviation (GSD) for coarse and fine aerosol viral RNA 
copy numbers per 30-min sample were 3·1E+3 (3·3) and 5·3E+3 (4·6), respectively. 
The maximum levels of shedding into coarse and fine aerosols were 2·79E+4 and 







Recipient status is shown in Table 2.3. There were similar rates of symptomatic non-
ILI and ILI in both IR and CR groups; no Recipient developed fever. One infection 
was confirmed by serology (HAI increased from ≤10 to 40 and MN increased from 
10 to 320) in a CR subject who was symptomatic and whose symptoms met the 
definition of ILI, but whose qRT-PCR evaluations were persistently negative. Two 
other CR were transiently qRT-PCR positive but neither met laboratory criteria for 
PCR positivity. Both were asymptomatic and had no change from baseline serology. 
Thus, there was only one confirmed transmission event. The CR and IR group SARs 
(2·9% and 0%) were not significantly different (p = 0·47).  
 
To compare these results with the SAR from the proof-of-concept study, we 
recomputed the latter results using the current more stringent outcome criteria. The 
adjusted proof-of-concept SAR was 8·3% giving an expected SAR of 16%. The 
observed SAR for the current study was not significantly different than that of the 
adjusted SAR from the proof-of-concept study, but was significantly lower than the 
expected doubling of the SAR (1·3% overall, p < 0·0001; and 2·9% for CR, p = 
0·035). Comparisons of observed and expected SAR using the proof-of-concept study 








To our knowledge, this is the largest human influenza challenge-transmission study 
undertaken to date. We applied measures to control and standardise environmental 
conditions and ventilation rates within and between exposure events, to emulate as far 
as possible indoor winter conditions when respiratory virus spread is maximal. We 
particularly sought to maintain low humidity conditions which have been associated 
with enhanced transmission (Lowen et al., 2007) and increased virus viability (Yang 
et al., 2012), together with a low ventilation rate to maximise recipient exposure to 
airborne virus. The near absence of transmission to control Recipients suggests that 
contact and large droplet spray did not contribute substantially to transmission under 
the conditions used in these EEs. The significantly lower than expected SAR in this 
study compared with the proof-of-concept study suggests aerosols as an important 
mode of influenza virus transmission in this model. The overall low SAR suggests 
that Donors in this model were minimally contagious and prevents definitive 
assessment of the modes of transmission.  
 
Having reported an SAR of 25% (3/12) in our earlier proof-of-concept study, we 
expected to observe an SAR of >25%, having doubled both the duration of the 
exposure and the number of Donors in each quarantine (Killingley et al., 2012). 
Indeed, the study was designed to examine an SAR of 40% in CR versus 20% in IR 
which would have required 125 Recipient volunteers; this was not met (R=75) and 






However, the outcome criteria used in the proof-of-concept study, which included as 
positive a single NPS positive by qRT-PCR without seroconversion, were made more 
stringent in the present study by requiring two or more NPS positive by qRT-PCR in 
the absence of seroconversion (SI Appendix 2.5). Applying the proof-of-concept 
criteria to the current study gives an SAR of 4% (3/75) overall, while applying the 
stricter criteria used in this study to the proof-of-concept study gives an SAR of 8·3% 
(1/12) rather than 25%. Given the lower than planned enrolment and the stricter 
outcome criteria, this study was doubly underpowered.  
 
The SAR reported here were well below expectations and were significantly lower 
than the expected SAR based on design changes developed to at least double the 
SAR. These observations raise two questions: 1) Why were SARs, using stringent 
criteria, low in both studies and what are the implications for future human challenge-
transmission studies? 2) Why was the SAR significantly lower in the present study 
compared with the expected doubling of the rate observed for the proof-of-concept?  
 
The low SAR in these studies suggests that, unless a much greater SAR can be 
achieved, type II error associated with underpowering will be a major obstacle to 
successful use of human challenge-transmission studies. Potential areas to consider 
addressing in order to raise the SARs in future studies include the virus used, the 
route of inoculation, susceptibility of the human volunteers, the rate of viral shedding 






In the proof-of-concept (2009) and follow-on (2013) studies we used a GMP A/WI 
challenge virus manufactured by Baxter BioScience (Vienna, Austria). Both studies 
produced similar clinical and serological infection rates (typically 60-70% and 70-
75%, respectively) after inoculation via nasal instillation, and similar spectrums of 
clinical illness severity in Donors. The illnesses we observed were similar to the 
range seen in healthy adults in the community, from asymptomatic to febrile 
symptomatic infection (Hayward et al., 2014). Thus, skewed illness severity does not 
seem to explain the low SAR. 
 
The virus preparation used in this study has been used in other human challenge 
studies with similar rates of infection via nasal instillation (Sobel Leonard et al., 
2016). Using deep sequencing, Sobel Leonard and colleagues showed that a sample 
of the Baxter stock “was at least partially adapted” to the egg and/or tissue 
environments in which it was produced (Sobel Leonard et al., 2016). They also found 
that nasal instillation of the stock into human volunteers resulted in rapid purification 
selection, although a fixed variant in the HA gene remained. We have performed a 
BLAST search and identified the fixed variant (G70A/D8N) in deposited sequences 
of wild-type H3N2 viruses. This suggests that, on its own, the fixed HA variant is 
unlikely to have been a key alteration. These results suggest that it is unlikely that the 
virus stock was the primary cause of the low SARs. But, the impact of positive 
selection of the challenge virus for growth in the production environment, rather than 
for human transmissibility, remains a potential contributing factor to consider in 






The route of infection with influenza virus is known to matter in the setting of 
experimental infection, with aerosolized virus infectious at lower doses and more 
likely to result in ‘typical influenza-like disease’ (fever plus cough) than intranasal 
inoculation (Alford et al., 1966; Henle et al., 1946). This anisotropic property 
(Milton, 2012) of influenza virus is not unique among respiratory viruses; e.g. it is 
exploited by the live, unattenuated adenovirus vaccine (Couch et al., 1963).  The 
implication for human challenge-transmission studies, however, may be that 
increased rates of lower respiratory tract infection via aerosol inoculation might be 
required to achieve sufficiently high rates of donors with fever, cough, and 
contagiousness to achieve a useful SAR.  
 
In the current quarantine-based human challenge-transmission model, consistent with 
historical precedent, screening for susceptibility was undertaken primarily by HAI 
antibody screening, although it is recognised that screening by MN titre or other 
assays (Park et al., 2018; Tang, 2012) could be an alternative or adjunctive approach. 
However, the exact correlates of immunity and severity using novel immunological 
assays have not been validated and selecting subjects based on these assays would 
have added substantial complexity and costs. Six Donors and five Recipients in the 
present study were discovered, in retrospect, to have seroconverted during the 3 to 
56-day interval prior to entering the quarantine facility, despite having as short a 
delay as possible between final screening for HAI and quarantine entry. However, the 





microneutralization tests. Prior immunity, as measured by the HAI and MN assays, 
does not therefore, appear to have been a major limitation nor account for failure to 
transmit from readily infected Donors to identically screened Recipients. Regarding 
future studies, however, as novel immune correlates of influenza protection and 
severity become established, additional approaches beyond HAI and MN assays 
could be employed for volunteer selection. This might enable selection of those likely 
to become infected, febrile, and have greater symptomatology including more 
frequent and greater levels of cough and runny nose. Unfortunately, such screening 
might also dramatically reduce the yield of suitable volunteers and substantially 
increase overall study costs. 
 
Results from serial nasopharyngeal swabs in Donors indicate that over 80% were 
positive by qRT-PCR testing on one or more post-challenge days. Thus, failure to 
shed virus into nasal secretions cannot explain the low SARs. The results from breath 
sampling with the Gesundheit-II device indicate that 26% (11/42) of infected Donors 
had virus detectable in exhaled air during the same period. By comparison, virus 
shedding into exhaled breath was detected in 84% (119 of 142) of symptomatically 
presenting influenza cases sampled on one to three days post onset of symptoms, 
mostly recruited from young adults on a college campus (Yan et al., 2018). When 
compared on a per-sample basis, infected Donors shed detectable virus less frequently 
than naturally infected college campus cases (Yan et al., 2018) in both coarse (7% 
and 40%, respectively) and fine aerosols (15% and 76%); all assays for both groups 





comparison was limited to positive aerosol samples from each study population, the 
average quantities of virus detected were similar (within 1 log), for the Donors as for 
the college community cases (GM coarse 3·1E+3 and 1·2E+4, GM fine 5·3E+3 and 
3·8E+4, respectively). The maximum exhaled breath viral aerosol from the 11 Donors 
was two to four logs lower than from the college campus cases (maximum coarse 
2·8E+4 and 4·3E+8, and maximum fine 8·0E+4 and 4·4E+7, respectively) (Yan et 
al., 2018). While this difference may merely represent the low probability of 
sampling from the tail of a log-normal distribution with only 11, as compared with 
119 cases, it may be relevant to the low SAR in the challenge-transmission model if 
aerosols disseminated by rare supershedders account for most transmission. If 
aerosols are largely derived from the lower respiratory tract, as has been suggested by 
analysis of the college community cases, this would also suggest that future 
challenge-transmission studies should employ methods designed to increase the 
frequency of lower respiratory tract infection.   
 
The proof-of-concept study was conducted in a hotel room with closed windows and 
thermal control provided only by a recirculating air conditioning unit. While the 
ventilation rate was not measured, it was likely to have been extremely low for the 
number of occupants, with only a small, intermittent, bathroom extract and natural 
building infiltration providing fresh air. The ventilation rate of 4 l/s/person during the 
main study was low compared to 10 l/s/person recommended in UK design standards 
(Chartered Institution of Building Services Engineers, 2015) but was likely 





significantly higher viral aerosol concentrations during the proof-of-concept EEs, 
assuming similar generation rates from Donors in both experiments. Given that the 
Donors in the two studies were similar in other respects, differences in shedding rates 
seem unlikely. Therefore, the difference in SAR between this study and the expected 
SAR based on design changes and prior results are possibly due to differing 
ventilation conditions. The implication for future challenge-transmission studies, 
given that the ventilation rate in the current study was as low as possible with a single 
pass ventilation system, is that recirculating air conditioning systems similar to that in 
the proof-of-concept study should be employed to limit dilution ventilation and 
maximize exposure to aerosols. This will be especially important if Donors in future 
studies continue to represent the lower end of the aerosol shedding spectrum seen in 
naturally infected cases.  
 
Achieving temperature and humidity to simulate winter conditions was challenging, 
particularly in Q3, conducted in June 2013 when the average external conditions were 
16oC and 64% relative humidity. It was necessary to strike a balance between 
volunteer comfort and conditions favourable to transmission, both of which were 
constrained by the capability of the mechanical systems in the building. However, the 
relative humidity in the current study overlapped with that during the proof-of-
concept study, which ranged between 38 and 53%, and thus, eliminated humidity as a 






Despite this study not having produced the planned SAR, it yields important findings. 
First, although fewer viral challenged subjects had virus-laden aerosols than seen in 
people with natural infections presenting with influenza-like symptoms, those 
volunteers who did produce viral aerosols did so at a rate similar to the average 
symptomatic naturally infected case. Second, given that a subset of the infected 
volunteers had moderate viral aerosol shedding in this model, observation of 
transmission via aerosols in quarantine studies may be strongly dependent on the 
dilution ventilation rate. Third, low risk of transmission to Control Recipients 
suggests that contact and large droplet spray transmission were not important modes 
of transmission in this model. The overall low SAR compared to that observed in the 
proof-of-concept study suggests that, given the main difference between the studies 
was the indoor air ventilation rate, aerosol transmission may be an important mode of 
influenza virus transmission between adults. Finally, sensitivity of transmission to 
details of the Donors selected, environment, and activity during exposure events, 
suggest that if a successful transmission model can be developed, carefully designed 
studies may be useful for investigating specific, targeted intervention strategies for 
prevention of specific transmission modalities. However, sensitivity to experimental 
conditions also demonstrates that it will be challenging to generalise the results of the 
quarantine-based transmission model to broad conclusions about the relative 
importance of aerosol, droplet spray, and contact modes of transmission. These 
complexities of the challenge-transmission model suggest that community-based 
transmission studies employing deep-sequencing based molecular epidemiologic 





or barracks, may be more attractive alternatives than previously thought. 
Unfortunately, although an important role for aerosols in transmission of influenza, at 
least between adults, is hinted at when comparing the proof-of-concept and current 
studies, this challenge model cannot provide a definitive answer to the importance of 








Table 2.1. Infected Donor Status 
 
Clinical Illness 
N (% of Infected) 
Laboratory Confirmed Infection Criteria4 




N/N (%) Symptomatic5 Febrile6 ILI7 
PCR Confirmed 
Infection 
PCR Confirmed Infection 
and Seroconversion 
Seroconversion by 
HAI : MN : Either 
11 15/20 (75) 11 (73) 4 (27) 8 (53) 12 (80) 11 (73) 12 : 14 : 14 
22 11/12 (92) 7 (64) 0 (0) 5 (45) 10 (91) 8 (73) 9 : 7 : 9 
33 16/20 (80) 14 (88) 2 (12) 12 (75) 14 (88) 12 (75) 14 : 11 : 14 
Total 42/52 (81) 32 (76) 6 (14) 25 (60) 36 (86) 31 (74) 35 : 32 : 37 
1 Via retrospective serology, on admission to quarantine four donors were found to have greater than anticipated immunity: three by HAI (>10), 
one of which seroconverted, and one by MN (≥80, and this donor also seroconverted).  
2 Via retrospective serology, on admission to quarantine two donors were found to have greater than anticipated immunity: one by MN and one by 
both HAI and MN. Neither of these donors seroconverted.  
3 Via retrospective serology, on admission to quarantine four donors were found to have greater than anticipated immunity prior to inoculation: 
two by HAI, one of which seroconverted; one by MN, and one by both HAI and MN, and this donor seroconverted.  
4 Laboratory confirmed infection was defined by evidence of acute infection based on: Seroconversion (four-fold or greater rise in either HAI or 
MN titres between the day -2 and day 28 serum specimens), and/or PCR confirmed infection (two or more positive NPS test results by qRT-
PCR). 
5 Symptomatic was defined as evidence of any respiratory symptom lasting ≥24 hours during study days 1-6, where "respiratory symptom" means 
self-reported grade ≥1 of runny nose, stuffy nose, sneeze, sore throat, cough, or shortness of breath, and where "lasting ≥24 hours" means 
evidence of a respiratory symptom during 3/3 symptom observations within a single day, or evidence of a respiratory symptom over two 
consecutive days at any frequency (i.e., occurring ≥1 out of three symptom observations on two consecutive days).  
6 All febrile cases met criteria for symptomatic. 
7 Influenza-like illness (ILI) was defined as an illness lasting ≥24 hours, during study days 1-6, with either: fever >37·9°C plus at least 1 
respiratory symptom of grade ≥1, or ≥2 symptoms of grade ≥1, at least one of which must be a respiratory symptom, where "respiratory 
symptom" and "lasting ≥24 hours" are as defined above and where the possible non-respiratory symptoms include headache, muscle/joint ache, 





Table 2.2. Exhaled Breath Viral RNA Detection and Copy Number Among Infected Donors by Quarantine Event and 
Aerosol Fraction 
 Coarse Aerosol (>5μm) Fine Aerosol (≤5μm) 















1 15 27 1 (7) 1 (4) 2.79e+04 3 (20) 5 (19) 3.32e+04 
2 11 30 3 (27) 3 (10) 2.16e+03 3 (27) 4 (13) 1.80e+04 
3 16 32 2 (12) 2 (6) 1.73e+03 5 (31) 5 (16) 1.70e+03 
Total 42 89 6 (14) 6 (7) 6.31e+03 11 (26) 14 (16) 1.76e+04 
* The arithmetic mean RNA copy number used data from positive samples only. The geometric means (GM) and geometric standard deviations 






Table 2.3. Recipient Status 
 
Clinical Illness (% of Exposed) 
Laboratory Confirmed Infection Criteria4  














Seroconversion by  
HAI : MN : Either 
11 
Control (CR) 0/11 (0) 4 (36) 0 (0) 3 (27) 0 (0) 0 (0) 0 : 0 : 0 
Intervention (IR) 0/10 (0) 2 (20) 0 (0) 1 (10) 0 0 0 (0) 0 : 0 : 0 
22 
Control (CR) 1/9 (11) 2 (22) 0 (0) 2 (22) 0 (0) 0 (0) 1 : 1 : 1 
Intervention (IR) 0/10 (0) 3 (30) 0 (0) 2 (20) 0 0 0 (0) 0 : 0 : 0 
33 
Control (CR) 0/15 (0) 6 (40) 0 (0) 4 (27) 0 (0) 0 (0) 0 : 0 : 0 
Intervention (IR) 0/20 (0) 6 (30) 0 (0) 2 (10) 0 0 0 (0) 0 : 0 : 0 
Total 
Control (CR) 1/35 (3) 12 (34) 0 (0) 9 (26) 0 (0) 0 (0) 1 : 1 : 1 
Intervention (IR) 0/40 (0) 11 (28) 0 (0) 5 (12) 0 0 0 (0) 0 : 0 : 0 
1 Via retrospective serology one of 11 CR were found to have greater than anticipated immunity prior to inoculation by HAI, and two of 11 CR 
were found to have greater than anticipated immunity prior to inoculation by MN. None of these CR seroconverted. One of 10 IR were found to 
have greater than anticipated immunity prior to inoculation by HAI, and two of 10 IR were found to have greater than anticipated immunity prior 
to inoculation by MN. None of these IR seroconverted.  
2 Via retrospective serology none of the nine CR were found to have greater than anticipated immunity prior to inoculation. None of the 10 IR 
were found to have greater than anticipated immunity prior to inoculation. 
3 Via retrospective serology one of 15 CR were found to have greater than anticipated immunity prior to inoculation by HAI, and two of 11 CR 
were found to have greater than anticipated immunity prior to inoculation by MN. None of these CR seroconverted. Two of 20 IR were found to 
have greater than anticipated immunity prior to inoculation by MN. Neither of these IR seroconverted.  
4 Laboratory confirmed infection was defined as described in Table 2.1 and methods. 









Figure 2.1. Schematic showing study timelines, physical segregation arrangements 







Figure 2.2. Viral detection in donors by day of exposure event. A) Columns show the 
proportion of all 42 infected donors who were positive for viral shedding as 
determined by qRT-PCR for coarse (>5µm) and fine (≤ 5µm) aerosols, and 
nasopharyngeal swabs. B) Mean and standard deviation error bars for qRT-PCR cycle 
threshold values from the positive nasopharyngeal swabs. C) Virus quantified from 
exhaled coarse and fine breath aerosols by qRT-PCR; the boxes show the inner-
quartile range (IQR) with a band to indicate the median, and whiskers extending to 




COMPARISON OF INFLUENZA A VIRAL SHEDDING IN 
EXHALED BREATH AEROSOLS FROM 
EXPERIMENTALLY INFECTED VOLUNTEERS AND 




It has long been known that nasal inoculation with influenza A virus tends to produce 
mild infections. Whether these infections are similar to mild natural infection and 
may be useful for studying human-to-human transmission remains an open question. 
We compared the influenza A viral aerosol shedding from volunteers nasally 
inoculated with A/Wisconsin/2005 (H3N2) and adults naturally infected with 
influenza A H3 recruited from a college community during 2012-13, selected for 
influenza-like illness with objectively measured fever or a positive Quidel QuickVue 
A&B test. Propensity scores were used to control for differences in symptom 
presentation observed between experimentally and naturally infected groups. Among 
39 experimentally infected influenza H3 cases with qRT-PCR positive 
nasopharyngeal swabs, symptom scores peaked on day 3 post nasal inoculation; 
Among 83 naturally infected influenza H3 cases, symptom scores were maximal on 
the first day post-onset of symptoms. On the day of peak aerosol shedding, median 
symptom scores for experimental infection were upper respiratory 4 (IQR 2, 5), lower 
respiratory 0 (0, 1), systemic 1 (0, 2), cough 0 (0, 1), and cough count 0 (0, 6) and for 
natural infections 7 (5, 9), 3 (2, 4), 6 (4, 8), 2 (2, 3), and 22 (8, 40) respectively. 
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Twenty-eight percent of experimental and 86% of natural cases shed into fine particle 
aerosols (p<0.001). The geometric means (geometric standard deviation) of positive 
fine aerosol samples for experimental and natural cases were 5.1E+3 (4.72) and 
3.9E+4 (15.12), respectively. To compare the fine aerosol shedders (11 experimental, 
71 naturally infected) on their peak day of shedding, accounting for differences in 
illness severity, we computed 14 sets of propensity scores based on various 
combinations of symptom scores (upper, lower, systemic, total, cough), cough count 
during aerosol sampling, fever (> 37.9oC), temperature, nasopharyngeal swab Ct 
value. Using each set of propensity scores for matching, stratification, and inverse 
weighting, demonstrated the almost complete lack of overlap between groups 
(standardized group difference 86% in best model) such that a propensity score 




There is uncertainty about the extent to which mucosal contact versus expiratory 
droplets contribute to influenza virus infection risk between humans. Studies that 
challenged humans by nasal instillation of virus, and others that challenged with 
aerosolized virus suggest that upper respiratory mucosal exposure, as opposed to 
airborne exposure results in more mild, afebrile illnesses (Alford et al., 1966; Little et 
al., 1979; Henle et al., 1946). Anisotropic infection is defined by Milton as infection 
whereby transmission mode influences illness presentation (Milton, 2012), has been 
used to characterize human influenza (Tellier et al., 2019). To minimize health risk 
associated with experimental human influenza infection, recent human challenge 
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models have adopted viral inoculation by nasal instillation (Killingley et al., 2011). 
Temporal associations between symptomatology and nasal and throat mucosal viral 
load following symptom onset have been reported among volunteers receiving 
intranasal influenza virus challenge and secondary household cases in Hong Kong 
(Carrat et al., 2008; Ip et al., 2016; Lau et al., 2010). Other analyses of the Hong 
Kong household transmission data did not observe temporal associations between 
symptom severity and upper respiratory viral load (Lau et al., 2013), and observed 
upper respiratory mucosal viral loads (Tsang et al., 2016, 2015) or respiratory 
symptoms (Wardell et al., 2017) to be poorly predictive of transmission to household 
secondary cases, suggesting that other biomarkers of contagion such as exhaled 
breath aerosols should be explored. The current study compares fine aerosol shedding 
between influenza A/H3 nasally inoculated and naturally infected cases to test 
whether experimentally nasally infected have similar risk and rate of fine aerosol 
shedding compared with mild, natural cases infected by any mode. Selection bias was 
introduced by sampling from symptomatic naturally infected cases with a positive 
QuickVue rapid test or febrile illness >37.8C plus cough or sore throat, whereas the 
true symptomatology profile for all naturally-acquired infections is likely to include a 
range of illness including many asymptomatic infections (Hayward et al., 2014). 
Propensity scores were used in an attempt to reduce the impact of this selection bias 
and isolate the mode of infection as the main difference between the experimental and 






Study design and data collection 
Study design and data collection procedures for the EMIT human-transmission trial 
and the observational study of naturally infected influenza cases University of 
Maryland campus community of are described in Nguyen-Van-Tam et al., 2019 and 
Yan et al., 2018, respectively. Relevant to current analyses, viral shedding was 
measured from nasopharyngeal (NP) swabs taken daily during the four days of 
quarantine exposure (days 1-4 post inoculation of experimental, nasally inoculated 
cases, or viral ‘Donors’) and on up to three days post-symptom onset for the naturally 
infected. Each experimental case provided half-hour exhaled breath specimens into a 
Gesundheit-II bioaerosol sampler (G-II) (McDevitt et al., 2013) on two to four days 
within four days of nasal inoculation. The G-II collects exhaled breath aerosols in fine 
(≤5µm) and coarse (>5µm) fractions. Among the naturally infected, participants who 
met case definition for influenza (either positive QuickVue rapid test, or oral 
temperature >37.8 C plus cough or sore throat) and presented within the first three 
days of symptom onset, were invited to provide G-II exhaled breath specimens for up 
to three consecutive days. Exhaled breath from both studies were evaluated using the 
standard CDC qRT-PCR primers and probes at the University of Maryland 
laboratory. Nasopharyngeal swabs from experimental and natural case were evaluated 
by qRT-PCR in separate labs using the same reagents. Assays were not tested against 
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a plasmid standard for experimental cases, thus limiting comparison of swabs to the 
cycle threshold (Ct) values. 
 
Symptom scores were measured three times per day for experimental cases and once 
per day for natural cases during a research clinic visit where exhaled breath was 
collected. In the analysis, as opposed to averaging multiple symptom score 
measurements per day for experimentally infected cases, scores taken closest in time 
to exhaled breath collection were selected for analysis. Upper respiratory score was 
sum of runny nose, stuffy nose, sneezing, sore throat, earache symptom scores (range 
0-15). Lower respiratory score was the sum of shortness of breath, and cough scores 
(range 0-6). Systemic symptom score was the sum of malaise, headache, muscle/join 
ache scores (range 0-9). Observed cough counts were recorded during breath 
collection. Experimental cases were defined as those with a qRT-PCR-positive a 
nasopharyngeal swab test on at least two of six follow-up days, or on one day plus 
serological evidence of infection. Natural cases were defined as those who met case 
criteria and had a single, qRT-PCR-positive nasopharyngeal swab on the day of 
enrollment.   
 
Statistical Analysis 
Tobit regression was used impute fine aerosol RNA copy number for qRT-PCR 
replicates below detection limit where one or more replicates for a sample had 
detectable RNA. Imputation of RNA copies was not done for samples without any 
replicates above detection limit, as done in Yan et al., 2018. It was more reasonable to 
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impute, as done by Yan and colleagues, all aerosol replicates below detection limit 
because there were a minority of fine aerosol samples below detection limit (14%). It 
is less reasonable to do the same for the experimentally infected population where 
72% of the observations would be imputed. In the current analysis exhaled breath 
samples were run in duplicate except for a few instances where assays were repeated 
in which case there were more than two replicates per sample. Here, Tobit regression 
to impute non-detectable replicates was performed only for positive samples (i.e., 
samples with qRT-PCR detectable RNA in at ≥1 replicate) for both experimentally 
and naturally infected cases, to maximize comparability. When performed, the Tobit 
regression predicted RNA copy numbers for all replicates in positive samples with ≥1 
nondetectable replicates was used. For both experimentally and naturally infected 
populations, Tobit models consisted of fixed effects of cough and study day with 
random effect of person. Fixed effects for these models were selected based on a 
priori evidence of an association with fine aerosol shedding (Yan et al., 2018).  
 
Cough count was imputed for 5/84 missing observations for experimental and 3/146 
for the natural cases. For the experimental case group, a linear mixed effect model 
with fixed effects of cough symptom score, study day, and sex, with a random effect 
of subject was used to predict cough count. Given that the unstandardized residuals 
were all within plus or minus 5 coughs (with 3 instances between 5 and 10 coughs), 
the model was accepted and used to impute the 5 missing cough counts in the 
experimental case group. To impute missing cough counts in the naturally infected 
group, we first used Tobit regression with fixed effect of study day and random effect 
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of person to estimate fine aerosol shedding values for each of the 146 observations. 
Next, to estimate a cough count for each of the three missing cough observations we 
used a linear mixed effect model with fixed effects of cough, estimated fine aerosols 
shedding, sex, age, BMI, and day post-symptom onset. 
 
The naturally infected cases used in this analysis were sampled from a symptomatic 
population and selected on the basis of positive QuickVue rapid test or febrile illness 
>37.8C plus cough or sore throat. On the other hand, experimentally infected cases 
were not selected on the basis of their symptoms, but rather on RT-PCR evaluation of 
their nasopharyngeal swab viral loads. This approach may result in a symptom 
distribution more representative of that of the overall population of influenza 
infections, which include a range in illness severity including many asymptomatic 
infections (Hayward et al., 2014). Thus, we expected differences in study design to 
introduce imbalance in symptom severity between groups. If symptoms are associated 
with aerosol shedding in an unselected population, then this would be an important 
variable to control for with the goal of assessing the mode of infection on shedding. 
To minimise the effect of this bias, we attempted to balance covariate distributions 
between populations with propensity score models. We evaluated model 
specifications by the standardized differences and variance ratios between 
comparison groups for each covariate, after adjustment by propensity score matching, 




Data were cleaned and analyzed in R (v3.5.1 R Development Core Team, Vienna, 
Austria) and SAS Studio (Release 3.7 (Enterprise Edition), v9.4M6, Cary, NC). 
Unadjusted effects on risk and rate of fine aerosol shedding were estimated for 
symptom scores, observed cough count, age, and sex. Analysis of shedding risk used 
all exhaled breath observations. Analysis of shedding quantity was refined to the 
maximum shedding day for each aerosol shedder. All analysis scripts and readme 





For 39 experimental and 83 naturally infected influenza A H3 cases, there were 84 
and 146 exhaled breath collection instances respectively. Of the 39 confirmed 
experimental cases, 36 were qRT-PCR positive two or more days, 31 of whom also 
had serological evidence of infection; three were qRT-PCR positive on one day only 
and also had serological evidence of infection. There were three, other, inoculated 
challenge study volunteers with serological evidence of infection but never a qRT-
PCR positive result. None of these shed virus at detectable levels into aerosols. A 
total of 52 challenge study volunteers were inoculated, giving an infection rate under 
the current criteria of 75%. The naturally infected influenza A H3 case population 
was drawn from a broader group of cases with various influenza subtypes including 





Cough count data was missing in five (6.0%) of the 84 exhaled breath collection 
instances for experimental cases and three (2.1%) of the 146 instances for the natural 
cases and missing values were imputed. Both study populations of young adults were 
generally healthy. The experimental group were on average 10 years of age older than 
the naturally infected group however the naturally infected group had a wider range 
of ages. The experimental cases were more likely to be male while naturally infected 
cases were balanced by sex (Table 3.1). Experimental cases were asymptomatic 
(12.8%) or had illness mostly characterized by mild, upper respiratory symptoms. 
There were small peaks in upper respiratory, lower respiratory, systemic, and cough 
scores, and cough counts on day 3 post inoculation. Naturally infected cases had 
much more severe symptoms scores and greater cough counts, with symptom scores 
peaking on day 1 post symptom onset and observed cough count during exhaled 
breath collection peaking on day 2 post symptom onset. Given the respective peaks in 
symptom severity, the day 3 post inoculation best aligned with day 1 post symptom 
onset (Figure 3.1). For all days combined, mean symptom scores and cough counts 
are substantially higher in natural compared with experimental infections (Table 3.1). 
Using the repeated symptom measures taken at all exhaled breath visits in both 
groups (84 experimental, 146 natural), scaled, density plots of upper respiratory 
symptoms and observed cough count showed the greatest similarity between the two 




The risk of shedding virus into coarse and fine aerosols for experimentally infected 
was 6/39 (15%) and 11/39 (28%), and for naturally infected 45/83 (54%) and 71/83 
(86%) respectively (Table 3.2). These differences in proportions for coarse and fine 
shedding between experimental and natural groups were significant with p<0.001. 
Shedding quantity by geometric mean and percentile is displayed in Table 3.2. 
Median coarse and fine aerosol shedding quantity between the groups was 
significantly higher for natural cases (coarse p<0.001; fine p<0.001). This finding 
remained significant after restricting Wilcoxon rank sum comparisons to positive 
samples (coarse p=0.032; fine p<0.003). Geometric mean (GM) (geometric standard 
deviation, GSD) for coarse and fine aerosols was 2.7E+3 (3.26) and  5.1E+3 (4.72) 
for experimental cases, and 1.8E+4 (13.9) and 3.9E+4 (15.12) for natural cases. Peak 
aerosol shedding was observed on day 3 post inoculation and day 1 post symptom 
onset for experimental and natural cases, respectively. Figure 3.2 aligns the two 
populations on these peak shedding days. Peak aerosol shedding days matched those 
of peak symptom scores (Figure 3.1). Elevated shedding risk and rate for naturally 
compared to experimentally infected cases is shown in Figure S3.2. On the day of 
peak aerosol shedding, median symptom scores for experimental infection were upper 
respiratory 4 (IQR 2, 5), lower respiratory 0 (0, 1), systemic 1 (0, 2), cough 0 (0, 1), 
and cough count 0 (0, 6) and for natural infections 7 (5, 9), 3 (2, 4), 6 (4, 8), 2 (2, 3), 
and 22 (8, 40) respectively.   
 
When using all of the detectable qRT-PCR nasopharyngeal swab samples from days 
1-6 post inoculation (N=179) and 1-3 post symptom onset (N=143), nasopharyngeal 
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swab Ct values were notably lower for naturally compared with experimentally 
infected cases (Figure S3.3). We aligned peak (lowest) Ct values temporally: day-1 
post symptom onset in naturally infected cases with day-3 post inoculation; 
differences in Ct values increased after this alignment day. 
 
To improve comparability between groups, we selected maximum aerosol shedding 
day observations for each volunteer and naturally infected case. Comparisons 
between shedding restricted to day 3 post inoculation against day 1 post symptom 
onset would have resulted in substantial loss of data since there was not always an 
exhaled breath sample collected on day 3 post inoculation. Restricted to maximum 
shedding observations for fine and coarse shedding, the GM (GSD) for coarse and 
fine aerosols was 2.7E+3 (3.26) and 5.0E+3 (5.83) for experimentally, and 2.1E+4 
(16.47) and 5.1E+4 (17.04) for naturally infected cases. Figure S3.4 shows shedding 
frequency and strength from maximum shedding instances for each group.  
 
Predictors of shedding risk and rate were restricted to maximum observed fine aerosol 
samples per study subject since the number of positive coarse samples was small. 
Table 3.3 provides the mean and standard deviation for continuous covariates, with 
frequencies and proportions for categorical variables, for all covariates for the 
maximum fine shedding observations in experimental and natural cases. Symptom 
scores and cough counts were all much higher for naturally compared with 
experimentally infected cases. Upper respiratory symptoms score distributions 
overlapped the most between groups, while differences in the distributions of lower 
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respiratory, systemic, and cough symptoms scores, and cough count were more 
pronounced (Figure 3.3). 
 
Crude analysis of maximum observed fine aerosol shedding quantity with each 
covariate as the sole effect variable in the absence of covariate adjustment showed 
that only febrile status (>37.9oC) and body temperature were statistically significant 
predictors when experimentally and naturally infected cases were combined (Table 
3.4). Compared with afebrile cases, febrile cases shed 3.66E+6 (95% CI 3.8E+5 – 
6.9E+6) more viral RNA copies into fine aerosols. For a single degree Celsius 
increase in body temperature, cases shed 2.1E+6 (95%CI 1.6E+5, 4.0E+6) more viral 
RNA copies per half hour sample. There were no significant predictors of shedding 
rate among experimental cases alone and among natural cases, only febrile status 
(>37.9oC) was significantly associated with viral shedding with febrile cases shedding 
4.5E+6 (95% CI 7.1E+5 - 8.3E+6) RNA copies. Confidence bounds were wide for all 
effects. Of the experimentally infected, only males shed virus into aerosols. 
 
We also performed univariate analysis of fine aerosol shedding risk using data from 
all 84 and 146 exhaled breath collection visits from experimentally and naturally 
infected cases and controlling for random effect (Table S3.1). For the experimental 
cases, with the exception of systemic symptom score and body temperature all 
symptom-related covariates were significantly associated with fine aerosol shedding 
risk. For naturally infected cases, lower respiratory symptom, cough symptom, and 
cough count were significantly associated with fine aerosol shedding risk. For 
 
 57 
experimental and naturally infected cases, respectively, the odds (95% CI) of 
shedding into fine aerosols were 6.49 (1.14 – 37.09) and 1.35 (1.04 – 1.76) higher for 
a single unit increase in lower respiratory score, 7.49 (1.28 – 43.91) and 1.9 (1.2 – 
2.99) for a unit increase in cough score, and 1.29 (1.02 – 1.62) and 1.02 (1.00 – 1.04) 
for a single unit increase in observed cough count. Nasopharyngeal swab qRT-PCR 
cycle threshold (ct) value had a negative effect on shedding risk, as expected, and this 
effect was significant in experimental and combined cases. Although ct values in the 
experimental group were not standardized to an influenza A plasmid, as was done in 
analysis of naturally infected cases, lower ct values for a specific amplicon within 
qRT-PCR assays indicate higher RNA copy number. 
 
Propensity score models were used in an attempt to balance symptom and 
demographic covariates in order to reduce bias introduced by the selection of 
influenza cases in the experimental and naturally infected studies. We tested 14 
propensity model specifications based on various combinations of symptom scores 
(upper, lower, systemic, total, cough), cough count during aerosol sampling, fever 
(>37.9oC), temperature, nasopharyngeal swab Ct value. Model specifications were 
guided by the strength and statistical significance of univariate analyses (Table 3.4, 
Table S3.1). All covariates that were significantly associated with risk or strength of 
shedding for experimental, naturally infected, or combined groups were included. 
Additional covariates that had strong effects, on shedding risk or strength, yet were 
not significant at p = 0.05 level, were added to models. Each propensity score model 
provided a set of propensity scores (i.e., probability of membership in the naturally 
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versus the experimentally infected group) as well as a set of corresponding, linearized 
propensity scores. These propensity scores were then used to adjust the experimental 
and natural cases to improve overlap of all symptom and demographic covariates in 
an attempt to achieve population balance closer to randomization. We tried matching 
on the propensity score, stratifying the propensity score by sextiles, quintiles, 
quartiles, and tertiles, and inverse probability weighting by average treatment effect 
for the treated (ATT), and average treatment effect (ATE) where the naturally 
infected group was considered the “treatment” group (Table S3.2).  
 
Propensity score model 13 (covariates: fever, body temperature, and upper respiratory 
symptom score) and adjustment by inverse probability weighting for ATE minimized 
the standardized differences between the populations with a mean absolute value 
standardized difference of 86. After inverse probability weighting adjustment with 
model 13, balance improved for some covariates, however not to the point where they 
could be considered similar (Table 3.5). Although it is recommended (citation) that 
absolute standardized differences for covariates be close to zero and no greater that 
10% between comparison groups, and that variance ratios be close to one (perhaps 
between 0.5 and 2), this optimized model with weighted adjustment had a wide range 
(provide range) of absolute value standardized difference beyond 10% and variance 
ratios of up to 29.06 (Figure 3.4). The substantial differences between covariate 
distributions did not support the use of propensity score adjusted approaches for 
making comparisons between these populations. Appendix 3.3 includes further 






We compared aerosol shedding in influenza A cases infected naturally and by nasal 
instillation under experimental conditions. A minority of experimental cases shed 
virus into aerosols (28%) and all who shed into fine aerosols also shed into coarse 
aerosols. Although a far greater proportion of the naturally infected study population 
shed into fine aerosols (86%, unadjusted p-value <0.001), it is uncertain to what 
extent this is reflective of all naturally-acquired infections. Among the experimentally 
infected who did shed, the fine aerosol RNA copy GM was within a log10 of that for 
naturally infected cases (Table 3.2), which may not be meaningfully different (despite 
parametric test type-I error rate below 0.001). A more substantial difference in fine 
aerosol shedding rate was observed at the level of the overall distribution, with 
naturally infected cases more likely to shed at the highest observed levels and 
Wilcoxon Rank Sum test indicating very low chance of median overlap (p <10E-13). 
Compared with naturally infected cases at the 95th percentile of fine aerosol shedding, 
experimentally infected cases shed about 3 log10 fewer RNA copies. RNA copies 
shed into aerosols peaked on day 3 post nasal inoculation aligns with peak shedding 
on day 1 post symptom onset in naturally infected cases (Figure 3.2). This represents 
a peak in aerosol shedding of one day later than that observed in upper respiratory 
mucosal shedding reported in previous challenge studies (Carrat et al., 2008). Aerosol 
shedding peak is consistent with the 1-2 day post symptom onset nose and throat 
swab viral load peak observed in Hong Kong household contact surveillance studies 
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(Ip et al., 2016). Fine aerosol shedding was detected on days 2, 3, and 4 post 
inoculation in 45% (5/11), 64% (7/11), and 18% (2/11) volunteers with positive 
aerosol shedding respectively, supporting day 3 post inoculation as the peak day for 
shedding frequency among experimentally infected cases. There is no available data 
with which to compare temporal dynamics of experimental or natural infection 
aerosol shedding. 
 
If we take previous estimates of ~1-2 days (25th-75th percentile) as the influenza A 
incubation period (Lessler et al., 2009), plus about 1 day post symptom onset to reach 
peak aerosol shedding in the naturally infected population, then we would observe 
~2-3 days following exposure to virus, to reach peak aerosol shedding. This is 
consistent with the observed peak in aerosol shedding in the experimentally infected 
cases at 3 days post exposure by intranasal instillation, suggesting that the 
progression of infection from exposure to replication is similar. Observations of less 
significant decline in viral load from nasopharyngeal swabs compared with fine 
aerosols following peak shedding at day 1 post symptom onset (Yan et al., 2018), and 
a tendency for nasal viral load to overestimate transmission risk after day 3 post 
symptom onset (Tsang et al., 2015), suggests that aerosol shedding may better fit 
epidemiologically observed transmission dynamics over time in the household 
setting.  
 
The presentation of natural influenza A infection has been reported as asymptomatic 
in a majority of infections (Hayward et al., 2014; Leung et al., 2015) and selection of 
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naturally infected cases from the community based on positive QuickVue rapid test or 
febrile illness plus cough or sore throat, was expected to inflate proportions of 
moderate and severe illness. Experimental cases were asymptomatic (12.8%) or 
mildly symptomatic with little variation over four days post inoculation (Figure 3.1). 
Temporal trends in symptom severity are mildly supportive that day 3 post nasal 
inoculation aligns with day 1 post symptom onset in naturally infected cases (Figure 
3.1). Our findings are consistent with peak symptom score on day 3 post H3N2 
inoculation reported in a meta-analysis of human challenge studies (Carrat et al., 
2008). A multi-year household surveillance study in Hong Kong showed mean 
systemic and respiratory scores peaked on day of symptom onset (Ip et al., 2016). 
Although our naturally infected population did not have symptom observations on 
day of illness onset, peak symptom scores on day 1 post symptom onset (i.e., the first 
day of symptom follow-up in our study) could approximate this previous finding. 
When comparing symptom observations on the peak day of detectable fine aerosol 
shedding, naturally infected cases had higher symptom scores and observed cough 
counts (Table 3.3). 
 
Peak symptom severity and aerosol shedding coincided for both experimental and 
naturally infected cases, consistent with the temporal dynamics of other studies 
(Carrat et al., 2008; Ip et al., 2016; Lau et al., 2010). However, in regression analyses 
that restricted observations to the peak day of fine aerosol shedding, the effects of 
symptoms on fine aerosol shedding rate were generally weak and contained within 
wide confidence intervals. Only fever >37.9oC in the naturally infected group was 
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significantly associated with shedding strength. Previously, using data from all 
naturally infected influenza cases who met case criteria (including H1N1, H3N2, and 
B infections) we reported count as the only symptom associated with fine aerosol 
shedding strength (Yan et al., 2018). We also reported an association between upper 
respiratory symptoms and viral shedding into nasopharyngeal swabs but not aerosols, 
concluding that “the head airways made a negligible contribution to viral aerosol 
generation and that viral aerosols represent infection in the lung.” In the Hong Kong 
household transmission cohorts, viral RNA copies detected in combined nose and 
throat swabs were 1-2 log10 higher in symptomatic compared with asymptomatic or 
paucisymptomatic (i.e., no more than 1 symptom reported per day) infection, which 
may be driven by a portion of individuals presenting with more upper as opposed to 
lower respiratory symptoms (Ip et al., 2017). Further analysis of the Hong Kong data 
showed that the presence of respiratory symptoms was not associated with 
transmission probability except in the case of child-to-child transmission and cough 
or phlegm is detected (Wardell et al., 2017), suggesting a level of independence 
between the presence of symptoms and transmission probability among symptomatic, 
adult index cases. This would be consistent with the notion that fine aerosol shedding 
strength, independent of symptom presentation in primary cases, plays a role in 
driving transmission.  
 
In the current study, when assessing symptoms as predictors of viral shedding above 
the detection limit (Table S3.1), we show that lower respiratory symptom score, 
cough score, and cough count were positively associated with fine aerosol shedding 
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in both experimental and naturally infected groups, however upper respiratory 
symptom score and nasopharyngeal swab Ct value were associated, positively and 
negatively, respectively, with fine aerosol shedding only for experimentally infected 
cases. Taken together these findings may suggest that, among minimally symptomatic 
influenza A cases initiated by intranasal challenge, upper respiratory viral replication 
drives illness with a low probability of lower respiratory replication required for fine 
particle aerosol shedding. These data should be interpreted with caution given a lack 
of heterogeneity in symptom severity, with mild illness characteristic of the 
experimental cases and moderate to severe illness characteristic of the naturally 
infected population. It may be for this reason that other studies have given mixed 
results with respect to observing associations between symptomatology and 
nose/throat viral load (Lau et al., 2013, 2010).  
 
Age was not associated with probability or strength of fine aerosol shedding in either 
the experimental or naturally infected study populations (Tables 3.4, S3.1). This 
finding is expected given that both study populations consisted of healthy, young 
adults. Despite the mean age different in years was about 8 years (Table 3.1), 
seasonal epidemic influenza subtypes generally do not pose heterogeneous infection 
risk across the young adult ages in the studies. Only males shed into aerosols in the 
experimentally infected group. This finding might be explained by the low probability 
of shedding into aerosols (28%) on top of the low number of females in the study 
(N=11). This difference could be worrisome for the generalizability of the challenge 
model used in EMIT. There may be immunological explanations for this phenomenon 
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that would call for further investigation. There is preliminary evidence from studies 
of vaccine-associated immunity that TLR7 is involved in adaptive immune response 
to influenza virus through B cell activation (Onodera et al., 2016). This could provide 
women with an immune system advantage given TLR7 encoding on the X-
chromosome and incomplete inactivation of the second allele (Berghöfer et al., 2006; 
Fischinger et al., 2019). The uncertainty surrounding sex-related immunology against 
influenza infection warrants future work.  
 
Given the associations between symptoms and shedding observed in the experimental 
and naturally infected study populations we attempted to adjust for these symptoms to 
understand the direct effect of experimental versus natural infection as a proxy for 
infection mode on the viral load in fine particle aerosols on the maximum day of 
shedding for each study volunteer or participant. The DAG describing the 
relationships between the variables is described in Figure S3.5. Propensity score 
modelling failed to balance the distribution of covariates in the experimental and 
naturally infected case groups and we concluded that the groups were simply too 
different to achieve an unbiased estimate of the main effect of group membership on 
shedding strength. Interactions terms and upper level terms were not included in 
propensity score models because of a lack of a priori rationale. Given the large 
standardized differences in the populations across numerous models it is unlikely that 
alternative model specifications would improve balance. If this, or other propensity 
score adjustments were to be considered for making group comparisons, further 
prerequisite assessment of the balance of propensity scores themselves, based on 
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Donald Rubin’s Rules would also warn against their use (Appendix 3.4). Thus, we are 
left with unadjusted shedding comparisons (Table 3.2) that do not avoid bias 
introduced with the selection bias of symptomatic naturally-acquired infections. Thus, 
assuming minimal contribution of potential confounders on the pathway between 
mode of inoculation and study population membership (i.e., age, sex, host immunity, 
virus pathogenicity, dose) we cannot conclude that the unadjusted differences in 
symptomatology and shedding are a result of mode of inoculation, or simply the 
result of the differences inherent in recruitment and enrollment procedures and 
potentially unobserved confounders in the absence of a randomized controlled design.   
 
There is growing evidence that airborne transmission plays an important role in the 
population spread of influenza (Cowling et al., 2013b; Nguyen-Van-Tam et al., 2019; 
Tellier, 2009; Tellier et al., 2019). Humans experimentally challenged to influenza 
virus by airborne particles were had a 50% risk of infection to a 0.6-3.5 TCID50 dose 
and exhibited increased propensity for moderate to severe illness with fever and 
cough compared with others experimentally challenged by nasal droplets (Alford et 
al., 1966; Little et al., 1979). The term anisotropic has been used to describe such 
infections where inoculation mode determines illness presentation (Milton, 2012). A 
population of cases with naturally-acquired infections would be expected to 
demonstrate a higher proportion of moderate-severe influenza-like illness compared 
with a population of cases exclusively infected by exposure to the nasal mucosa. We 
observed illnesses in experimentally infected cases mostly characterized by upper 
respiratory symptoms with minimal lower respiratory and systemic symptom scores. 
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Naturally infected cases presented with strong lower respiratory and systemic 
symptom scores, especially when compared with those of experimentally infected 
cases (Figures 3.1, 3.3). Compared with other symptoms, systemic scores declines 
more rapidly following day 1 post symptom onset, consistent with previously 
reported findings (Ip et al., 2016) and suggestive of the immune system clearing 
systemic infection. These findings suggest that natural infections observed here may 
be more likely to result in lung and systemic infection initiated by an airborne dose, 
whereas experimentally infected cases with nasal mucosal exposure had illness 
localized to the upper respiratory tract.  
 
 Identifying naturally infected reference groups that represent the true distribution of 
symptom severity presents a challenge. Although a substantial proportion of cases are 
asymptomatic, symptomatic community cases are prone for inclusion in 
epidemiologic studies upon seeking medical attention (Carrat et al., 2002). Multi-year 
sero-surveillance of large cohorts in the UK shows influenza infections presented 
asymptomatically at a rate of 77 per 100 person-seasons (Hayward et al., 2014). 
While noting the influence of study design, a meta-analysis of longitudinal studies 
using serological evidence of infection and controlling for background illness 
reported a 65%-85% asymptomatic fraction (Leung et al., 2015). The household 
transmission design, as conducted in Hong Kong, represents a powerful strategy to 
observe secondary cases before, during, and after exposure to a potentially infectious 
primary household case (Cowling et al., 2009). Still, considerations regarding 
generalizability aside, this design may be unable to detect short or mild infections 
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because nose and throat swab collection to confirm infection by RT-PCR occurred 
every several days and not daily. Additionally, the household design has so far not 
collected exhaled breath aerosols from primary or secondary cases. New studies with 
comprehensive surveillance of naturally-acquired influenza infection would be useful 
for addressing questions related to infectious potential in asymptomatic, and mild, 
moderate, severe infections.  
 
The infectious dose for airborne influenza, and the infectious potential of cases 
infected by various modes is largely unknown. If the typical fine aerosol shedding 
rate from influenza cases is important for driving airborne transmission, then our 
findings would indicate that nasal mucosal exposure in the experimental challenge 
model produces cases with airborne infectious potential similar to cases infected 
naturally by contact, large droplets, or fine aerosols. If above average shedders are 
important for driving airborne transmission (i.e., superspreader hypothesis), then 
infections acquired through nasal mucosa may not pose as much airborne infectious 
potential.  
 
If we assume that the symptomatic naturally infected UMD cases represent the upper 
1% of symptom severity and shedding strength in the overall population, and if we 
also assume that the experimental cases are representative of total community 
infections, the chances of an experimental case reaching the level of fine aerosol 
shedding observed in the naturally infected group would be .39% (1% of 39 
experimental cases). If shedders in the upper percentiles of shedding rate are 
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responsible for driving transmission, then it would take many more experimental 
cases to adequately simulate transmission events in a human transmission challenge 
trial model. This introduces logistical challenges and motivates work to identify, 
among naturally infected shedders, characteristics predictive of aerosols (and 
mucosal) shedding. It is plausible that symptomatic cases with observed high levels 
of aerosol shedding could be placed in a controlled exposure setting where recipients 
would receive exposure to just these symptomatic cases, however such a design 
would be resource intensive. 
 
We cannot make conclusive comparisons between the experimentally and naturally 
infected populations given the selection bias in the recruitment of the naturally 
infected comparison group. If we assume that virus used in the challenge model was 
appropriately pathogenic (i.e. representative of real wildtype virus with the dose, 
environmental, and host conditions required for infection), our observations are 
suggestive that the population of influenza infections naturally-acquired by any mode: 
a) present with a symptom profile suggestive of airborne infection, b) are more likely 
to shed virus into fine particle aerosols, and c) shed 2-3 log10 more viral RNA at the 
upper end of the shedding distribution. Future work should examine the relationships 
between inoculation mode, dose, environmental conditions, and host immunity across 
different age groups. In particular, immune responses to influenza virus by and across 
modes may vary between children and adults, with implications for subsequent 









Table 3.1. Demographics and symptomatology of influenza A Cases 
 Experimental Natural p value 
N-Participants 39 83  
Breath collection visits 84 146  
Age   < 0.001 
Mean (SD) 29.9 (7.0) 22.3 (7.6)  
Range 20.0 - 45.0 15.0 - 63.0  
Sex   0.003 
Female 11 (28.2%) 47 (56.6%)  
Male 28 (71.8%) 36 (43.4%)  
Frequency fever > 37.9oC (%) 6 (15.4%) 17 (20.5%) 0.502 
Temperature (C)*   < 0.001 
N-Missing 2 1  
Mean (SD) 36.6 (0.6) 37.3 (0.6)  
Range 35.3 - 38.4 36.3 - 39.7  
Upper respiratory symptom score   < 0.001 
Mean (SD) 1.4 (1.9) 7.0 (3.0)  
Range 0.0 - 6.0 0.0 - 15.0  
Lower respiratory symptom score   < 0.001 
Mean (SD) 0.2 (0.4) 3.2 (1.5)  
Range 0.0 - 1.0 0.0 - 6.0  
Systemic symptom score   < 0.001 
Mean (SD) 0.7 (1.2) 5.4 (2.4)  
Range 0.0 - 5.0 0.0 - 9.0  
Total symptom score   < 0.001 
Mean (SD) 2.2 (2.9) 15.5 (5.5)  
Range 0.0 - 11.0 4.0 - 29.0  
Cough symptom score**   < 0.001 
Mean (SD) 0.2 (0.4) 2.2 (0.8)  
Range 0.0 - 1.0 0.0 - 3.0  
Cough count***   < 0.001 
Mean (SD) 1.7 (4.8) 26.7 (32.5)  
Range 0.0 - 35.0 0.0 - 265.0  
Nasopharyngeal swab Ct value   < 0.001 
N-Missing 20 3  
Mean (SD) 27.1 (5.0) 22.6 (5.6)  
Range 17.0 – 36.3 13.1 – 38.1  
Symptom scores, body temperature, and observed cough counts are reported per visit, with 
multiple visits per person. Ten symptoms were rated from 0 to 3 with maximum possible 
composite score of 15 for upper respiratory, 6 for lower respiratory, and 9 for systemic 
symptoms. ANOVA (t-tests with equal variances) and chi-squared tests were used for 
continuous and categorical variables, respectively.   
 
* Tympanic temperature for experimental and oral for naturally infected cases. It is known that 
tympanic temperature is between 0.3 and 0.6 degrees C higher than oral temperatures. ** 
Cough symptom score is included  as part of the composite lower respiratory score. *** Cough 
count per half hour exhaled breath collection. 
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Table 3.2. Viral shedding into exhaled breath aerosols  
All experimental and natural infections 
  
Experimental Natural   
(39 subjects; 84 GII obs.) (83 subjects; 146 GII obs.) p value** 
  Coarse Fine Coarse Fine Coarse Fine 
No. positive 
subjects (%) 
6 (15) 11 (28) 45 (54) 71 (86) <0.001 <0.001 
No. positive 
samples (%) 









(15.12) <0.001 <0.001 
RNA copies by percentile 
25th  ND ND ND 1.3E+3   
Median  ND ND ND 8.8E+3 <0.001 <0.001 
75th  ND ND 8.8E+3 9.8E+4   
90th  ND 2.5E+3 8.2E+4 1.3E+6   
95th 1.3E+3 7.9E+3 9.7E+5 6.6E+6   
Maximum  3.4E+4 1.3E+5 4.9E+8 4.9E+7   
Maximum shedding observations for experimental and natural infections 
  
Experimental Natural   
(11 subjects; 11 GII obs.) (71 subjects; 71 GII obs.) p value*** 
  Coarse Fine Coarse Fine Coarse Fine 
RNA copies by percentile 
25th percentile  0.0E+  0.0E+  0.E+  3.0E+3    
Median  0.0E+  0.0E+  1.7E+3  1.3E+4  <0.001 <0.001 
75th percentile  0.0E+  1.1E+3  1.0E+4  1.4E+5    
90th percentile  1.4E+3  3.1E+3  4.2E+5  3.3E+6    
95th percentile  2.2E+3  6.4E+4  9.8E+5  1.2E+7    
Maximum  2.8E+4  8.0E+4  4.3E+8  4.4E+7    
Samples collected Days 1-4 post inoculation in the experimentally infected and Days 1-3 post 
symptom onset in the naturally infected. Shedding given per half hour sample.  
 
*GM, geometric mean. GSD, geometric standard deviation (only positive samples were included in 
computation of GM and GSD. Tobit regression was used to impute RNA copies for samples where 
there were replicates below detection limit); ND, not detected. **Fishers exact tests were used to 
compare binomial proportions between experimental and natural cases for fine and coarse shedding 
subjects and samples. Welsh’s t-test for unequal variance was used to compare GM. Wilcoxon rank 
sum test was used to compare medians. When restricting analysis to samples with detectable RNA 
quantities, the Wilcoxon rank sum test gave p-values of 0.0316 and 0.00275 for coarse and fine 
comparisons, respectively. *** When restricting analysis to samples with detectable RNA 






Table 3.3. Covariates in experimental and naturally infected cases from fine 
aerosol shedders on day of maximum shedding 
Variables  Experimental Natural  
Standardized 
Difference % 
P value  
(parametric)* 
P value  
(non-
parametric)** 
Age 31.09 (8.01)  21.82 (6.70)  -123.0  <0.001  <0.001  
Frequency ever febrile 
(%) 
4.95 (45) 28.40 (40) -18.5  0.599  1.000  
Temperature (oC)  36.76 (0.66)  37.46 (0.67)  99.9  0.001  <0.001  
Upper respiratory 
score  
3.64 (1.80) 7.01 (2.75)  117.4  <0.001  0.002  
Lower respiratory 
score  
0.46 (0.52) 3.37 (1.40)  176.7  <0.001  <0.001  
Systemic symptom 
score  
1.18 (1.25) 5.86 (2.10)  182.4  <0.001  <0.001  
Total symptom score  5.27 (2.61) 16.24 (4.70)  187.8  <0.001  <0.001  
Cough score 0.46 (0.52) 2.32 (0.75)  193.6  <0.001  <0.001  
Cough count  4.00 (6.42) 28.48 (28.10)  88.9  <0.001  0.002  
Nasopharyngeal swab 
Ct value  
23.18 (2.84)  22.40 (6.02)  -13.6  0.479  0.048  
Propensity score 0.44 (0.32) 0.93 (0.14)  204.3  0.000  <0.001  
Linear propensity score  -0.85 (2.74)  4.78 (3.05)  157.8  0.000  0.000  
Reporting mean (standard deviation) for each variable except for frequency ever febrile, from N=11 
experimental and N=71 naturally infected cases. The mean and max absolute value standardized differences 
were 130.3% and 204.3%, respectively. Kolmogorov-Smirnov test for the mean standardized difference was 
0.686 (p<0.001).Sex was removed because no females shed into fine aerosols in the experimental group. 
 
* t-tests; ** Kolmogorov-Smirnov tests 







Estimate (CI)  
Age 4.20E+2 (-2.59E+3, 3.43E+3)  5.62E+4 (-1.80E+5, 2.93E+5)  -1.68E+3 (-1.84E+5, 1.81E+5)  
Sex -  8.19E+5 (-2.33E+6, 3.97E+6)  1.87E+5 (-2.56E+6, 2.93E+6)  
Fever >37.9oC 1.00E+4 (-4.13E+4, 6.13E+4)  4.51E+6 (7.05E+5, 8.32E+6)  3.66E+6 (3.81E+5, 6.93E+6)  
Body temperature  1.39E+4 (-2.12E+4, 4.90E+4)  2.21E+6 (-1.14E+5, 4.53E+6)  2.06E+6 (1.60E+5, 3.96E+6)  
Upper respiratory score  -1.72E+3 (-1.51E+4, 1.16E+4)  -1.26E+5 (-7.03E+5, 4.50E+5)  5.90E+2 (-4.78E+5, 4.79E+5)  
Lower respiratory score  1.84E+4 (-2.58E+4, 6.26E+4)  -1.32E+5 (-1.27E+6, 1.00E+6)  1.82E+5 (-6.52E+5, 1.02E+6)  
Systemic symptom score  -6.40E+3 (-2.51E+4, 1.24E+4)  -4.03E+5 (-1.15E+6, 3.46E+5)  -5.90E+4 (-5.95E+5, 4.77E+5)  
Total symptom score  -1.55E+3 (-1.07E+4, 7.64E+3)  -1.35E+5 (-4.71E+5, 2.01E+5)  3.24E+3 (-2.32E+5, 2.39E+5)  
Cough symptom score (as continuous)  1.84E+4 (-2.58E+4, 6.26E+4)  1.41E+6 (-6.69E+5, 3.50E+6)  1.23E+6 (-1.64E+5, 2.63E+6)  
Cough symptom score (as factor) 
No symptom REF REF REF 
Mild 1.84E+4 (-2.58E+4, 6.26E+4) 1.02E+6 (-1.30E+7, 1.50E+7)  6.58E+5 (-5.02E+6, 6.33E+6) 
Moderate  - 9.92E+5 (-1.25E+7, 1.45E+7)  9.87E+5 (-4.21E+6, 6.19E+6) 
Severe  - 3.34E+6 (-1.01E+7, 1.68E+7)  3.33E+6 (-1.76E+6, 8.42E+6) 
Cough count  2.37E+3 (-9.56E+2, 5.69E+3)  2.12E+4 (-3.51E+4, 7.74E+4)  2.70E+4 (-2.26E+4, 7.67E+4)  
Nasopharyngeal swab Ct value -3.39E+3 (-1.15E+4, 4.75E+3)  -1.32E+5 (-3.94E+5, 1.30E+5)  -1.34E+5 (-3.74E+5, 1.06E+5) 
Effect of a single unit increase in temperature or symptom scores. Effect of febrile compares ever febrile >37.9oC to afebrile. Effect of sex compares 
male to female. Bolded values are significant at p=0.05. Only males shed into aerosols in the experimental group. Cough scores of 2 or 3 were never 
observed in the experimental group. Observations from the maximum fine aerosol shedding day for each subject were used (11 experimental, 71 




Table 3.5. Covariates with propensity score ATE weighted adjustment 




P value  
(parametric)* 
P value  
(non-
parametric)** 
Age  27.55 (7.11) 21.78 (6.00) -85.2 0.018 0.015 
Frequency febrile 
(%) 
2.42 (45)  (33) -24.9 0.640 1.000 
Temperature (C)  37.21 (0.67) 37.32 (0.66) 16.2 0.708 0.858 
Upper respiratory 
score  
3.991 (1.24) 6.37 (2.76) 90.0 0.000 0.242 
Lower respiratory 
score  
0.27 (0.47) 3.11 (1.37) 162.2 0.000 0.000 
Systemic symptom 
score  
1.20 (1.18) 5.04 (2.63) 132.8 0.000 0.008 
Total symptom 
score  
5.46 (1.98) 14.52 (5.46) 144.7 0.000 0.000 
Cough score 0.27 (0.47) 2.26 (0.71) 179.1 0.000 0.001 
Cough count  2.15 (4.73) 27.62 (25.47) 103.7 0.000 0.008 
Nasopharyngeal 
swab Ct value  
22.46 (2.01)  22.87 (5.54) 8.5 0.613 0.454 
Propensity score 0.69 (0.29) 0.78 (0.34) 27.2  0.571 0.044 
Linear propensity 
score  
0.90 (2.12) 3.39 (3.89) 68.6  0.051 0.044 
Reporting mean (standard deviation) for each variable except for frequency febrile, with weighted ATE 
adjustment used data from 5.38 experimental and 25.37 naturally infected cases. The mean and max 
absolute value standardized differences were 86.9 % and 179.1%, respectively. Kolmogorov-Smirnov 
test for the mean standardized difference was 0.609 (p<0.001). Sex was removed because no females 
shed into aerosols in the experimental group. 
 








Figure 3.1. Mean symptom scores and observed cough counts over time. Day 3 
post inoculation is aligned with day 3 post symptom onset. Upper respiratory 
score (sum of runny nose, stuffy nose, sneezing, sore throat, earache, score range 
0-15). Lower respiratory score (sum of shortness of breath, and cough, range 0-6). 
Systemic symptom score (sum of malaise, headache, muscle/join ache, range 0-9). 
Total symptom score (sum of all symptom scores, range 0-30). Symptoms scores 
were measured once, on each day of sample collection for natural infections, and 
three times per day for experimental infections. For experimentally infected cases, 
the symptom score measurement that was taken at the time closest to exhaled 
breath collection was used as the symptom for each day post inoculation. 
Observed cough counts were those recorded during half-hour exhaled breath 




Figure 3.2. Fine and coarse aerosol shedding over time. Includes all shedding 
observations from 84 (experimentally infected cases) and 146 subject-days 
(naturally infected cases). Day 3 post inoculation was aligned with day 1 post 
symptom onset. Detectable aerosol shedding in log10 aerosol copies, with boxes 
showing the inner-quartile range (IQR) with a band to indicate the median, and 






Figure 3.3. Comparison of self-reported symptoms and observed coughs from 
maximum fine aerosol shedding day observations. Includes data from 11 
experimental, 71 natural observations. Density plots, scaled so that the highest 
value for a single moment is equal to one, compare (A) upper respiratory 
symptoms (runny nose, stuffy nose, sneezing, sore throat, and earache, score 
range 0-15), (B) lower respiratory symptoms (shortness of breath, and cough, 
score range 0-6), and (C) systemic symptoms (malaise, headache, muscle/joint 
ache, score range 0-9). (D) Total symptom score (range 0-30). (E) Cough 
symptom score (range 0-3). (F) Observed cough counts with boxes showing the 
inner-quartile range (IQR) with a band to indicate the median, and whiskers 


























































































Figure 3.4. Balance diagnostics for propensity score adjustment by ATE 
weighting. ATE: Average treatment effect approach, where the naturally infected 
cases are considered “treatment.” Each naturally infected cases is weighted 
1/(propensity score) and each experimentally infected case is weighted as 1/(1 – 
propensity score). Plots were done using the propensity score model that led to the 
lowest mean standardized difference across all covariates (A) Absolute 
standardized differences between experimental and naturally infected case 
covariates plotted for each covariate, the propensity score (PS) and the linear PS. 
The dotted line represents 10%. Balanced populations should have absolute 
standardized differences close to zero and not exceeding 10%. (B) Variance ratios 
for naturally infected cases to experimental cases, plotted for each covariates, PS, 
and linear PS. Dotted lines represent 0.5 and 2, the range for which balanced 




ESTIMATING THE AIRBORNE INFLUENZA 
QUANTUM GENERATION RATE FROM A HUMAN 






Quantifying influenza transmission risk by airborne, contact, and large droplet 
spray transmission modes informs the strategic use of prevention strategies to 
reduce the burden of seasonal epidemics, and the threat of pandemics. We used 
data from the largest human influenza challenge-transmission trial (Evaluating 
Modes of Influenza Transmission, ClinicalTrials.gov number NCT01710111) to 
estimate the average generation rate of airborne infectious doses sufficient to 
infect 63% of exposed susceptibles (Well’s quantum of airborne infection). We 
quantified influenza A viral RNA exhaled into fine particle aerosols (≤ 5µm) from 
experimentally infected Donors and used the rebreathed-air equation to estimate 
the airborne quantum generation rate q and its relationship to RNA shedding. Out 
of 42 infected influenza Donors, 11 shed detectable levels of influenza RNA into 
fine particle aerosols with adjusted geometric mean 4.7E+3, geometric standard 
deviation 6.0, and range 2.6E+2 - 1.6E+5, accounting for observations below 
detection limit and where no exhaled breath sample was collected. The exposure 
room where the single transmission event occurred had one of the three highest 
inhalation exposures. The average quantum generation rates for infected Donors 
(N = 42) and aerosol shedding Donors (N = 11) were 0.029 (0.027, 0.03) and 0.11 
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(95% CI 0.088, 0.12) per hour, respectively. There were 1.4E+5 (1.0E+5, 1.8E+5) 
RNA copies shed into fine particle exhaled breath aerosols per quantum. We 
present methodology for estimating influenza airborne infectious dose to facilitate 
the prediction of secondary attack rates given measured or estimated infectious 
airborne viral source strength and indoor and outdoor CO2 concentrations. The 
estimate quantum dose generation rate appears reasonable and consistent with the 
limited scientific literature available for comparison. Further validation of these 




The substantial, annual global disease burden attributed to seasonal influenza and 
the threat of influenza pandemics demand increased preparedness. Yet efforts to 
improve vaccines, engineering controls, and other population prevention strategies 
are hindered by a lack of understanding about the competing risk contributions of 
contact, large droplet, and droplet nuclei (i.e., airborne) transmission modes. 
There is evidence that airborne transmission via virus contained in exhaled breath 
droplet nuclei likely plays a role in epidemics, and that influenza infections 
initiated this way lead to illnesses of greater severity (Henle et al., 1943; Knight et 
al., 1965; Alford et al., 1966; Couch et al., 1970; Little et al., 1979; Tellier, 2009; 
Hayden, 2012; Cowling et al., 2013a). Quantifying the risk posed by airborne 
transmission is widely accepted as a major goal for translational public health 
practice. To this end mathematical modelling techniques applied to droplet nuclei 




Wells postulated an airborne quantum as an infectious dose generated by an 
infected individual during exposure with a susceptible (Wells, 1955). The Wells-
Riley equation for estimating the probability of indoor airborne transmission 
requires assumptions of well-mixed air space and steady-state conditions and is 




=  1 − exp (−
𝐼𝑝𝑞𝑡
𝑄
)       (1) 
with P probability of infection for S exposed susceptibles, D secondary infections, 
I infectors in their infectious stage (i.e., when they are emitting virus), p breathing 
rate per indoor occupant, q quantum generation rate from each I, t exposure time, 
and Q outdoor air supply rate (Riley et al., 1978). Rudnick and Milton have 
described the q term as the “average infectious source strength of infected 
individuals.” They emphasize that a) q is not an organism but rather a dose that 
reflects the stochasticity of airborne contagion, and b) an infectious dose may not 
be greater than a single organism that reaches a vulnerable locus (Rudnick and 
Milton, 2003a).  
 
Rudnick and Milton’s rebreathed-air version of the Wells-Riley equation uses 
indoor and outdoor CO2 levels to estimate indoor occupant exposure to exhaled 
breath, based on the facts: a) droplet nuclei are emitted through the exhaled breath 
of infectious individuals and b) CO2 contained in exhaled breath is constant at 
38,000 ppm and is the predominant source of CO2 in buildings. Assuming a well-
mixed space, the rebreathed-air equation uses measured CO2 levels to directly 
estimate exposure to exhaled breath that may be contaminated with a quantifiable 
level of infectious particles. This approach enables exposure assessment under 
non-steady state conditions representing an advantage for practical exposure 
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assessment compared with the Wells-Riley equation. The rebreathed-air equation 




=  1 − exp (−
𝑓𝐼𝑞𝑡
𝑛
)       (2) 
where 𝑓 is the time-weighted average fraction of indoor air that is exhaled breath 
with n individuals in the room contributing CO2. Thus, 
𝐼
𝑛
 equals the fraction of the 
𝑓, or the “rebreathed fraction,” that is from an infectious individual.  
 
Solving the rebreathed-air equation for q requires measurement or estimation of 
the other variables and assurance that the exposure between infectious cases and 
susceptibles resulted in transmission to secondary cases, D. Such data could be 
derived from an experimental human transmission model, or intensive 
epidemiologic surveillance with accurate quantification of viral exposure by 
transmission mode. These study designs have so far been challenging to 
operationalize, and few have been carried out, however a 2013 US CDC-funded 
influenza transmission-challenge trial provides an appropriate dataset (EMIT; 
ClinicalTrials.gov number NCT01710111; (Nguyen-Van-Tam et al., 2019)). One 
transmission event was observed yielding an overall secondary attack rate (SAR) 
of 1/75 = 1.33% and Nguyen-Van-Tam and colleagues suggest a role for airborne 
transmission when discussing the findings in context. We use this trial data and 
apply the rebreathed-air equation to examine the relationship between airborne 
exposure and infection risk, to estimate an airborne infectious dose 63% (ID63) 
generation rate, q, for influenza, and to estimate the RNA copies in fine particle 






The EMIT challenge-transmission trial methods are described elsewhere 
(Nguyen-Van-Tam et al., 2019). In short, seronegative volunteers were 
randomised to viral ‘Donor’ (N=52), ‘Intervention Recipient’ (N=40) and 
‘Control Recipient’ (N=35) groups. Donors were inoculated with 0.5ml per nostril 
of a suspension containing 5.5log10TCID50/ml of influenza H3/Wisconsin/67/2005 
manufactured under current good manufacturing practices. Recipients were 
exposed to Donors for four consecutive days and assessed for evidence of 
infection. Continuous CO2 monitoring was conducted in exposure rooms where 
mechanical ventilation controlled indoor CO2 concentrations, relative humidity, 
and temperature to produce what were considered as favorable conditions for 
influenza transmission, while balancing the thermal comfort of volunteers, and the 
capacity of the building’s mechanical ventilation system to attain comparable 
conditions in exposure rooms throughout the study. Viral shedding into exhaled 
breath aerosols was collected from Donors with a Gesundheit-II (McDevitt et al., 
2013; Yan et al., 2018).  
 
Data were cleaned and analyzed in R Studio (Rv3.5.1 R Development Core Team, 
Vienna, Austria) and SAS Studio (Release 3.7 (Enterprise Edition), v9.4M6, Cary, 
NC). The development of new equations to evaluate the relationship between q 
and aerosolized RNA copies is described in Results. Empirical bootstraps with 





The rate of Donor viral shedding into exhaled breath aerosols was computed from 
samples with detectable viral RNA in one or both qRT-PCR duplicates with 
values imputed for samples where at least one duplicate was below detection 
limit. Imputed values were generated from Tobit regression (SAS Proc 
NLMIXED) (Twisk and Rijmen, 2009) with fixed effects of self-reported cough 
symptom and study day, and random effect of person, using 100 quadrature 
points. Tobit regression parameter coefficients were taken from generalized linear 
models (SAS Proc GENMOD) with fixed effects of self-reported cough symptom 
and study day. Self-reported cough symptoms were collected thrice daily on an 
ordinal scale 0-3 (3 most severe) and daily averages were used in regression 
models. 
 
For infected Donors who shed into aerosols with at least one detectable qRT-PCR 
replicate (“ever-aerosol-shedders”) on at least one study day, aerosol shedding 
was assumed to exist at levels below the detection limit in samples where one or 
no qRT-PCR replicates had detectable RNA and on days where no sample was 
collected. No Donors demonstrated detectable RNA in fine particle aerosols on 
day 1 of exposure so the fine aerosol shedding period was assumed to be study 
days 2-4. Tobit regression was used as described before using all symptom scores 
and exhaled breath sample data from ever-aerosol-shedders during study days 2-4. 
Parameter estimates for fixed effects for cough, day, and random effect of person 
were then used to estimate aerosol shedding rates for ever-aerosol-shedders on 




Laboratory evaluation of biological specimens by qRT-PCR was done alongside 
those described by Yan et al., 2018 and the assay’s limit of quantification was 
2000 RNA copies per half-hour sampling period, representative of the “most 
dilute sample that gave a positive result in all replicates”. University of Maryland 
dormitory room CO2 surveillance and calibration is reported in Jenkins, 2018. 
Sensitivity of indoor CO2 level on q and 𝜎 was performed by modulating indoor 
CO2 concentrations upwards and downwards by 10% intervals to +/-50%. Scripts 




Linking q with measurable airborne virus 
We applied the rebreathed-air equation to the EMIT transmission trial data to 
estimate an airborne influenza infectious dose generation rate, q, to give rise to 
1.33% SAR. Because of the controlled environment dictated by the experimental 
design, the single, secondary infection was assumed to have resulted from 
exposure to viral Donors. Based on the discussion in Nguyen-Van-Tam et al., 
2019, we assume for this analysis that the transmission event occurred via the 
airborne mode. Evidence described later supports this assumption.  
 
The transmission trial was carried out over the course of three, quarantine periods 
during which exposure events occurred in up to five exposure rooms over four 
days, where exposure between Donors and Recipients ranged from approximately 
13 to 16 hours per day. Quarantines 1, 2, and 3 used five, three, and five exposure 
rooms, respectively for a total of 13 exposure rooms. Recipients were assigned to 
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exposure groups (EGs) on day 1 and switched rooms each day with their group. 
Donors assigned to EGs on day 1 were reallocated on day 2 to new EGs where 
they remained through the end of exposure. Donor EG reallocation was done 
according to clinical presentation in an attempt to evenly distribute viral source 
strength. Donors never shed detectable influenza RNA into fine particle aerosols 
on study day 1 and airborne exposure on this day was considered negligible. 
Three Recipients were withdrawn from exposure at different time points due to 
symptom presentation in order to prevent a second generation of transmission; 
None tested positive for influenza by Sofia rapid test. Each EG had a defined 
airborne exposure as a function of the level of rebreathed air and rate of shedding 
into exhaled breath aerosols. The single transmission event occurred in quarantine 
2 EG C.  
 
The relationship between q and the observed rate of RNA copy shedding into fine 
particle exhaled breath aerosols per hour, ⋁, is defined by: 
𝑞 =  
⋁
𝜎
          (3) 
where 𝜎 is the number of RNA copies per ID63 and represents the difference 
between estimated RNA copy airborne exposure, and the viral RNA quantity that 
reaches a vulnerable locus in the respiratory tract and evades the host immune 




=  1 − exp (−
𝑓𝐼⋁𝑡
𝑛𝜎
)       (4) 
 
Exposure to exhaled breath from infectious case 
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The integrated exposure to exhaled breath over time in an indoor space, 𝑓, was 
computed for each EG by integrating over the CO2 concentrations observed in the 
room over the four exposure days (i.e., study days 1-4) after subtracting 
background CO2 levels and dividing by the constant CO2 concentration in exhaled 
breath, 3.8E+4. This fraction is described as the “rebreathed fraction” by Rudnick 
and Milton. Figure 4.1 plots observed CO2 concentrations in each exposure room 
during 5-minute intervals throughout each quarantine experiment. Background 
levels were computed as the average CO2 concentrations observed between 02:00 
and 03:00 hours in each exposure room during the four nights following daytime 
exposure events. Their arithmetic means (standard deviations) were 418.30 
(23.13), 434.55 (22.16), and 422.31 ppm (12.15) for quarantines 1, 2, and 3, 
respectively. During nights, viral Donors and Recipients were housed outside 
exposure rooms. No study staff occupied exposure rooms during this time either. 
Thus, the nighttime CO2 concentrations are good proxies for outdoor CO2.  
 




displayed in Figure 4.2a. Three EGs had no Donors who shed into fine particle 
aerosols (quarantine 1 EGs B and D, and quarantine 2 EG A). EG 4 in quarantine 
2 had a substantially higher 
𝑓𝐼
𝑛
 because there were two shedding Donors compared 
with a maximum of one in every other exposure room. Otherwise, EGs across all 
quarantines had relatively similar exposure to exhaled breath from Donors.  
 
Viral RNA shed into exhaled breath aerosols from infectious donors 
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Measured exhaled breath fine aerosol shedding rates enables translation of Donor 
exhaled breath exposure to viral inhalation exposure. Of the 52 inoculated donors, 
N=4, 41, 4, and 3 gave G-II samples on one, two, three, and four days, 
respectively for a total of 110 sampling instances. There were a total of 25, 31, 30, 
and 24 G-II samples collected on study days 1, 2, 3, and 4, respectively. Among 
inoculated donors, 42 were determined to have been infected with influenza A by 
serology, or by two days of positive qRT-PCR tests on nasopharyngeal swabs 
between days one and six after inoculation.  
 
Among the 42 infected Donors, Influenza A viral RNA was detected in 14 fine 
aerosol exhaled breath samples from 11 Donors, and in six coarse aerosol samples 
from six Donors. All who shed into coarse aerosol also shed into fine aerosols. A 
Donor deemed uninfected but with evidence of airborne shedding was excluded 
(Appendix 1). Out of the 14 positive fine aerosol samples,  four had one out of 
two qRT-PCR replicates below detection limit. Imputing for these samples to 
account for uncertainty of replicate values below detection limit, the geometric 
mean (GM) of the 14 positive fine aerosol samples, was 1.0E+4 RNA copies per 
hour, the geometric standard deviation (GSD) was 4.7, and the range was 2.0E+3 
– 1.6E+5. We assumed the 11 Donors who shed virus into fine aerosols had some 
positive quantity of viral shedding below the detection limit on study days 2-4 
where no RNA copies were detected, or no exhaled breath samples were 
collected. Study day 1 was excluded because fine aerosol shedding was never 




For each infected Donor who ever shed into fine aerosols (i.e., at least 1 fine 
aerosol sample qRT-PCR replicate positive) i, on each study day j, the rate of 
RNA copy shedding into fine aerosols per hour is defined by ⋁𝑖𝑗. Imputed values 
of ⋁𝑖𝑗, given by ⋁̂𝑖𝑗, for days without measurements (N=14) and samples with one 
or both non-detectable qRT-PCR duplicates, assumed to exist below the limit of 
detection (N=9 samples) were estimated using Tobit regression with fixed effects 
of cough symptom and study day, defined by equation 5.  
⋁̂𝑖𝑗 ~ 𝛽0 + 𝛽1  ∗  𝑐𝑜𝑢𝑔ℎ𝑖𝑗 + 𝛽2  ∗  𝑠𝑡𝑢𝑑𝑦 𝑑𝑎𝑦𝑖𝑗  +  𝑏0  +  𝑏1  ∗  𝑖  (5) 
For samples where both qRT-PCR duplicates were above the limit of detection 
(N=10), a duplicate mean was taken directly from measured values. This yielded a 
total 33 RNA copy shedding rate person-day observations for 11 positive Donors, 
adjusted GM (GSD) of 4.7E+3 (6.0) and range 2.6E+2 – 1.6E+5. Table 4.1 
describes ⋁𝑗𝑘 and ⋁𝑘, Figure 4.2b illustrates ⋁𝑗𝑘 and Figure S4.1 shows the 
model performance compared with observed values. For comparison, Table S4.1 
reports the fine aerosol shedding RNA copy numbers where one or both qRT-PCR 
duplicates were above the limit of detection (N=14 samples) and Tobit estimation 
was used to estimate sample RNA quantities where only one duplicate was 
detected. Figure S4.2 presents the fine aerosol shedding rates by study day. Tobit 
regression diagnostics and parameters are presented in Appendix 4.2.  
 
While fine particle aerosols are involved in airborne exposure, coarse particle 
aerosols (≥5µm) represent larger droplets that may be emitted during speaking or 
coughing, and could potentially initiate infection should they land directly on a 
mucosal membrane of a susceptible or contaminate a fomite that is handled by a 
susceptible. They settle to the ground relatively quickly. In total, six Donors shed 
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into coarse aerosols, all of whom also shed into fine aerosols. There were only 
two coarse exhaled breath aerosol samples with both detectable replicates and 
their replicate averages were 5.6E+4 and 4.2E+3 RNA copies shed per hour, from 
Donors in quarantine 1 EG E and quarantine 3 EG B, respectively. There were 
four other positive coarse aerosol sample replicates that ranged from 2.6E+3 to 
6.8E+4 RNA copies per hour. Virus contained in coarse aerosols was assumed to 
not contribute to transmission risk. 
 
Using 75 discrete exposure events to compute q 
Because the transmission trial represents a discrete level of exposure to each of 
the 75 susceptibles, there are a total 75 exposure scenarios one led to infection. By 
summing the probability of infection, P for each Recipient, we solve for 𝑞 for the 
trial as a whole. Riley, Murphy, and Riley (1978) used a similar approach to sum 
risk of transmission across multiple exposure periods between school children 
during a measles outbreak. Because two Recipients were withdrawn before the 
end of study day 4, we adjusted for their absence in their respective EGs from the 
moment of their withdrawal. The withdrawal of a Recipient terminates the 
exposure for the withdrawn Recipient and partitions the exposure in the EG for 
the remaining Recipients into l partitions within k EG, on j study day, for 
Recipient i, described by equation 6.  
𝑅𝑡𝑜𝑡𝑎𝑙 − 𝑅𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 = ∑ exp (−
𝑓̅𝑡𝑖𝑗𝑘𝑙𝐼𝑖𝑗𝑘𝑞
𝑛𝑖𝑗𝑘𝑙
)𝑖𝑗𝑘𝑙      (6) 
where 𝑅𝑡𝑜𝑡𝑎𝑙 is 75, the total number of Recipients in the study, and  𝑅𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑  is 
one, the total number of secondary cases in the study. Solving Equation 6 by 
minimizing the difference between the sides of the equation with I as the number 
of Donors ever observed during the exposure period to have shed into fine 
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aerosols results in q=0.11 (95% CI 0.088, 0.12) quanta generated per hour. 
Solving for q with I as the number of infected donors results in q=0.029 (0.027, 
0.03). The sensitivity of the q values with respect to indoor air CO2 levels is 
reported in Table S4.2 and Figure S4.3. 
 
Using 75 discrete exposure events to compute 𝜎 
 
Riley, Murphy, and Riley summarized airborne viral exposure with an r term, 
which we adapt here using the rebreathed air equation as: 
𝑟 =  
𝑓𝐼⋁𝑡
𝑛
         (7) 
Substituting r into Equation 4 yields a simpler form of the rebreathed air equation 
given by Equation 8 that shows the relationship between the exposure to exhaled 




=  1 − exp (−
𝑟
𝜎
)       (8) 
The viral exposure term per Recipient 𝑟𝑖 is a cumulative exposure term over all 
study days, EGs and Recipient withdrawal partitions. It is defined as: 
𝑟𝑖 =  ∑
𝑓̅𝑡(𝑗𝑘𝑙)𝑖⋁(𝑗𝑘)𝑖
𝑛(𝑗𝑘𝑙)𝑖
(𝑗𝑘𝑙)𝑖         (9)  
After accounting for withdrawal partitions, Figure 4.2c and Figure 4.2d plot 𝑟𝑗𝑘 
and 𝑟𝑘, respectively. The EG where the transmission event occurred (quarantine 2, 
EG C), indicated by the red bar in Figure 4.2d had among the highest exposure to 
viral RNA (Table 4.2). Taking the same approach used for computation of q, we 
use Equation 10 to solve for 𝜎. 
𝑅𝑡𝑜𝑡𝑎𝑙 − 𝑅𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 = ∑ exp (−
𝑟𝑖
𝜎
)𝑖       (10) 
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Solving equation 10 by minimizing the difference between the sides of the 
equation gives 𝜎=1.4E+5 RNA copies/ID63 (95% CI 1.0E+5, 1.8E+5). The 
sensitivity of the 𝜎 values with respect to indoor air CO2 levels is reported in 
Table S4.2 and Figure S4.3. Applying the ratio of RNA copies to fluorescent 
focus units for influenza virus of approximately 1.0E+3, from Yan et al., 2018, 
translates 𝜎 to 1.4E+2 fluorescent focus units, representative of infectious 
particles per ID63. We note that Yan and colleagues reported a correlation between 
quantitative culture and fine aerosols (r=0.34, p<0.0001).  
 
Application of q and 𝜎 to airborne exposure scenarios 
Applying q to influenza challenge transmission ‘proof-of-concept’ study 
A proof-of-concept study prior to the EMIT trial demonstrated the feasibility of 
human transmission following nasal inoculation of seronegative volunteers 
(Killingley et al., 2012). Nine viral Donors were inoculated (with the identical 
virus, mode, and dose used in the EMIT trial). Six Donors were used in three 
exposure rooms, two per room. Five of these donors were confirmed by serology 
and qRT-PCR tests, to have been infected, all of whom met ILI as defined by 
Killingley and colleagues. Five susceptible Recipients were placed in each of the 
three exposure rooms four were considered to be seronegative and susceptible to 
infection. We applied the Well’s Riley equation (Equation 1) given an 8.3% SAR 
(1/12 seronegative Recipients), and assumed infected Donors generated q at the 
same rate as in the EMIT trial (for all infected Donors: 0.029 per hour or 4.8E-4 
per minute), a standard pulmonary ventilation rate of 8 l/min, to estimate the 
ventilation rate in the exposure rooms (Equation 11). There was no knowledge of 
rate of RNA copy shedding into fine aerosols in the proof-of-concept study. 
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𝑅𝑡𝑜𝑡𝑎𝑙𝑠𝑒𝑟𝑜𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 − 𝑅𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 = ∑ exp (−
𝐼𝑖𝑠𝑒𝑟𝑜𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑘𝑞𝑝𝑡
𝑄
)𝑖𝑠𝑒𝑟𝑜𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑘  (11) 
 Solving Equation 11 gave Q=112 L/min. This is probably a fairly low estimate 
given that exposure rooms with attached bathrooms had bathroom exhaust of 
roughly 1.4E+3 L/min (based on standards for bathrooms of size 50 square feet 
and smaller) with operation of the bathroom exhaust (which turned on with the 
light switch during bathroom use) likely about 10-20% of the exposure time. 
Thus, mechanical ventilation rate in the attached bathrooms would be estimated at 
140-280 L/min. However, if some of the makeup air comes from the bathroom 
(e.g., leaks in plumbing chase), then a lower ventilation rate could be expected in 
the exposure space outside the bathroom, and thus the calculated rate of 112 
L/min may be reasonable. 
 
If instead we use the EMIT q computed from the fine aerosol shedding Donors of 
0.11 quanta/hour (1.8E-3 quanta/minute) and apply this to Equation 11, we get a 
ventilation rate of 395 L/minute. It would be reasonable to estimate the q for the 
proof-of-concept study to be somewhere in the range between the EMIT quanta 
generation rate using infected Donors and shedding donors. Thus, applying the 
EMIT trial q to the proof-of-concept study yields estimated ventilation rates 
within a reasonable range of 112 – 395 L/minute. 
 
Estimating the q for symptomatic, naturally infected cases presented by Yan et al., 
2018 
Yan et al., 2018 report the influenza viral shedding (RNA copies and quantitative 
fluorescent focus units) on 218 half-hour exhaled breath samples from 142 
symptomatic individuals from a population of mostly young adults in the 
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University of Maryland community. Taking into account samples assumed to 
contain RNA in quantities below the limit of detection, the adjusted geometric 
mean RNA copies recovered from exhaled breath fine particle aerosols was 
2.4E+4 (95% CI 1.4E+4, 2.8E+4) per hour. Applying Equation 3 and the 𝜎 of 
1.4E+5 RNA copies/ID63, a q computed with the data presented by Yan and 
colleagues is 0.17 ID63 per hour (95% CI 0.10, 0.27). We note that the influenza 
cases in the University of Maryland population were selected from symptomatic 
individuals who presented to the University health center or directly to the study 
within the first 3 days of illness and were febrile >37.8 oC with cough or sore 
throat or had a positive QuickVue rapid test. This population may not be 
representative of the viral shedding that might be expected from a larger 
population of influenza cases given that many cases are asymptomatic or mildly 
symptomatic. If symptom severity is positively correlated with shedding strength, 
then the q computed for the Yan et al., 2018 study may over-estimate the q for the 
greater influenza infected population.  
 
Comparing EMIT trial q with Moser et al., 1979 
Moser et al., 1979 reported on an influenza outbreak in a Boeing 737 attributed to 
exposure to an intensely ill passenger during a 4.5-hour delay with no mechanical 
ventilation. Given the SAR of 72% among 54 people on board, well above the 
average reproduction ratio for influenza, it is plausible that the individual on board 
was a super shedder. The maximum RNA copies detected in exhaled breath fine 
aerosols by Yan et al., 2018 was 8.8E+7 per hour. If we assume that the super 
shedder on the Boeing 737 was shedding at the same rate, then we can apply the 𝜎 
of 1.4E+5 and Equation 3 to compute a q for the airplane scenario of 630. Using 
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their non-steady-state version of the Wells-Riley equation Rudnick and Milton 
(2003) computed a q of 79 or 128, under outdoor air exchange rates of 0.1 and 
0.5/h, respectively. Their estimate is within a single log10 of the estimated value 
obtained using the maximum fine aerosol shedding rate observed in Yan et al., 
2018. 
 
Estimating risk of airborne transmission between dormitory roommates 
The computed 𝜎 can be used to estimate probability of airborne transmission in a 
variety of non-experimental settings using the Wells-Riley of rebreathed-air 
equations (Equations 1 and 2). Viral shedding rates into aerosols from 
symptomatic, influenza cases during the 2012-13 influenza season in the 
University of Maryland campus community has been characterized by G-II (Yan 
et al., 2018). For this naturally infected population, the geometric mean shedding 
rate into fine aerosols, adjusted for samples below detection limit, was 2.4E+4 
RNA (95% CI 1.4E+4, 2.8E+4) copies per hour. Calibrated, continuous dormitory 
room CO2 concentration has been measured over several semesters at the 
University of Maryland. Nighttime indoor CO2 concentration for a typical room in 
one dormitory has been measured as 1.1E+3 ppm (GSD 453) and typical 
nighttime outdoor CO2 concentration was 450ppm. Thus, for a hypothetical 8-hour 
exposure period during the night while two roommates are sleeping, if one 
roommate is an average aerosol shedding, shedding 2.4E+4 RNA copies per hour 
into fine aerosols, then the risk of airborne transmission to a susceptible roommate 
would be 1.2%. In a different dormitory with a typical nighttime indoor CO2 room 
concentration measured at 1.7E+3 ppm (GSD 796 ppm), the risk of airborne 
transmission to the susceptible roommate increases to 2.3%. This risk increases to 
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3.4% if the exposure time increases from 8 to 12 hours. Figure 3 shows the 
probability of infection as a function of indoor CO2 concentration in the two 
dormitory rooms, and fine aerosol shedding rates for positive samples only, 
reported in Table 2 in Yan et al., 2018. Probability of infection in the dormitory 
rooms is low until an infector is shedding at one GSD above the GM and exposed 




We applied the rebreathed-air equation and computed an airborne influenza 
quanta generation rate, q, and the influenza viral RNA copy number per ID63 from 
a human challenge-transmission trial. We also presented a framework for these 
computations using the rebreathed-air equation with measured viral shedding and 
CO2 concentrations. The infectious dose generation rates (95% CI) were q=0.11 
(0.088, 0.12) and q=0.029 (0.027, 0.030) doses/hr for aerosol shedders and 
infectious Donors, respectively, are relatively low, consistent with a typically low 
reproductive number for influenza of 1.5-2 and prolonged exposure associated 
with larger outbreaks (Boelle et al., 2011; Moser et al., 1979b). Compared with 
the computed 𝜎 of 1.4E+5 (95% CI 1.0E+5, 1.8E+5) RNA copies per quantum, 
the fine aerosol viral shedding rate per hour from the 26% infected Donors with 
detectable fine aerosol shedding was small, with GM 4.7E+3 and range 2.6E+2 – 
1.6E+5. The maximum fine aerosol shedder among the experimentally infected 
Donors barely produced a single quantum per hour into aerosols, while a Donor 
shedding at the GM generated 0.03 quanta per hour. Based on the aerosol 
shedding strength observed in a study of symptomatic, naturally infected influenza 
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cases in an H3 predominant season (Yan et al., 2018), a typical case generated 
0.17 quanta per hour (95% CI 0.10, 0.27). Meanwhile, a symptomatic, naturally 
infected case shedding the maximum quantity of RNA into fine aerosols 
produced, 630 quanta per hour, suggesting a role for supershedders in airborne 
influenza transmission. 
 
It appears reasonable to assume airborne transmission in the single, observed 
transmission event. The transmission trial resulted in 1.3% SAR, although a 
proof-of-concept experimental human influenza transmission trial using half the 
exposure time and fewer than half the infectious Donors gave SAR 8.3%, using 
the infection criteria of the former (Killingley et al., 2012). Compared with proof-
of-concept, after increasing the magnitude and duration of exposure, the follow-on 
transmission trial was expected to produce a 16% SAR. Thus, the observed SAR 
of 1.3% was much lower than expected under identical study conditions (p<0.001) 
(Nguyen-Van-Tam et al., 2019). As detailed in Nguyen-Van-Tam and colleagues, 
the main difference between these studies was likely the ventilation. The proof-of-
concept study was carried out in hotel rooms, with what was likely to be relatively 
little ventilation compared with the follow-on trial in a controlled environment. 
That the SAR did not increase between the proof-of-concept and follow-on trials, 
yet the magnitude and duration of direct and indirect contact between infectious 
and susceptible volunteers more than doubled, and the air exchange rate likely 
increased – which would promote dilution of infectious airborne particles – 
supports the interpretation that airborne particles and not contact or large droplets 
drove transmission in this model. The finding that the single transmission event 
occurred in a Recipient with one of the highest levels of airborne exposure and 
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that volunteers with no viral aerosol exposure were not infected further supports 
the interpretation that transmission was via fine aerosols. Coarse aerosols are less 
likely to contribute to airborne transmission because they settle quickly. Coarse 
aerosol shedding was a couple of logs lower among naturally infected aerosol 
shedders, supporting the hypothesis that coarse aerosols contribute lower risk 
relative to fine aerosols.  
  
In this study, the two main factors contributing to transmission risk were the rate 
of fine aerosol shedding from infectious cases, and the level of rebreathed air in 
the indoor exposure space governed by the air exchange rate. The estimated SARs 
in the modelled University of Maryland dormitory room (Figure 4.3) were similar 
to those estimated in studies of influenza transmission in households. The airborne 
SARs ranging from 1.2% to 3.4% for a single night of exposure (up to 10.2% for 
3 nights of exposure) between one infected and one susceptible roommate in a 
dormitory room is similar to reported household SARs of 8% and 21% (Cowling 
et al., 2009; Simmerman et al., 2011). Analysis of these household trials – which 
used hand hygiene and facemask interventions to control for transmission model – 
has reported that airborne influenza could be responsible for about half of 
influenza transmission events and that interventions to interrupt contact and large 
droplet modes may not reduce overall risk, but rather shift transmission mode 
(Cowling et al., 2013a). Thus, accounting for the SAR due to airborne risk alone 
in the household trials makes the SAR comparison between the household 




An analysis of a separate household cohort found that among 52 sample pairs 
between primary and potential secondary household transmission cases with 
sequence data of sufficient quality, 47 (90%) were considered phylogenetically 
supported transmission events (McCrone et al., 2018). This lends credence to the 
assumption that household transmission events in the aforementioned household 
studies were between household contacts. Despite this, it may be a minority of 
infections that are acquired from household contacts in the residential setting. 
Reanalysis of household transmission data described in McCrone et al., 2018 
assuming one case in each household came from an outside source, shows 72% of 
influenza cases originated from sources outside the household. This is consistent 
with literature on TB transmission in high-burden settings. Risk attributable to 
non-household resident sources have been estimated as 81% in suburbs of Cape 
Town, South Africa (Verver et al., 2004), >75% in a periurban township outside 
of Cape Town (Wood et al., 2010), 77% in rural Vietnam (Buu et al., 2010), and 
>65% in Lima, Peru (Brooks-Pollock et al., 2011), pointing toward shorter-term 
shared air exposure to supershedders as important for TB transmission. There may 
also be a similar role for supershedders in airborne influenza transmission.  
 
Using the rebreathed-air equation to estimate airborne transmission risk between 
roommates in University of Maryland dormitory rooms with measured CO2 
concentrations provides insight on the behavior of transmission probability as a 
function of the rebreathed fraction and the rate of infectious airborne particles 
containing influenza virus (Figure 4.3). If a roommate is shedding virus at one 
GSD above the GM observed in a population of symptomatic influenza cases 
observed in the University of Maryland campus community (Yan et al., 2018), 
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then the rebreathed fraction in the room is very influential in determining 
infection risk in a susceptible roommate, ranging in risk of about 10% for an 
indoor air CO2 level one GSD below the GM in a well ventilated dorm, to about 
90% at  two GSDs above the GM in a poorly ventilated dorm. When the rate of 
shedding approaches the highest percentiles the probability of infection becomes 
quite high regardless of rebreathed fraction. This suggests that influenza 
transmission could be driven by poorly ventilated environments inhabited by 
average viral shedders or the highest viral shedders (i.e., supershedders) regardless 
of ventilation level. Phylogenetic studies could evaluate the theory that a minority 
of viral shedders are responsible for the bulk of transmission. An analytical 
framework to explore this hypothesis has been described (Colijn and Gardy, 
2014). Studies that can refine predictors of high-level aerosol shedding, as done 
by Yan and colleagues, or can refine predictors of transmission related to indoor 
environments are of great importance to population level disease prevention 
programs.  
 
The Wells-Riley equation has been used in numerous studies to estimate 
transmission risk for Tuberculosis (Riley et al., 1978). The rebreathed-air equation 
adapts the Wells-Riley equation by directly estimating inhalation exposure to 
concentrations of airborne contaminants in exhaled breath by using CO2 to 
estimate exhaled breath concentration (Rudnick and Milton, 2003a). In the current 
EMIT trial analysis, we assumed the pulmonary ventilation rates of Donors and 
Recipients (and study monitors who also spent time in the rooms) were relatively 
similar. Given that volunteers were participating in similar activities, were not 
participating in heavy physical activities, and never experienced severe illness, the 
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main differences in the contribution to exhaled breath in the room would be 
related to baseline respiratory function, which was not likely to be substantially 
different between healthy, young adult volunteers. To test the assumption that the 
exposure rooms were well mixed spaces, tracer gas studies were conducted in one 
of the exposure rooms. CO2 sensors in the corners and center of the room 
followed similar patterns in CO2 concentration levels that reflected CO2 releases 
into the rooms. These finding were robust to the opening and closing of the door 
(Appendix 3.3).  
 
This study provides the beginnings of a scientific basis for specifying indoor 
ventilation rates sufficient to prevent transmission from average infectious 
influenza cases. Despite the inability to compute confidence bounds for q due to 
the low SAR, given the single transmission event in the trial, the computed q and 
𝜎 estimate lower bounds from which transmission probability in various scenarios 
can be projected. Although the computed q was found to be reasonable after 
application to the proof-of-concept transmission study ventilation conditions 
(Killingley et al., 2012), replication of these findings in other settings is needed to 
translate these findings into control measures that can be incorporated into 
building design or and operation and maintenance requirements. Additional 
discussion about q and the connection to viral exposure and SIR modelling can be 
found in Appendix 3.4. 
 
As required by the nature of the human challenge model, volunteers were all 
young adults above age 18. Other variables in the challenge model were selected 
to maximize the transmission potential to Recipients. Volunteers were selected 
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with low levels of preexisting antibodies to influenza H3 virus. Volunteer 
psychosocial stress levels were not observed despite its importance in infection 
susceptibility following exposure (Cohen et al., 1991). The temperate temperature 
and humidity were selected to optimize environmental conditions favorable for 
influenza transmission (Lowen and Steel, 2014; Shaman et al., 2010). Comparison 
of wildtype reference virus to the laboratory prepared A/Wisconsin/67/2005 
(H3N2) used for inoculation showed partial adaptation to laboratory culture 
environments yet conservation of a fixed variant in the HA gene, suggesting that 
the laboratory prepared virus was not likely to be the cause of the low SAR 
(Nguyen-Van-Tam et al., 2019; Sobel Leonard et al., 2016). Thus, although the 
current challenge model provided a platform to carefully control, examine and 
quantify transmission, heterogeneity in host immunity, viral, coinfection, contact 
exposure networks, and environmental factors related to transmission risk were 
not observed in this model. Addressing how additional variation in these factors 
influences transmission risk by airborne and other modes is required to increase 
generalizability and translate findings into actionable public health strategies 
aimed at promoting healthy built environments. To this end, a hybrid challenge 
study approach could be explored with recruitment of naturally infected cases as 
Donors and a demographically and immunologically diverse population as 
Recipients, however the feasibility of conducting such a study would pose a 
challenge. The isolation of H1N1 variants unique to lower respiratory tract 
compared with the nasal mucosa points toward the possibility of transmission 
mode tracing through sequencing samples from community exposure networks 




Given our limited data on transmission in the EMIT trial, we have presented what 
appear to be reasonable estimates for q and 𝜎. We also presented a powerful and 
feasible methodology for estimating influenza airborne infectious dose and 
predicting transmission risk given measurements of the source strength of virus 
shed into exhaled breath and CO2. The airborne infectious dose generation rate for 
experimentally infected Donors with A/WI virus in the controlled challenge 
environment was low, consistent with expectations. Typical experimentally 
infected aerosol shedders and naturally infected community cases generate few 
infectious doses per hour, however observed cases that shed the most virus 
generate several hundred infectious doses per hour. Airborne risk in the presence 
of an average shedder could be substantially mitigated by increased ventilation, 
but not in the presence of a supershedder. Future work is needed to explore the 
role of supershedders and refine risk attributable to the airborne mode while 
addressing heterogeneity in host immunity, virus, coinfection, contact exposure 
networks, and environmental factors related to transmission risk. In addition to 
providing a scientific foundation for promoting built environments that reduce 
transmission, this work builds toward enabling the public health community to 
gain the capacity to rapidly quantify viral shedding from early cases in an 
outbreak, characterize the probability of transmission through the airborne mode 

















A  8.8E+3 (1, 2)  1.6E+5 (1, 2)  1.3E+4 (0, 2)  1.8E+5 (2, 6)  
 B* ND (0, 2)  ND (0, 1)  ND (0, 2)  ND (0, 5)  
C  1.2E+3 (0, 3)  1.3E+4 (1, 2)  1.3E+3 (0, 1)  1.6E+4 (1, 6)  
 D* ND (0, 2)  ND (0, 2)  ND (0, 2)  ND (0, 6)  
E  1.4E+4 (0, 2)  1.3E+5 (1, 3)  1.6E+4 (1, 3)  1.6E+5 (2, 8)  
2  
 A* ND (0, 2)  ND (0, 4)  ND (0, 0)  ND (0, 6)  
B  2.7E+3 (1, 4)  2.7E+4 (1, 2)  2.9E+3 (0, 1)  3.3E+4 (2, 7)  
   C** 9.8E+3 (1, 4)  1.3E+5 (1, 4)  1.2E+4 (0, 3)  1.5E+5 (2, 11)  
3  
A  4.1E+3 (0, 2)  4.0E+4 (0, 2)  4.3E+3 (1, 2)  4.9E+4 (1, 6)  
B  2.0E+3 (1, 2)  2.0E+4 (0, 1)  2.1E+3 (0, 2)  2.4E+4 (1, 5)  
C  2.6E+2 (0, 2)  2.6E+3 (1, 2)  2.8E+2 (0, 2)  3.2E+3 (1, 6)  
D  3.9E+3 (1, 2)  2.5E+4 (0, 2)  2.7E+3 (0, 2)  3.2E+4 (1, 6)  
E  3.4E+2 (0, 2)  3.9E+3 (1, 3)  4.1E+2 (0, 2)  4.6E+3 (1, 7)  
RNA copies shed into fine particle exhaled breath aerosols per hour by day-EG, ⋁𝑗𝑘 , by EG, ⋁𝑘 from 
observed and imputed samples (number samples with at least 1 detectable qRT-PCR replicate, number 
samples tested).  
* EGs with no Donors observed to shed any fine aerosols with at least one qRT-PCR replicate positive.  












A  3.8 
  B*  0.0 
C  2.9 
  D*  0.0 
E  3.9 
2  
  A*  0.0 
B  3.3 
    C**  3.8 
3  
A  3.3 
B  3.1 
C  2.3 
D  3.2 
E  2.3 
* EGs with no Donors observed to shed any fine 
aerosols with at least one qRT-PCR replicate positive. 







Figure 4.1. Observed CO2. Concentrations measured at 5-minute intervals over 










Figure 4.2. Exposure related to transmission risk. A shows, for each Recipient in 
each exposure group (EG), the fraction of inhaled air containing exhaled breath 
from Donors who shed into fine aerosols. B shows Donor shedding in each EG by 
day, and C and D show Recipient exposure to viral RNA aerosols in each EG by 
day, and cumulatively, respectively. The single transmission event occurred in 




Figure 4.3. Probability of infection in dormitory rooms with different rebreathed 
fractions. The grey lines indicates GM, GM + 1GSD, and GM + 2GSD shedding 
rates, reported in Yan et al., 2018, transformed to per hour. Dormitory room CO2 
measured during the 2017-2018 academic year at the University of Maryland 











SUMMARY AND CONCLUSION 
 
Summary of key findings 
 
This dissertation used data from the EMIT human challenge-transmission trial to 
address three hypotheses: 
 
1. The fraction of secondary cases attributable to airborne transmission will be 
greater than those attributable to contact and large droplet spray. 
2. The fine aerosol shedding profiles of natural, community-acquired influenza 
cases are well approximated by artificial infection initiated by nasal 
instillation of virus. 
3. The infectious quantum generation rate for influenza is estimated as a function 
of the quantity of infectious aerosols exhaled by infectious cases, and the rate 
of airborne virus removal mainly driven by ventilation, given the susceptible 
immune status of the human trial volunteers.  
 
Assessment of hypotheses has generated three main findings: 
i. Comparison of a proof of concept human influenza trial with a larger, follow-
on trial, with the main difference being ventilation levels, suggests a minimal 
role in contact and large droplet spray transmission and a possible role for 
airborne transmission.  
ii. Comparison of experimentally inoculated infections with symptomatic, 
naturally infected cases suggests that the probability of the artificial nasal 
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inoculation resulting in the highest levels of symptom severity and viral 
shedding observed in the naturally infected group is low.  
iii. The airborne quantum generation rate (95% CI) for influenza in the controlled 
human transmission trial environment among infected Donors and airborne 
viral shedding Donors is at most 0.029 (0.027, 0.03) and 0.11 (0.088, 0.12) per 
hour, respectively. The number of RNA copies per infectious quantum was 
1.4E+5 (95% CI 1.0E+5, 1.8E+5). Given this quantum generation rate, and 
levels of viral shedding in a college campus community in dormitory rooms 
evaluated for exhaled breath exposure, the typical viral shedder presents low 
risk of transmission to a susceptible roommate during a nighttime of exposure 
in a well-ventilated dormitory but a moderate risk in a poorly ventilated 
dormitory. Supershedders at the 95th percentile of fine aerosol shedding 
present high risk regardless of indoor levels of ventilation (Figure 5.1). 
 
The computed infectious quantum generation rate (q, described in Chapter IV) 
enables the comparison between estimated exposure to influenza virus and 
infection risk. Thus, given levels of exhaled breath aerosol viral shedding and 
ventilation rates for indoor shared air spaces, the Wells-Riley equation can be 
applied to estimate infection risk. Of course, this assumes that the assumptions 
inherent in the computation of the q in the EMIT human challenge-transmission 
trial can be generalized to other transmission scenarios. The population of 
susceptible volunteers had low HAI and MN titres, representing above average 
susceptibility than the general population, suggesting q may be overestimated. 
The computed q must also be interpreted with caution because it represents a point 
estimate, with confidence bounds generated by empirical bootstrap, given that it is 
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derived from a single transmission event. The q for influenza is relatively low 
compared with that estimated for other respiratory infections. Few studies have 
estimated q, but some estimations exist for influenza and other infections known 
to be transmissible by the airborne mode.  
 
Figure 5.1. Risk of infection as a function of aerosol shedder, ventilation, and 
immunity. 
 
Limitations and questions for future research 
 
The EMIT challenge-transmission trial, like Alford’s challenge study with aerosol 
viral exposure, used a population with low pre-existing antibodies to the challenge 
virus subtype. Thus, these studies are useful for demonstrating transmission 
dynamics with susceptible secondary cases, but lack generalizability to the general 
population with varying levels of immunity. Additional issues with 
generalizability are explored in Chapter 3. That only one transmission event was 
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observed in a Control Recipient represents a major limitation, as the mode of 
transmission cannot be ascertained with certainty and the risk ratio represents the 
lower bound for infection risk and lends uncertainty to the confidence bounds. 
Nonetheless, the analyses in this dissertation attempted to a) learn what was 
possible about influenza transmission given that EMIT was unique in its design 
and the largest human-transmission trial conducted to date, and b) fully assess the 
limitations of the study design to inform future investigations.   Numerous 
questions exist to drive future studies aiming to refine risk assessment and 
optimize population prevention strategies. Such questions include: 
a) To what extent do temperature, humidity, latitude, subtype, and 
engineering controls such as ventilation, air flow, and UVGI effect 
transmission risk?  
b) To what extent do social contact networks of direct contact exposure 
predict observed transmission risk?  
c) What is the optimal set of social contact network and indoor air quality 
variables to predict observed transmission events in a contained 
community setting (i.e., dormitories, military barracks, boarding schools, 
nursing homes, hospitals, schools, occupational settings, etc.)? 
d) Evaluate the influence of engineering control strategies – ventilation, 
airflow dynamics, filtration – on influenza risk reduction, while accounting 
for variability in human susceptibility to illness, and the concurrent 
deployment of administrative and behavioral interventions. 
e) To what extent does infection mode influence the immune response and 
subsequent viral shedding peak, temporal trend, and virion infectiousness, 
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and to what extent are age, sex, prior infection, vaccination, and immune 
status modify these effects? 
f) Could viral load by site (lung produced aerosols versus upper respiratory 
tract produced mucosa) be a biomarker of mode of infection?  
g) How do symptoms correlate with shedding from lung versus upper 
respiratory mucosa across age, sex, socio-behavioral factors, immune 
status, and subtype? What does this mean related to the subset of the 
population that is being sampled in studies that recruit medical care 
seeking respiratory infection cases? There is limited data about the extent 
of shedding as a function of symptom profile. Asymptomatic individuals 
have been shown to shed 1-2 log10 RNA copies fewer into nasal mucosa 
than symptomatic cases (Ip et al., 2017). If symptomatic cases are more 
likely the result of airborne transmissions, then asymptomatic infections 
may be more representative of population infected by upper respiratory 
mucosal exposure.  
h) Is an epidemiologic framework that could identify exposure networks and 
confirm transmission events, potentially by infection mode, feasible given 
the current state of the science? 
i) To what extent is aerosol shedding a function of viral concentration in the 
respiratory fluid of the distal airways versus expiratory volume, cough, 
and other drivers of expiratory particle generation?  
 




We would like to see if findings from the experimental challenge-transmission 
model are borne out in real-world epidemiology and population transmission 
dynamics. This way we can assess a range of other important variables including 
heterogeneity in immunity by age, sex, prior infection, coinfection, immunization, 
coinfections, shedding dynamics by age, sex, and immune status, a range of socio-
behavioral variables related to human-human transmission including 
psychological stress (Cohen et al., 1991), sleep, physical activity, diet, overall 
well-being, and the physical built environment including temperature, humidity, 
ventilation, and the importance of other particulates and exposures (mixtures). 
The advantage of the experimental trial in a controlled environment is that a 
relationship can be drawn between strength of viral shedding and subsequent 
secondary attack rate, giving a dose response relationship. However recent 
advances in genomic sequencing and bioinformatics are beginning to show a path 
forward for using molecular markers, in combination with epidemiological 
contact and exposure surveillance, to confirm who transmitted to whom 
(Campbell et al., 2019; Volz et al., 2009; Volz and Frost, 2013). Preliminary data 
shows that transmission chains may be able to give information about mode of 
transmission if it is true that viral communities evolve distinctly in the lung versus 
the upper respiratory mucosa.   
 
There is evidence that influenza may manifest as compartmentalized infections in 
the lung and nasopharynx (Yan et al., 2018). Preliminary sequence data on a few 
aerosol-nasopharyngeal swab paired samples from the study conducted by Yan 
and colleagues shows distinct variants evolved in these compartments. Deep 
sequencing with an average read depth of 15,000X (range 12,000X-20,000X) per 
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sample was conducted on three pairs of nasopharyngeal (NP) swabs and aerosol 
samples from qRT-PCR confirmed influenza A cases. Single nucleotide variants 
were identified after trimming reads with FLASH (ver. 1.2.11), assembling de 
novo using SPAdes (ver. 3.10.1), and mapping assembled to contigs with bowtie 2 
(ver. 2.3.2). There were no shared variants between NP swabs and aerosol 
samples, and 20-147 variants unique to either NP or aerosol samples per pair, 
giving a Jaccard similarity coefficient of 0. Airborne transmission likely involves 
viral communities produced in the lung, while contact transmission likely involves 
nasal communities, thus enabling a path to identify infection route that requires 
characterization. Considering the nasopharynx and lung as separate entities that 
carry the ability to infect independently, reconstruction of transmission chains in 
observed contact networks can be achieved by analyzing shared variants (Worby 
et al., 2017). Bayesian approaches can be used to infer transmission events for 
outbreaks that are not completely sampled and/or are ongoing (Didelot et al., 
2017).  
 
Relevant ongoing research at University of Maryland 
 
Current work at the University of Maryland (Characterizing and Tracking College 
Health, the “CATCH the virus study”) has been employing an epidemiologic, 
observational approach to understand transmission risk and modes of influenza 
and other respiratory pathogens on the university campus community. Three years 
of surveillance of a healthy cohort spanned assessment of a wide range of health-
related data including on sleep and stress, and upon infection, symptom 
assessment, collection of specimens for quantification of mucosal and exhaled 
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breath viral load, viral community, and immune biomarkers. Comprehensive 
environmental monitoring to assess exposure to exhaled breath (e.g., with CO2 
measurement and sampling for airborne viral RNA) has been carried out in 
dormitories and other campus buildings. Contacts with potentially high levels of 
exposure to infectious cases have been followed prospectively for evidence of 
infection yielding rich data on temporal trends in symptoms, viral shedding, and 
biomarkers indicative of impending infection and shedding. Contact and exposure 
networks are based on knowledge of dormitory room location, class schedules, 
and a location tracking application.  
 
Such a study design enables the investigation of associations between indoor air 
environment, exposure networks, and sociobehavioral variables related to 
exposure and immunity. This model, while focusing mostly on a narrow 
population range of young adults can be expanded to a pediatric community on 
campus, and older adults in the campus and surrounding communities, 
representing a microcosm of a healthy, age-inclusive community. 
 
Implications for public health practice 
 
Although new studies are needed to refine estimates of transmission risk by 
various modes to understand relationships between infection mode, dose, age, sex, 
immunity, environment, symptoms, and human  and viral infectivity, our findings 
are substantial enough to begin supporting the scientific underpinnings of public 
health interventions aimed at reducing transmission and population epidemics 
through targeted exposure control strategies. Finding suggest that ventilation and 
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airflow controls, to reduce exposure to contaminated exhaled breath, could have 
major impact on preventing disease in shared air spaces. Preventive measures that 
are precautionary in nature could take these findings into consideration.  
 
In the case of influenza, it may be that the infectious generation rate of the 
average infectious aerosol shedder is low enough to pose only mild risk under 
well ventilated conditions but may pose moderate to severe risk under less 
ventilated conditions (Figure 5.1). Fine particle aerosol supershedders may pose 
substantial risk regardless of indoor ventilation. However, supershedders may be 
quite rare in the population. These findings are described in more detail in Chapter 
4.  
 
Understanding exactly how much risk is attributable to airborne transmission, and 
the extent to which risk can be attenuated by engineering controls, as opposed to 
behavioral and administrative controls, opens the door for well-informed 
exploration of building design and operation and other strategies to minimize 
transmission. Results from this proposed research respond to the Surgeon 
General’s Call to Action to Promote Healthy Homes by driving an area of 
transdisciplinary research to launch “public health actions that will have a 
significant impact on health [through] a more holistic understanding of how 
housing affect’s people’s health” (Office of the Surgeon General (US), 2009). 
Results from this research directly respond to the Surgeon General’s notion of 
using a “broad approach involving many disciplines,” by providing an integrative 
framework for improving health indoors that involves engineers, epidemiologists, 




Figure 5.2 provides a basic representation of the form disease prevention 
recommendations could take given the achievement of improved risk 
quantification for airborne particles with the goal of suppressing the reproductive 
ratio for ARIs below one. The top right cloud shows that there is likely a threshold 
at which environmental controls alone cannot contain an outbreak, but it is 
unlikely that they will ever be used exclusively. Here we underscore that, as 
demonstrated by Nardell et al., 1991 in the case of TB, there exist potential limits 
to the extent that engineering controls alone can control transmission risk in 
shared air environments. Given that the extent of strategies to prevent the spread 
of one pathogen may not be the same for all pathogens it is important to quantify 
risk dynamics in indoor settings for a variety of pathogens. Measles, for instance, 
is highly contagious. Infected cases have been estimated to shed over on average 
500 quanta per hour (Rudnick and Milton, 2003b). Based on this estimation, if the 
typical measles case were dropped in the University of Maryland dormitory 
roommate transmission scenario, they would infect a susceptible roommate at a 
similar probability as the maximum fine particle influenza shedder from Yan et 
al., 2018, in which case engineering-based controls may not provide much 









The population health burden posed by influenza and other respiratory infections 
is expansive. The risk of emerging infectious diseases to initiate pandemics is 
greater than ever. This dissertation begins to fill a major knowledge gap and 
advances the field through improving understanding of airborne transmission risk. 
The long-term goal of this work is to increase the validity of quantum generation 
rate estimates, enable prediction of infection dynamics immunologically 
heterogeneous populations, and test the effectiveness of various strategies to 
minimize infections. With pandemics in mind, the idea is for the public health 
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community to gain the capacity to rapidly quantify viral shedding from early cases 
in an outbreak and characterize the probability of transmission through the 
airborne mode and mount and effective response. This is especially necessary in 
hospital setting with high exposure. PPE can be better recommended and enforced 
in cases where building design and airflow, ventilation, filtration, and other 
techniques are known to be inadequate in reducing risk to acceptable levels. 
 
Completion of this work motivates studies to refine parameters of infection 
transmission and to strengthen methods to observe and understand the 
implications of viral shedding into exhaled breath aerosols. This proposal sets up 
future work to test the effectiveness of indoor air environmental controls on 
transmission, an area where little is known. Modelling studies on airflow and 
ventilation strategies to mitigate airborne pathogens (e.g., Gao et al., 2016) benefit 
from new information relating airborne exposure to risk that informs model 
parameters. Other future work will focus on the influence of vaccines, human 
immunity, and coinfections on susceptibility to infection and propensity for 
contagiousness.  
 
Results from this dissertation show that CO2 measurements can be effectively 
used in a risk assessment framework. This framework can be used in a variety of 
settings. In the long-term, CO2 monitoring could promote a citizen science 
approach to tracking airborne exposures and risk across communities everywhere. 
It forms the basis for environmental justice work where indoor exposures may 
disproportionately affect some workplaces, housing developments, and 
communities. Future studies that examine the interaction between chemical 
 
 121 
airborne particulate exposure and infectious disease exposure via the airborne 
mode could yield increasingly meaningful exposure models for predicting health 
outcomes. Particulates, volatile organic compounds, semi-volatile organic 
compounds, as well as thermal and psychological comfort are important 
considerations in buildings to prevent diseases and optimize cognitive function 
(Allen et al., 2016; Milton et al., 2000; Myatt et al., 2002). 
 
It is becoming increasingly clear that the indoor environment has a major 
influence on health and well-being. New research is needed to better understand 
the design and operation standards to optimize human wellness in these indoor 
spaces. This body of future research is bound together by its translational nature in 
that it builds toward informing the improved design and remediation of indoor 
spaces, where humans spend over 90% of their time, to promote well-being, and 
to hamper preventable infections. This path of investigation inevitably links with 
fields of research promoting energy sustainability in built environments and 
research related to dual goals of optimizing ventilation for public health and 
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Appendix 2.1. Efficacy of a Face Shield to Reduce Transmission of Influenza 
Virus in Large Droplets  
 
Study Objective  
The objective was to determine the efficacy of a face shield to selectively reduce 
transmission of large droplets containing viable influenza viruses without 
impeding droplet nuclei transfer in a mannequin model. The results of this study 
defined the feasibility of this intervention in selectively blocking such particles in 
a subsequent human-to-human influenza transmission study (EMIT).  
 
Rationale  
Large particle (> 10μm) behave as ballistic particles and will be stopped by a face 
shield while small particles (<5μm) can float over an extended period of time and 
distance and will be less effected by a face shield. It remains unknown how 
particles between 5 and 10μm will behave. Therefore, this study focused on the 
efficacy of a face shield in selectively blocking large particles from reaching the 
upper respiratory tract of human subjects while allowing small particles to enter.  
 
Methods  
Established human aerosol dispersal patterns were used to evaluate the effect of a 
face shield in filtering out the large droplet fraction carrying influenza. For this 
purpose, we produced a range of particles sizes (<1 to >100μm) of a live Influenza 
virus (H1N1 Influenza virus A/WS/33) using an airbrush system. The carrier 
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particle size was assessed in real time by an aerodynamic particle sizer (APS) for 
the particle range <1 to 20μm. Airborne virus was recovered by a six stage 
Andersen sampler with a styrofoam anatomical head placed on top allowing air to 
flow through a hose connecting the mouth opening to the sampler. The Styrofoam 
head allowed the anatomically correct positioning of the face shield to the mouth 
opening (Fisherbrand Full Face shield, Thermo Fisher Scientific Inc., Waltham, 
MA). Plaque forming units were counted by tissue culture plates (MDCK) for 
each sampler stage. The effect of a face shield was tested under the following 
conditions: absolute humidity (6·9 g/m3 [20°C, 40%RH]), air spray direction to 
face shield (straight, 90°), and air flow (none, 110ft/min). The face shield was 
modified during the trial to optimise small particle penetration while blocking 
large droplets. In addition to the virus exposure we also used latex beads of 
defined sizes (1, 5, 10, 15, 20, and 50μm) to conclusively determine the collection 
efficacy of our mannequin model. Beads were detected by flow cytometry (BD 
Accuri C6 system). Results are expressed in total counts and percent reduction of 
the viral/bead recovery load.  
 
Endpoint 
The endpoint was the percent reduction in viral air load through a face shield by 
<20% for small particles <5μm (droplet nuclei) and >90% for large particles > 10 
μm (droplets). This was tested under the following conditions: air flow directions 
(straight vs. 90° turn, Figure S2.1) and air velocities (no air movement vs. ~2·4 






Wearing a face shield led to a 98·8% (straight; Figure S2.2) and 97·6% (90° 
rotated; Figure S2.3) reduction in large particles >4·7μm (p<0·05) compared with 
not wearing a face shield and facing straight toward the source. Small particles 
<4·7μm were not significantly affected (0·7% reduction [straight, Figure S2.4], 
10·6% reduction [90° rotated, Figure S2.5]) (p>0·05) compared with not wearing 
a face shield and facing straight toward the source. Generating a directional air 
flow reduced large particles by 68.0% (straight, Figure S2.2) and 99·4% (90° 
turn, Figure S2.3) without face shield, and 98·7% (straight, Figure S2.2) and 
99·5% (90° turn, Figure S2.3) with face shield (p<0·05). With directional airflow, 
small particles were reduced by 73·0% (straight, Figure S2.4) and 54·6% (90° 
turn, Figure S2.5) without face shield, and 83·9% (straight, Figure S2.4) and 










Figure S2.2. Effect of Face Shield on Virus Transmission - Large Particle 
>4·7μm, error bars = standard deviation 
 
  
Figure S2.3. Effect of Face Shield on Virus Transmission - Large Particles 




Figure S2.4. Effect of Face Shield on Virus Transmission - Small Particles < 
4·7μm Straight Airflow, error bars = standard deviation  
 
 
Figure S2.5. Effect of Face Shield on Virus Transmission - Small Particles 




The collection of beads was broken down by bead size and detection in the 
Andersen sampler stages for small particle <4·7μm and large particle stages 
>4·7μm. The face shield reduced 1 μm beads by 11·4% (straight) and 43·3% (90° 
turn) in the small particle stages and by 99·6% (straight) and 37·9% (90° turn) in 
the large particle stages. Directional airflow increased bead recovery by 185·4% 
in the small particle stages and reduced collection by 32·7% in the 90° head 
position. An overall reduction of 1μm beads was noted in the large particle stages 
(-98·3% [straight], -28·2% (90° turn). Only less than seven 5 μm beads per run 
were detected in the small particle stages as expected. In the large particle stages 
the face shield reduced 5μm bead collection by 7·9% (straight) and 77·1% (90° 
turn). Airflow led to a reduction by 12·5% (straight) and an increase of 17·8% 
(90° turn). Based on the expected absence of 5 μm bead findings in the smaller 
particle stages only the results of the large particle stages are reported for the 10, 
15, 20, and 50μm bead sizes. In summary, the face shield successfully reduced 
beads by 95·2 to 100% (straight) and 23·3 to 87·7% (90° turn). Directional 




The face shield successfully blocked large particles >4·7μm from reaching the 
mouth and nose of a mannequin head while allowing passage of particles <4·7μm 
in a head-on air flow pattern in both virus and bead runs. Turning the head (90° 
rotation) significantly decreased the total virus detection compared to a head-on 
airflow pattern to very low concentrations (78.0-97·4%). Addition of a face shield 
while turned slightly increased the virus detection with face shield for both small 
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and large particles (22-24%), while bead counts >4·7μm decreased (23-86%). The 
effects were not significant indicating negligible changes due to the face shield at 
the low recovery level. Increase of the air flow (turbulent) led to a decrease in 
virus detection in both small and large particles (straight and 90° rotated). With a 
head-on airflow 1 μm beads increased, however larger beads decreased (>90% for 
10-50 μm beads). Combined with a 90° turn 1 to 50 μm beads decreased.  
The modified face shield met the endpoint by reducing virus particles >10 μm by 
more than 90% while maintaining exposure to particles <5μm (<20% reduction). 
Turning the head perpendicular to the exposure source alone led to a substantial 
reduction of the overall virus recovery negating any significant effects of the face 
shield. The method of blocking selected particle sizes from reaching the human 
respiratory tract through a face shield is feasible and can be used to study virus 




Appendix 2.2. Full inclusion and exclusion criteria 
 
Inclusion 
• Age 18 to 45 years, inclusive.  
• In good health with no history of major medical conditions from medical history, 
physical examination, and routine laboratory tests as determined by the 
Investigator by a screening evaluation.  
• A total body weight ≥50 kg and a body mass index (BMI) >18 (if BMI is >32, a 
body fat percentage within WHO and NIH range for gender and age). BMI 
[kg/m2] = Body weight [kg] ÷ Height2
 
[m2].  
• Non-sterilised males must agree to refrain from fathering a child from the point of 
entering Quarantine until the day 28 follow up visit by using an effective method 
of contraception.  
• Sexually active females of child-bearing potential must agree to use 2 effective 
methods of avoiding pregnancy that are deemed to be effective from the point of 
entry into the Quarantine unit until the day 28 follow up visit.  
• An informed consent document signed and dated by the subject and investigator. 
• HAI titre ≤10 against challenge virus 
 
Exclusion 
• Subjects who have a significant history of any tobacco use at any time (≥ total 10 
pack  
• year history, e.g. one pack a day for 10 years). 
• Subjects who are pregnant or nursing, or who have a positive pregnancy test at 
any point in the study. 
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• Presence of any significant acute or chronic, uncontrolled medical illness (full list 
available on request), that in the view of the Investigator(s), is associated with 
increased risk of complications of respiratory viral illness.  
• Abnormal pulmonary function in the opinion of the investigator as evidenced by 
clinically significant abnormalities in spirometry. 
• History or evidence of autoimmune disease or known immunocompromise of any 
cause. 
• Subjects with any history of asthma, COPD, pulmonary hypertension, reactive 
airway disease, or any chronic lung condition of any aetiology. The history of 
childhood asthma until and including the age of 12 is acceptable. 
• Positive human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C 
(HCV) screen.  
• Any significant abnormality altering the anatomy of the nose or nasopharynx.  
• Any clinically significant history of epistaxis (nose bleeds).  
• Any nasal or sinus surgery within 6 months of inoculation.  
• Recent (within the last 3 years of the screening visit) and/or recurrent history of 
clinically significant autonomic dysfunction (e.g. recurrent episodes of fainting, 
palpitations, etc.).  
• Any laboratory test or ECG which is abnormal and deemed by the investigator(s) 
to be clinically significant.  
• Confirmed positive test for class A drugs or alcohol that cannot be satisfactorily 
explained (e.g. recent use of codeine tablets).  
• Venous access deemed inadequate for the phlebotomy (and IV infusion) demands 
of the study.  
 
 133 
• Subjects symptomatic with hayfever on admission into the unit for a quarantine 
session or prior to inoculation will be excluded.  
• Any known allergies to the excipients in the challenge virus inoculums.  
• Health care workers (including doctors, nurses, medical students and allied 
healthcare professionals) anticipated to have patient contact within two weeks of 
human viral challenge. Healthcare workers should not work with patients until 14 
days after challenge or until their symptoms are fully resolved (whichever is the 
longer). In particular, any health care workers who work in units housing elderly, 
disabled or severely immunocompromised patients (e.g. bone marrow transplant 
units) will be excluded from participating in the study. 
• Presence of household member or close contact (for an additional 2 weeks after 
discharge from the isolation facility) who:  is less than 3 years of age; has known 
immunodeficiency; is receiving immunosuppressant medication; is undergoing or 
soon to undergo cancer chemotherapy within 28 days of viral inoculation; has 
been diagnosed with emphysema or chronic obstructive pulmonary disease 
(COPD), is elderly and resides in a nursing home, or who has severe lung disease 
or another significant medical; has received a bone marrow or solid organ 
transplant 
• Intending to travel within the next 3 months (to countries for which travel 
vaccinations are recommended). 
• Those employed or immediate relatives of those employed at RVL or staff and 
students working directly in or for any of the units in which the Chief Investigator 
works. 
• Receipt of blood or blood products, or loss (including blood donations) of 450 mL 
or more of blood, during the 3 months prior to inoculations.  
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• Acute use i.e. within 7 days prior to human viral challenge of any medication or 
other product (prescription or over-the-counter), for symptoms of hayfever, 
rhinitis, nasal congestion or respiratory tract infection. 
• Receipt of any investigational drug within 3 months prior inoculation  
• Receipt of more than 4 investigational drugs within the previous 12 months  
• Prior participation in a clinical trial with the same strain of respiratory virus.  
• Participation in any other respiratory virus challenge within 1 year prior to 
challenge.  
• Receipt of systemic glucocorticoids, antiviral drugs, and immunoglobulins or any 
other cytotoxic or immunosuppressive drug within 6 months prior to dosing. 
Receipt of any systemic chemotherapy agent at any time.  
• Presence of significant respiratory symptoms existing on the day of challenge or 
between admission for challenge and challenge with / exposure to virus.  
• History suggestive of respiratory infection within 14 days prior to admission for 
challenge / exposure.  
• Any other finding in the medical interview, physical exam, or screening 
investigations that, in the opinion of the investigator, GP or sponsor, deem the 
subject unsuitable for the study.  
 
Power Calculation 
Having achieved a secondary attack rate (SAR) of 25% in the ‘proof-of-concept’ 
study,(Killingley et al., 2012) we assumed that with increased numbers of donors 
per room, improved environmental control (temperature, humidity, ventilation 
rate), and a longer exposure time (increased from 2 days in the proof-of-concept 
study to 4 days) we would achieve an SAR of 40%. Based on a predicted SAR of 
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40% in CR and to detect a reduction of 50% (the magnitude of difference 
specified by the funder) in the IR group (i.e. a modified SAR of 20%), the 
statistical power of the overall experiment was estimated by conducting a 
computer simulation. 
 
Handling of Breath Samples 
Concentration of fine aerosol samples and extraction of coarse aerosol samples 
were performed at the quarantine site. All samples were stored at -80˚C, shipped 
to the University of Maryland on dry ice, and stored at -80˚C until analysis. 
 
Outcome Definitions 
Symptoms ‘lasting ≥24 hours’, were considered present if reported on 3/3 
symptom observations within a single day, or over two consecutive days at any 
frequency (i.e., occurring ≥1 out of 3 symptom observations on 2 consecutive 
days). Fever was defined as temperature >37·9 oC.  
Appendix 2.3. Baseline Characteristics 
 
Table S2.1 shows the baseline characteristics of the study volunteers, which were 
randomized as viral Donors (D), Intervention Recipients (IR), and Control 








Table S2.1. Baseline Characteristics 
 




   Female 15 (28.8%) 13 (32.5%) 12 (34.3%) 









Appendix 2.4. Trial profile 









Appendix 2.5. Comparing the Current Study and Proof-of-Concept Study 
Using Current Outcome Criteria and Applying Infection Criteria from The 
Proof of Concept Study  
 
As shown in Results, the observed SAR in the current study was significantly 
below the expected 16% SAR that would have resulted from a doubling of the 
proof-of-concept SAR in response to design changes including doubling the 
number of Donors per Recipient and doubling the number of days of Recipient 
exposure to Donors. The observed SAR was also lower, but not significantly 
different from the 8·3% (1/12) observed in the proof of concept study, applying 
the main study infection criteria to the proof of concept study data (proof-of-
concept v overall p = 0·26, proof-of-concept v CR p = 0·45, and proof-of-concept 
v IR p = 0·23).  
 
The proof of concept study published by Killingley and colleagues (2012) used 
less stringent qRT-PCR-based infection classification criteria. Whereas the current 
study required two days of qRT-PCR positive nasopharyngeal swabs, the proof of 
concept study required just a single day of PCR or culture positive nasal wash or 
throat swab. Seroconversion criteria for infection was the same for both studies. 
None of the recipients from the proof of concept study were culture positive, two 
had a single day each of PCR positive nasal wash, and one had evidence of 
seroconversion. The recipients with single PCR positive washes did not 
seroconvert and the seroconversion did not have a positive wash. The PCR criteria 
were tightened because a single positive PCR, especially with high Ct values and 
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without concomitant seroconversion, could represent random laboratory errors 
and because it is not clear that they represent true infection.  
 
If we were to apply the proof-of-concept study’s infection classification criteria to 
the main quarantine transmission study, we would have observed 2 more infected 
donors and 2 more infected CR. Tables S2.2 and S2.3 reproduce Tables 2.1 and 
2.3 from the manuscript main text (Donor and Recipient status, respectively), but 
apply the infection criteria used in the proof of concept study. 
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Table S2.2. Donor Status using infection criteria from proof of concept study 
 Clinical Illness (% of Infected) 
Laboratory Confirmed Infection Criteria (% of 
Infected) 








HAI : MN : Either 
1 15/20 (75) 11 (73) 4 (27) 8 (53) 13 (87) 12 (80) 12 : 14 : 14 
2 11/12 (92) 7 (64) 0 (0) 5 (45) 11 (100) 9 (82) 9 : 7 : 9 
3 18/20 (90) 16 (89) 2 (11) 14 
(78) 
17 (94) 13 (72) 14 : 11 : 14 
Total 44/52 (85) 34 (77) 6 (14) 27 
(61) 





Table S2.3. Recipient Status using infection criteria from proof of concept study 












HAI : MN : Either 
1 
Control (CR) 0/11 (0) 4 (36) 0 (0) 3 (27) 0 (0) 0 (0) 0 : 0 : 0 
Intervention (IR) 0/10 (0) 2 (20) 0 (0) 1 (10) 0 (0) 0 (0) 0 : 0 : 0 
2 
Control (CR) 3/9 (33) 2 (22) 0 (0) 2 (22) 2 (22) 0 (0) 1 : 1 : 1 
Intervention (IR) 0/10 (0) 3 (30) 0 (0) 2 (20) 0 (0) 0 (0) 0 : 0 : 0 
3 
Control (CR) 0/15 (0) 6 (40) 0 (0) 4 (27) 0 (0) 0 (0) 0 : 0 : 0 
Intervention (IR) 0/20 (0) 6 (30) 0 (0) 2 (10) 0 (0) 0 (0) 0 : 0 : 0 
Total 
Control (CR) 3/35 (9) 12 (34) 0 (0) 9 (26) 2 (6) 0 (0) 1 : 1 : 1 
Intervention (IR) 0/40 (0) 11 (28) 0 (0) 5 (12) 0 (0) 0 (0) 0 : 0 : 0 
 
The original proof of concept reported an SAR of 25% (3/12). If we were to apply the 
less stringent, proof of concept infection criteria to the main study, we would observe 
an overall SAR of 4%, with three infections among CR and zero among IR. This 
represents a significant difference between the proof-of-concept and the main study 
overall (p = 0·03), in contrast to the non-significant difference between studies using 
the more stringent outcome criteria. The difference between the proof-of-concept and 
the CR group (p = 0·16 would continue to fall short of being statistically significant. 
However, the main study was designed to more than double the exposure and thus the 
expected SAR. Thus, in comparison with an expected SAR of 50%, the observed 
SAR was significantly lower (4% overall, p <0·0001; and 9% among CR, p <0·0001). 
The observed is similarly statistically significantly lower than the more conservative 
expected SAR of 40% used in the power calculations.  
 
These alternate approaches to the outcome criteria produced similar results. Using the 
less stringent criteria increased the level of statistical significance showing that the 
difference between the larger challenge-transmission experiment and the proof-of-
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Table S3.1. Unadjusted odds ratios on shedding into fine aerosols above LOD 
Predictor  
Experimental  
OR (95% CI) 
Natural  
OR (95% CI)  
Combined Groups 
OR (95% CI) 
Age 1.05 (0.92-1.19)  0.98 (0.93-1.04) 0.9 (0.85-0.95)  
Sex - 2.22 (0.99-4.97)  1.19 (0.62-2.29)  
Study day* 
Day 1 - REF - 
Day 2 REF  0.25 (0.06-1.03)  - 
Day 3 50.89 (0.07-
36,036.30) 
 
0.17 (0.04-0.73)  - 
Day 4 0 (0-7.51) - - 
Febrile >37.9oC 4.51 (0.48-42.28) 0.87 (0.35-2.18) 1.64 (0.72-3.71)  
Temperature (C) 4.77 (0.94-24.17)  1.88 (0.87-4.06)  6.11 (3.11-12)  
Upper respiratory symptom 
score  
2.24 (1.07-4.69)  1.07 (0.93-1.22)  1.42 (1.26-1.61)  
Lower respiratory symptom 
score  
6.49 (1.14-37.09)  1.35 (1.04-1.76)  2.12 (1.67-2.69)  
Systemic symptom score  1.73 (0.94-3.16)  1.15 (0.97-1.36)  1.56 (1.34-1.82)  
Total symptom score  1.64 (1.09-2.47)  1.07 (0.99-1.15)  1.21 (1.13-1.29)  
Cough score (as continuous) 7.49 (1.28-43.91)  1.9 (1.2-2.99)  3.44 (2.32-5.09)  
Cough (as factor) 
No symptom REF REF REF 
Mild 7.49 (1.28-43.91) 8.5 (0.81-88.85) 10.54 (4.1-27.11)  
Moderate - 12.92 (1.32-126.08) 23.69 (9.31-60.28)  
Severe - 20.4 (2.06-202.21) 37.4 (14.15-98.84)  
Cough count 1.29 (1.02-1.62) 1.02 (1-1.04)  1.07 (1.04-1.09)  
Nasopharyngeal swab Ct 
value  
0.74 (0.6-0.92)  0.98 (0.91-1.05)  0.89 (0.84-0.94)  
* Study day refers to day post nasal inoculation for experimentally infected cases with a range of 1-
4. For naturally infected cases, study day refers to day post symptom onset with a range of 1-3. No 
fine aerosol shedding was observed on day 1 post inoculation for experimentally infected cases. 
Because of differences in meaning for the study day variable between groups, combined estimates 
are not given.  
 
Using all exhaled breath observations for the 39 experimental and 83 natural infections (N=84, 146, 
respectively and 230 combined). Effect of a single unit increase in temperature or symptom scores. 
Effect of febrile compares ever febrile>37.9oC to afebrile. Effect of sex compares male to female. 





OR (95% CI) 
Natural  
OR (95% CI)  
Combined Groups 
OR (95% CI) 
Cough scores of 2 or 3 were never observed in the experimental group. Limit of detection (LOD) 
for influenza A aerosols was 500. Per Yan et al., 2018, LOD represents “the most dilute sample that 
gave a positive result in any replicate.” 
Table S3.2 (part 1/3). Quality of covariate balance after propensity score adjustment 































































Propensity subclassification by stratification***  













































































































































* Range across all covariates (not only covariates in the propensity score model) 
** Greedy match: experimentally infected were selected randomly, one by one and matched with the observation in the naturally 
infected group that had the nearest linear propensity score.  
*** Bottom quantiles reported only: Only bottom quantiles for stratification by sextiles, quintiles, quartiles, and tertiles had enough 
samples in both groups to take standardized differences and variance ratios for all covariates.  
**** ATT. Average treatment effect for the treated (where naturally infected cases are considered “treated”) 
***** Propensity weighting by ATE (average treatment effect approach, where naturally infected cases are considered “treated”) 
consistently provided the best balance between groups. For this reason, mean absolute standardized differences are given to 
provide an additional indicator of balance beyond standardized difference ranges. 
 
Model 1 covariates: lower respiratory score, cough score, cough count  
Model 2 covariates: lower respiratory score, cough score, cough count, upper respiratory score  
Model 3 covariates: lower respiratory score, cough score, cough count, NP swab ct value  
Model 4 covariates: lower respiratory score, cough score, cough count, body temperature 




Table S3.2 (part 2/3). Quality of covariate balance after propensity score adjustment 

















Stand. Dif. Var. Rat. 








































Propensity subclassification by stratification  




































































































































Model 6 covariates: lower respiratory score, cough score, cough count, upper respiratory score, body temperature 
Model 7 covariates: lower respiratory score, cough score, cough count, upper respiratory score, NP swab ct value , body 
temperature 
Model 8 covariates: cough and cough count 
Model 9 covariates: cough count and body temperature 




Table S3.2 (part 3/3). Quality of covariate balance after propensity score adjustment 















































Propensity subclassification by sextiles 












































































































Model 11 original covariates: lower respiratory score, age, cough, cough count, upper respiratory score, 
systemic symptom score, NP ct value, body temperature (Algorithm did not converge, so chose 
new model 11 covariates.) 
Model 11 new covariates: cough score, body temperature (Variables were dropped from the original 
model 11 specification one by one, in order of lowest effect strength to highest; algorithm failed to 
converge until I arrived at the new model 11 specification.) 
Model 12 covariates: fever and body temperature 
Model 13 covariates: fever, body temperature, and upper respiratory symptom score  
Model 14 covariates: febrile, body temperature, and total symptom score 




Figure S3.1. Comparison of self-reported symptoms and observed cough counts with 
all observations. From N=84 experimental, and N=146 natural infection sample days 
where aerosols were also collected. Density plots, scaled so that the highest value for 
a single moment is equal to one, compare (A) upper respiratory symptoms (runny 
nose, stuffy nose, sneezing, sore throat, and earache, score range 0-15), (B) lower 
respiratory symptoms (shortness of breath, and cough, score range 0-6), and (C) 
systemic symptoms (malaise, headache, muscle/joint ache, score range 0-9). (D) Total 
symptom score (range 0-30). (E) Cough symptom score (range 0-3). (F) Observed 
cough counts with boxes showing the inner-quartile range (IQR) with a band to 
indicate the median, and whiskers extending to the highest and lowest data points 
























































































Figure S3.2. Comparison of natural and experimental RNA copy shedding into fine 
and coarse aerosols. (A) Histogram of RNA copies shed into fine and coarse aerosols. 
(B) Boxplot comparison by group and aerosol fraction includes all positive samples. 
Scatter plots of log10 RNA copies in ascending order (along x-axis) of shed into 
aerosols over quantiles (relative to experimental or naturally infected group, with 
normal distribution assumed): (C) samples below LOD plotted as zero; (D) plotted 




Figure S3.3. Nasopharyngeal swab Ct values over time. Includes all qRT-PCR 
detectable nasopharyngeal swab samples during days 1-6 post-inoculation, and days 
1-3 post symptom onset for experimental and naturally infected cases, respectively. 
Boxes show the inner-quartile range (IQR) with a band to indicate the median, and 




Figure S3.4. Maximum fine and coarse aerosol shedding, limited to samples above 
LOD, (A) histogram of RNA copies shed into fine and coarse aerosols, (B) RNA 
shedding comparison by group and aerosol fraction, (C) RNA shedding quantity of 




SI.3 Appendices  
 
Appendix 3.1. Selection of naturally infected cases for analysis from larger 
population of naturally infected community cases collected at University of 
Maryland 
 
The set of data from the community cases observed in the University of Maryland 
campus community are different from that of the “complete data” used in the analyses 
of Yan et al., 2018. The data in the current manuscript come from the set of 158 qRT-
PCR confirmed influenza cases with exclusion of all breath collection visits from four 
dual influenza infections, breath collection visits on days 0 and >3 post symptom 
onset, as well as those with incomplete qRT-PCR data, and those that were not H3 
infections confirmed by qRT-PCR of nasopharyngeal swab. Cough counts from three 
exhaled breath sampling visits that were missing and thus excluded by Yan and 
colleagues, were imputed for this analysis. Table S3.3 provides a summary of cases 
and exhaled breath collection visits selected for analysis from 178 enrolled 
community cases.   
Table S3.3. Community case exclusion and inclusion to achieve analytical dataset 
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Total screened - - - - - 355 276 
Case inclusion 
criteria* 
177 0 0 0 0 178 276 
Not confirmed 
by qRT-PCR 
20 26 0 0 26 158 250 
Day 0, >3 post 
symptom onset 




5 6 1 1 7 144 225 
Dual 
infection*** 
3 4 0 0 4 141 221 
Non H3 
infection 
58 75 0 0 75 83 146 
Overall 95 119 10 11 130 83 146 
* Positive Quidel QuickVue rapid influenza test, or oral temperature >37.8 °C, plus cough or sore throat, and (ii) presented within the 
first 3 d of symptom 
onset. 
 
** Description of the incomplete PCR data: 
• Drop subject 333 1 and only G-II visit because lost coarse aerosol sample (although good data exists for the NP and the fine 
aerosol) 
• Drop subject 52 because false positive (this makes 52 a negative case and thus we exclude all sampling instances) 
• Drop subject 58 because false positive (58 only had 1 G-II sampling instance so this was excluded) 
• Drop subject 182 2nd G-II visit because bad inter-run calibrator on the PCR (there is still a 1st G-II visit for 182 so this 
subject is not excluded entirely) 




• Drop subject 337 because bad inter-run calibrator on the PCR (this was the only G-II sampling instance, so this subject is 
excluded entirely) 
 
*** Dual infections: 
• 1 instance: H3N2 and Pandemic H1 
• 1 instance: B and unsubtypable A 
• 1 instance: B and H3N2 
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Appendix 3.2. Propensity score workflow 
Table S4. Codebook of the data frame used in propensity score analyses 
Variable Type of Variable Description 
subject.id Subject ID # (numeric, integer 
variable) 
ID numbers below 400 are UMD Flu 
Cases. ID numbers above 400 are 
Infected Donors. 
Group Factor with two levels, 0 and 1 
(the “Group” variable is actually 
numeric and uses 0 and 1 as the 
only possible options: 0 for 
Infected donors and 1 for UMD 
flu cases; but the “Group_factor” 
variable is the factor variable and 
uses the text “Infected donors” 
and “UMD Flu Cases” as the 
levels. 
Coded as 0 = Infected donors; 1 = 
UMD flu cases 
Group_factor Factor with two levels 0 and 1 Coded as 0 = Infected donors; 1 = 
UMD flu cases (the levels of the 
variable are written as “Infected 
donors” and “UMD Flu Cases”  
Age Numeric, integer variable  Age in years 
Sex Factor with two levels, 0 and 1 
(although technically this “sex” 
variable is coded as numeric with 
possible levels 0 and 1 and the 
sex_factor variable is the one that 
is factor with levels “female” and 
“male”) 
0 = female, 1 = male 
Sex_factor Factor with two levels “female” and “male” (with female 
coded as 0 and male as 1 in the “sex” 
variable) 
Upper_resp Numeric, discrete  Sum of the ordinal (4-level from 0-3 
with 0=none and 3=severe symptom) 
for the following symptoms: runny 
nose, stuffy nose, sneezing, sore throat, 
and earache, score range 0–15. 
Lower_resp Numeric, discrete Sum of the ordinal (4-level from 0-3 
with 0=none and 3=severe symptom) 
for the following symptoms: shortness 
of breath, and cough, score range 0–6 
Systemic_sx Numeric, discrete  Sum of the ordinal (4-level from 0-3 
with 0=none and 3=severe symptom) 
for the following symptoms: malaise, 
headache, muscle/joint 
ache, score range 0–9 
Total_sx Numeric, discrete  Sum of the ordinal (4-level from 0-3 
with 0=none and 3=severe symptom) 
for the following symptoms: runny 
nose, stuffy nose, sneezing, sore throat, 
earache, shortness of breath, cough, 
malaise, headache, muscle/joint 
ache: score range 0–30. 
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Cough Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe 
symptom 
Cough_factor Factor, 4 levels "0-none", "1-mild", "2-moderate", "3-
severe" coded for cough self-reported 
symptom scores of 0, 1, 2, and 3, 
respectively.  
cough_count_full Numeric, discrete.  Number of times coughed during 30-
minute sample collection in the g-ii 
machine. Included 2 instances of 
missing cough in the Infected donor 
group 
Body_temp Continuous (1 decimal place)  
Ever_febrile Numeric, discrete (factor with 2 
levels) 
1 = had fever > 37.9 degrees C on any 
of the days of observations (1-4 days 
post inoculation for donors and 1-3 day 
post symptom onset for UMD Flu 
Cases). 0 = temperature reading was 
below the study threshold for “febrile 
illness” 
Ever_febrile_factor Factor (2 levels) Coded as “yes” = 1 (yes, was febrile at 
some point during observation), “no” = 
0 (no, was never observed to reach the 
body temperature threshold for febrile).  
NP_ct Continuous (2 decimal places) CT value on the qRT-PCR assay for 
influenza A viral RNA.  
sample_mean_copies Continuous outcome RNA copies – the mean of replicates 
for samples with detectable virus (have 
not used tobit to impute for samples 
where there was not at least 1 replicate 
above detection limit).  
Variables in dataframe but not used 
study.day Character variable with 4 levels. The 4 levels represent the possible 
study days. For UMD Flu Cases the 
study day refers to the three days post 
symptom onset and for Infected donors 
the study day refers to the four days 
post inoculation.  
sample.type Character variable with 2 
possible levels 
For this df this variable is always 
“Condensate” because the fineflu data 
frame has been filtered to included only 
the condensate samples and their 
associated clinical evaluation data.  
Date Character Date of the data collection for the 
associated observation.  
Nose_run Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Nose_stuf Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Sneeze Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Throat_sr Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Earache Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
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Malaise Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Sob Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Headache Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Mj_ache Numeric, discrete (factor with 4 
levels) 
4 levels for symptoms severity with 0 
as no symptom to 3 as most severe  
Febrile_day Numeric, discrete (factor with 2 
levels) 
1 = had fever > 37.9 degrees C on the 
associated day of data collection. 0 = 
temperature reading was below the 
study threshold for “febrile illness” 
Cough_number Numeric, discrete.  Number of times coughed during 30-
minute sample collection in the g-ii 
machine. Included 2 instances of 
missing cough in the Infected donor 
group 
This table describes data that has been restricted to the maximum day observation of shedding for 
those who shed into fine aerosols. There are 71 observations for UMD Flu Cases and 11 for Infected 
donors. Each observation corresponds to the day with the highest observed RNA copy number 
(average of replicates) shed into fine aerosol for each subject. Note that there were a total of 83 
UMD flu cases (flu A) and 39 Infected donors so we can already see that only 28% of the Infected 
Donors shed into fine particle aerosols, while 86% of UMD Flu A Cases shed into fine particle 
aerosols. Analysis with the outcome of the odds of shedding into fine aerosols will also be done.  
 
Propensity work with outcome as continuous shedding 
 
Specifying the propensity score model 
The propensity score model is a logistic regression model. It regresses the logit of the 
study population (natural versus experimental infection) on a set of covariates. 
Comparison groups conditioned on an appropriately specified propensity score should 
have similar means and variances, with standardized differences of close to 0 and 
variance ratios of close to 1 (Austin, 2009). Propensity score models that achieved 
comparison group balance after conditioning on propensity score were considered for 
use in estimating the effect of comparison group membership on the outcomes of 
interest. Propensity score model specifications that achieved balanced population 
means were also tested against Donald Rubin’s propensity score balancing criteria. 
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Rubin’s criteria assesses the degree of overlap between propensity scores in each 
group. Correctly specified propensity score models that also have enough overlap in 
propensity scores sufficiently minimize bias introduced by lack of group 
randomization, with the acknowledgement that unmeasured confounders may still 
introduce bias. None of the 14 propensity score models tested achieved enough 
covariate balance between naturally and experimentally infected study populations, 
even after truncating the sampling frame from both groups. Thus, we conclude that 
the populations are too different to make support valid comparisons between groups 
with respect to the outcome, even if covariate adjustment should be used.   
 
In the initial propensity score model, predictors of experimental or natural infection 
group were selected on the basis of their relationship with the outcome of observed 
shedding into fine aerosols above the detection limit. The lower respiratory symptom 
score, cough symptom score, and the cough count observed during half-hour exhaled 
breath collection all had positive, statistically significant effects on the odds of viral 
shedding into fine aerosols. Since the cough symptom score makes up 50% of the 
lower respiratory score and likely drives the effect seen in the lower respiratory score, 
the cough score and not the lower respiratory symptom score was included. Thus, the 
initial propensity score model included only cough symptom score and observed 
cough count as predictors. Overlap in propensity scores between study population 




Propensity score model specifications need not be concerned with multicollinearity 
because the estimated propensity scores and not the variances are of main interest. 
Age was associated with study population, however published literature assessing 
propensity score model specification have warned against including variables that are 
associated with group membership but not the outcome of interest because of the risk 
of increasing variance in the estimated effect without reducing bias (Austin et al., 
2007; Brookhart et al., 2006).  
 
Donald Rubin’s rules for assessing propensity score balance were used to evaluate 
propensity score model specifications (Rubin, 2001) (add citation: 2001 paper from 
Rubin about using propensity scores to design studies – Rubin DB 2001 Using 
Propensity Scores to Help Design Observational Studies: Application to the Tobacco 
Litigation. Health Services & Outcomes Research Methodology 2: 169-188). Failure 
of balance between covariates in the two study populations indicates the need for 
adjustment using three propensity score balancing methods: matching, 
subclassification, inverse probability weighting. Valid of the effect of natural 
infection compared with experimental infection, in our specific studies, can be carried 
out after improving balance to an acceptable range.  
• First rule: The absolute value of the standardized difference of the linear 
propensity score should be close to 0 and definitely less than 50. 
• Second rule: The ratio of variances of the linear propensity score between the 
comparison groups (i.e., natural to experimental infection). This should be 
close to 1 and definitely between ½ and 2. 
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• Third rule: After regressing the residuals for each covariate specified in the 
propensity score model on the linear propensity score, the ratio of variance of 
residuals between comparison groups (i.e., natural to experimental infection) 
close to 1.  
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Appendix 3.3. Description of comparison analysis and profile of studies that 
generated data 
 
Figure S3.5 shows the enrollment profiles of the two studies and DAG (directed 
acyclic graph) used for making comparisons between experimentally and naturally 
infected influenza A/H3 cases. The main outcomes of interest are the probability of 
shedding virus into aerosols and the rate of viral shedding in aerosols. Given their 
role in transmission, fine particle aerosols are of particular interest. These outcomes 
are illustrated in the DAG (Figure S3.5). Other comparisons of interest are the 
temporal dynamics of illness, the temporal dynamics of aerosol shedding, and the 
overlap of symptoms with strength and duration of shedding.  
 
The main independent variable of interest is the mode of inoculation, with the 
experimentally challenged infections representing contact transmission via exposure 
to nasal mucosa, and the naturally infected cases representing transmission by any 
plausible mode (the red rectangle in the DAG). Other differences may exist in the two 
study populations related to the conditions of infection initiation including systematic 
differences in age, sex, immunity, and dose. Although these potential confounders 
may not be completely controlled for by study design, they are not likely to play a 
major role in confounding the interpretation that experimentally infected cases 
represent contact or large droplet spray transmission to the upper respiratory tract and 
naturally infected cases represent transmission by any plausible mode. Brief 




The source population for the observational study and the inclusion criteria for the 
challenge study favored recruitment of healthy, young adults. The age of the young 
adults was several years higher but unlikely to drive differences in susceptibility. 
Susceptibility is likely to be higher for young children or elderly populations. Male 
and female were well balanced in study population of naturally infected cases; 
however, this distribution was skewed in the trial study with a majority male 
infections. Epidemiological evidence from various influenza seasons, and illnesses in 
various age groups suggests that males may have elevated risk hospitalization, 
suggesting a potential role for sex in influenza pathogenesis (Gabriel and Arck, 
2014). It is uncertain to what extent sex may influence susceptibility to infection, but 
it is acknowledged as a potential confounder in the relationship between study 
population membership and infection initiation for members of the studies. Virally 
challenged volunteers were screened for low levels of pre-existing antibodies (HAI 
≤10), while the naturally infected population was not. The symptomatic, naturally 
acquired infections were likely to have had less immunity compared with the total 
source population because they were infected. But, a small subset of naturally 
infected cases had been immunized for influenza for the current and/or previous 
influenza seasons, pointing toward a range of pre-existing antibodies above the 
exclusion threshold of the trial study (Yan et al., 2018). Thus, pre-existing antibodies 
were unmeasured in the naturally infected study population and could be a 
confounding factor related to the infection conditions between the study populations. 
The laboratory prepared virus used for human challenge could have been attenuated 
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compared with wildtype, but virologic investigation of this virus suggests that the HA 
variant matches other wildtype viruses and may not be a major source of difference 
(Nguyen-Van-Tam et al., 2019; Sobel Leonard et al., 2016). Finally, the dose leading 
to infection may have been different between the two study populations and could 
also be a confounding variable. Volunteers received an intranasal dose of 5.5 log10 
TCID50, however the dose leading to infection in the naturally infected populations 
was unmeasured. It has been shown that low doses of aerosolized virus can initiate 
infection (Alford et al., 1966). In naturally infected cases not infected by aerosols 
(i.e., infected similarly to infected volunteers, via contact exposure to upper airway 
mucosa), they may have been exposed to a range of doses and correlations between 
dose and viral shedding peak and duration have been reported in volunteers 
challenged with influenza virus (Keitel et al., 1990). Overall, potential confounding 
factors between transmission mode – the main independent variable of interest – and 
the initiation of infection that may not have been fully controlled for in the designs of 
the experimental and observational studies were age, sex, host immunity, viral 
pathogenicity, and dose. Assessment of these potential confounders leads us to 
believe that they are not likely to have a substantial effect in obscuring the main 
effect of mode on the conditions of infection in the study populations.  
 
Covariates are illustrated as confounders because there is reported evidence and/or 
biological plausibility for considering them so based on their expected effects on the 
independent variable (study population membership) and the dependent variables 
(aerosol shedding probability and rate). We attempted to achieve acceptable balance 
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across these confounders with propensity score model adjustment, however, were 
unable to do so because the populations were simply too different in their 
distributions for these variables.  
 
Figure S3.5. Profiles of the EMIT studies and DAG. (Top) study profiles used to 
make comparisons between experimental and naturally infected populations. Cloud 
shapes depict unobserved variables that are believed to be true. DAG (directed 
acyclic graph, bottom) for comparing aerosol shedding in the study populations.   
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CHAPTER IV SUPPLEMENTARY INFORMATION 
 
EMIT Team Members 
EMIT team members were: Walt Adamson, Blanca Beato-Arribas, Werner Bischoff, 
William Booth, Simon Cauchemez, Sheryl Ehrman, Joanne Enstone, Neil Ferguson, 
John Forni, Anthony Gilbert, Michael Grantham, Lisa Grohskopf, Andrew Hayward, 
Michael Hewitt, Ashley Kang, Ben Killingley, Robert Lambkin-Williams, Alex 
Mann, Donald Milton, Jonathan Nguyen-Van-Tam, Catherine Noakes, John Oxford, 
Massimo Palmarini, Jovan Pantelic, and Jennifer Wang. The Scientific Advisory 






Table S1. Fine particle aerosol shedding strength from detected samples 
Quarantine  
Exposure 
Group Day 2 Day 3 Day 4 Daily Average*** 
1  
A  8.8E+3 (1, 2)  1.6E+5 (1, 2)  ND (0, 2)  5.6E+4 (2, 6)  
  B*  ND (0, 2)  ND (0, 1)  ND (0, 2)  ND (0, 5)  
C  ND (0, 3)  1.3E+4 (1, 2)  ND (0, 1)  4.4E+3 (1, 6)  
  D*  ND (0, 2)  ND (0, 2)  ND (0, 2)  ND (0, 6)  
E  ND (0, 2)  1.3E+5 (1, 3)  1.6E+4 (1, 3)  5.0E+4 (2, 8)  
2  
  A*  ND (0, 2)  ND (0, 4)  ND (0, 0)  ND (0, 6)  
B  2.4E+3 (1, 4)  3.5E+3 (1, 2)  ND (0, 1)  2.0E+3 (2, 7)  
    C**  9.8E+3 (1, 4)  1.3E+5 (1, 4)  ND (0, 3)  4.6E+4 (2, 11)  
3  
A  ND (0, 2)  ND (0, 2)  4.3E+3 (1, 2)  1.4E+3 (1, 6)  
B  2.0E+3 (1, 2)  ND (0, 1)  ND (0, 2)  6.7E+2 (1, 5)  
C  ND (0, 2)  2.6E+3 (1, 2)  ND (0, 2)  8.8E+2 (1, 6)  
D  3.9E+3 (1, 2)  ND (0, 2)  ND (0, 2)  1.3E+3 (1, 6)  
E  ND (0, 2)  3.9E+3 (1, 3)  ND (0, 2)  1.3E+3 (1, 7)  
RNA copies shed into fine particle exhaled breath aerosols per hour by day-EG, ⋁𝑗𝑘 , by EG, ⋁𝑘 from 
samples with at least one detectable qRT-PCR replicate (number samples with at least 1 detectable 
qRT-PCR replicate, number samples tested). ND: not detected = 0/2 qRT-PCR replicates detected, or 
no sample collected.  
* EGs with no Donors observed to shed any fine aerosols with at least one qRT-PCR replicate 




Table S2. Infectious quanta generation rate and sigma 
Change in CO2  q(all Donors) q(aerosol shedders) sigma 
-50%  0.089 (0.083, 0.094)  0.32 (0.26, 0.36)  2.4E+5 (1.7E+5, 3.0E+5)  
-40%  0.063 (0.059, 0.066)  0.23 (0.19, 0.26)  2.2E+5 (1.5E+5, 2.8E+5)  
-30%  0.048 (0.046, 0.051)  0.18 (0.15, 0.2)  2.0E+5 (1.4E+5, 2.5E+5)  
-20%  0.04 (0.037, 0.042)  0.14 (0.12, 0.16)  1.8E+5 (1.3E+5, 2.3E+5)  
-10%  0.033 (0.031, 0.035)  0.12 (0.1, 0.14)  1.6E+5 (1.1E+5, 2.0E+5)  
Observed  0.029 (0.027, 0.03)  0.11 (0.088, 0.12)  1.4E+5 (1.0E+5, 1.8E+5)  
+10%  0.025 (0.024, 0.027)  0.093 (0.077, 0.11)  1.2E+5 (8.5E+4, 1.5E+5)  
+20%  0.023 (0.021, 0.024)  0.084 (0.07, 0.094)  1.0E+5 (7.2E+4, 1.3E+5)  
+30%  0.021 (0.019, 0.022)  0.076 (0.063, 0.085)  8.0E+4 (5.8E+4, 1.0E+5)  
+40%  0.019 (0.018, 0.02)  0.069 (0.057, 0.078)  6.0E+4 (4.4E+4, 7.6E+4)  
+50%  0.017 (0.016, 0.018)  0.063 (0.053, 0.071)  4.0E+4 (3.0E+4, 5.0E+4)  






















Figure S4.1. Depicts observed minus Tobit model expected values for all 33 sample 




























Figure S4.2. Depicts log10 (RNA copies) shed per hour into exhaled breath fine 
particle aerosol by study day, for samples with at least one detectable qRT-PCR 
replicate and for all samples with at least one detected qRT-PCR replicate in addition 
to samples below detection limit or unobserved with Tobit estimated shedding rates 
among ever-aerosol shedders; the boxes show the inner-quartile range (IQR) with a 
band to indicate the median, and whiskers extending to the highest and lowest data 




Figure S4.3. Infectious quanta generation rate and sigma. Effect of indoor CO2 level 





Appendix 4.1. Note about one volunteer excluded as an infected or aerosol 
shedding Donor 
There was an instance where a Donor (subject 109) had one replicate qRT-PCR 
detected for fine aerosols but no positive swabs and no indication of seroconversion, 
so we did not count this as a true infection and did not include their aerosols samples 
as positive below LOD in the final analysis.  
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Appendix 4.2. Tobit regression model parameters and diagnostics 
I. Tobit model using 19 samples (N=10, four, and five, where two, one, and zero 
out of two qRT-PCR duplicates were detectable, respectively) from a total of 
11 Donors who ever shed into fine particle aerosols. Model: fixed effects of 
cough and study day with random effect of person to predict fine aerosol 
shedding (RNA copies per hour).  
Fit Statistics 














0.3568 0.1636 10 2.18 0.0542 -0.00772 0.7214 -0.00010 
Random effect 
of person 
0.04104 0.01532 10 2.68 0.0231 0.006913 0.07517 0.001449 
Intercept 2.9801 0.2074 10 14.37 <.0001 2.5180 3.4421 -0.00001 
Cough score 
(daily average) 
0.08768 0.2605 10 0.34 0.7434 -0.4928 0.6681 0.000129 
Study day 3 vs 
study day 2 
0.9946 0.1825 10 5.45 0.0003 0.5880 1.4013 0.000196 
Study day 4 vs 
study day 2 
0.02316 0.1773 10 0.13 0.8987 -0.3720 0.4183 0.000080 
 
 
II. Tobit model using 14 samples (N=10 and four, where two and one out of two 
qRT-PCR duplicates were detectable, respectively) from a total of 11 Donors 
who ever shed into fine particle aerosols. Model: fixed effects of cough and 
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study day with random effect of person to predict fine aerosol shedding (RNA 
copies per hour).  
Fit Statistics 














0.3534 0.1626 10 2.17 0.0549 -0.00896 0.7157 2.357E-6 
Random effect 
of person 
0.04063 0.01549 10 2.62 0.0255 0.006107 0.07515 0.000011 
Intercept 2.9345 0.2091 10 14.03 <.0001 2.4685 3.4005 1.893E-6 
Cough score 
(daily average) 
0.03770 0.2624 10 0.14 0.8886 -0.5469 0.6223 -0.00002 
Study day 3 vs 
study day 2 
1.0832 0.1939 10 5.59 0.0002 0.6513 1.5151 -0.00002 
Study day 4 vs 
study day 2 




Appendix 4.3. BSRIA Report on indoor air conditions in the quarantine facility 




Appendix 4.4. Relationship between q, fine aerosol shedding, and SIR models 
Variables related to infectious dose that are absorbed by the 𝑞 value include: a) host 
immune status (influenced by genetics, prior/recent or concurrent infectious disease 
exposures, vaccination history, psychosocial stress, coinfection, chemical or physical 
exposures, etc.), b) viral virulence, c) deposition probability in various vulnerable loci 
in the lung, d) number of viruses per infectious particle, e) biological and physical 
decay rate of infectious particles, and f) stochasticity of inhaled air viral exposure. 
These variables represent effect modifiers with potential to dramatically influence the 
relationship between inhalation exposure to air containing a quantifiable level of 
infectious influenza virus, and infectious risk. Understanding the strength of these 
effect modifiers, individually and together, improves airborne risk assessment under 
more specific exposure scenarios. Thus, the quantum is not solely related to the 
strength of airborne viral contamination, but also a function of these other variables 
that modify the effect of the viral exposure. A quantum could be dramatically 
different between individuals. 
 
Issarow et al., 2015 builds upon the rebreathed-air equation to give the transmission 
risk for susceptibles as: 




,     
 (12) 
with 𝑇 time at infection, 𝑡 time until infection, 𝐼 infectious individuals shedding virus 
into exhaled breath aerosols, 𝑛 room occupants contributing exhaled breath, 𝜃 
deposition fraction of particles to vulnerable loci in the respiratory tract, 𝜇 particles 
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that do not reach the lung due to physical decay, and 𝛽 concentration of infectious 
particles in the environment. This formulation describes the relationship between 
airborne virus present in an indoor space and the effective exposure dose that reaches 
vulnerable loci in the respiratory tract. An alternative formulation to takes 𝑞 as the 
product of: a) 𝜃, the deposition fraction, b) 𝛾, the average probability of escaping the 
host defenses given deposition at a vulnerable locus, and c) 𝛽, this time taken to mean 
the rate of viral contamination of the air through exhaled breath. Thus, compared with 
the Issarow, et al. version 𝑞 = (𝛽 − 𝜇)𝜃, we take 𝑞 = 𝜃𝛾𝛽. The multiplicative form 
is generally more computationally suitable for these models. This formulation for 𝑞 
can be generalized for various size fractions or limited to solely the fine-particle size 
fraction as presented here, thus introducing host immunity, virulence, and deposition 
considerations into to the q term. Additional nuance on risk by deposition site can be 
introduced and has been explored elsewhere (Cheng et al., 2016). 
 
The effect of biological and physical decay can be addressed by using 𝜃𝜌𝜇 as the lung 
deposition equal to 𝜃 reduced by the predicted biological decay 𝜌 and physical decay 
𝜇, which includes diffusional deposition. Biological decay is governed by 
environmental temperature and humidity, and by virus robustness. Physical decay 
would be influenced by particle size and room air turbulence.  
 
By using the Equation 13: 




where 𝜈 is the number of infectious virions per aerosol particle, we incorporate the 
additional risk posed by particles that may be comprised of multiple infectious agents. 
Multiple virions may be packaged into a fine particle during  aerosol production in 
the lung. Vesicles carrying multiple pathogens for enteric viruses have been observed 
and support motivation for the investigation of similar packaging for airborne 
influenza virus-carrying particles (Altan-Bonnet, 2016).  
 
Accounting for stochasticity in airborne exposure and infection risk effectively 
increases the upper bound for the amount of inhaled virus, given the precautionary 
principle and modelling for the highest risk level required to prevent transmission. 
Noakes and Sleigh, 2009 implemented a stochastic zonal model to deal with 
imperfect air mixing and report that transmission risk is otherwise underestimated by 
as much as 15%. A summary of improved model considerations to improve the 
precision of the 𝑞 term is provided in Table S4.3. 
 
Table S4.3. Variables absorbed by q 
Variable Existing models Proposed model 
Host immunity 𝜃 (Issarow et al., 2015) 𝛾 (Population averaged probability 
of escaping host defenses 
influenced by host immunity and 
virulence of virus) 
Virulence of pathogen 𝜃 (Issarow et al., 2015) 𝛾 (Population averaged probability 
of escaping host defenses 
influenced by host immunity and 
virulence of virus) 
Deposition fraction to vulnerable 
loci in respiratory tract 
𝜃 (Issarow et al., 2015) 𝜃 (Deposition fraction of particles 
on vulnerable loci, based on the 
various size fractions) 
Infectious viruses per particle None 𝜈 (Infectious particles per aerosol 
particle) 
Biological decay rate 𝜃 (Issarow et al., 2015) 𝜌 (May be influenced by particle 
size and the type of virus) 
Physical decay rate 𝜇 (Issarow et al., 2015) 𝜇 
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Stochasticity of exposure and 
infection risk 
(Noakes and Sleigh, 
2009) 
Incorporate stochasticity term to 
account for potential increases in 
exposure to inhaled particles 
and/or stochastic increases in 
infection risk (increases the effect 
of the 𝜃 term) 
 
Linking airborne infection risk with SIR modelling 
Models of airborne infection risk have been linked with SIR models to make 
inferences about population infection dynamics and the potential for disease control 
(i.e., Noakes et al., 2006). SIR models are specified as three ordinary differential 
equations with respect to time, 𝑡, that relate the change in the number of susceptibles, 
𝑆, with the number of infectors, 𝐼, and the population removed from the susceptible 
pool through immunity or death, R: 
𝑑𝑆
𝑑𝑡
=  −𝛽𝑆𝐼, 
𝑑𝐼
𝑑𝑡
=  𝛽𝑆𝐼 − 𝛾𝐼,
𝑑𝑅
𝑑𝑡
=  𝛾𝐼, 𝑆 + 𝐼 +
𝑅 = 𝑁, where 𝛽 is the contact rate between susceptibles and infectors that leads to 
infection, and 𝛾 is the removal rate. We point out that compared with 𝛽 as discussed 
in SIR models 𝛽 as discussed in airborne transmission risk models refers to viral 
exposure that leads to infection. For the purpose of assessing the effect of indoor air 
conditions on airborne transmission risk, Gammaitoni and Nucci, 1997 proposed a 






𝐼𝑆, where 𝑉 is the volume of the shared indoor 




. When we compared the SIR formulation with the rebreathed-air equation, we 
found SIR 𝛽 = 𝑓𝑞. Refinement of 𝑞 can be directly translated back into SIR models 
to model population dynamics. Information from airborne risk models can be used to 
inform SIR models including the effect of latency period, length of infectious period, 




The behavior of specified models can be tested extensively by parameterizing the 
variables from Table S4.3 and the SIR equations, and by examining the relationships 
between the variables. This approach has been as has been successfully used in 
numerous studies of infection risk and population infection dynamics (i.e., Nardell et 
al., 1991; Gammaitoni and Nucci, 1997; Noakes et al., 2006; Issarow et al., 2015; 
Cheng et al., 2016). Parameterization is informed by available knowledge or 
reasonable estimates and models tested under a range of simulated conditions can 
show the extent to which individual or groups of variables influence the system. 
Model validation can be done using observational data. 
 
We have shown that 1) we can estimate the relationship between observed aerosol 
shedding and infectious quanta, 2) synthesis and refinement of available infection risk 
models responds to the major critique that current models fail to accurately reflect the 
biological and physical process of transmission, and 3) refined infection risk models 
can be integrated into SIR models for powerful generalizability and application to 
population infection dynamics prediction and control. Models can be tested by human 
challenge transmission trials under controlled conditions as done in the EMIT trial. 
However greater external validity could be achieved using epidemiologic study 
designs that surveil infectious acute respiratory infection cases and their close 
contacts and characterize indoor air conditions in which exposure occurs. Advances 
in molecular epidemiology that could confirm transmission chains enables the 
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shifting of transmission work from the controlled experimental environment into the 
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